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ABSTRACT OF DISSERTATION 
THE ROLE OF FAT GRAFTING AND ADIPOSE-DERIVED STEM CELLS 
IN BREAST RECONSTRUCTION  
Fat grafting is a common surgical procedure that involves the transfer of fat from one 
area of the body to another in order to improve contour deformities, such as in breast 
reconstruction. Advantages of the technique include using autologous tissue rather than a 
foreign body and the added benefit of having liposuction to remove fat from an 
undesirable location. Although adipose tissue could be the ideal soft tissue filler, fat 
grafting is plagued by tremendous variability in long-term retention, with volume 
survival rates of 20-80%, resulting in suboptimal outcomes and repetitive procedures.  
The mechanisms contributing to long-term fat graft survival and resorption are not well 
understood. The discovery of multipotent mesenchymal adipose tissue-derived stem cells 
(ASCs) in subcutaneous adipose tissue has encouraged the study of their role in fat graft 
survival. ASCs are observed to survive after grafting, and in fact play a major role in 
adipocyte survival, regeneration and differentiation through adipogenesis and paracrine 
effects. In fact, lipoaspirate supplemented with ASCs has been shown to improve 
angiogenesis and long-term graft retention through the release of factors. Many adipose 
graft enrichment strategies encompassing growth factors, platelet-rich plasma, stem cells, 
gene therapy and tissue engineering have been attempted to augment and improve the 
viability of fat grafts. Therefore, a systematic review was undertaken to optimize safety 
and outcomes related to these enrichment strategies.  
Recently, concerns have been raised from several regulatory bodies, including the FDA, 
regarding safety of fat grafting in the setting of breast reconstruction. ASCs within 
lipoaspirate have been postulated to create an inflammatory tumor microenvironment, to 
encourage angiogenesis, and to potentially contribute to tumorigenesis. Therefore, a 
review of both local data and a systematic review was undertaken to determine 
oncological outcomes of fat grafting to the breast.  
Finally, we test the hypothesis that ASCs derived from obese donors exhibit 
compromised ASC functionality, leading to reduced fat graft retention when compared to 
non-obese subjects. Collectively, the studies that comprise this dissertation generate and 
critically appraise evidence for the safety, efficacy and outcomes of fat grafting in the 
setting of breast reconstruction.   
Keywords: adipose tissue; adipose-derived stem cell; plastic and reconstructive surgery; 
lipotransfer, fat grafting, obesity 
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Chapter 1: Introduction
Autologous fat grafting is a common surgical procedure that involves the transfer of fat 
from one area of the body to another in order to improve contour deformities. Fat grafting 
refers to the procedure in which fat is harvested by liposuction from a part of the body 
where it is unwanted and injected into an area where it can be used to add volume or 
correct a contour deformity. Advantages of the technique include using autologous fatty 
tissue rather than a foreign body and the added benefit of having liposuction to remove 
fat from an undesirable location.  
There is tremendous clinical interest in the utilization of fat grafting for soft tissue 
reconstruction, with thousands of cases performed each year in the treatment of volume 
loss due to trauma, scars, wounds, fistulas, disease, congenital defects, or the natural 
process of aging (7). In the setting of breast reconstruction, for example, fat grafting 
provides significant aesthetic improvement in breast reconstruction (8), is a viable option 
for improving the quality of irradiated breast skin (9), and can help to alleviate post-
mastectomy pain syndrome (10). Ideally, fat grafting could become an alternative to 
breast implants or complex microvascular tissue flap surgery in breast reconstruction (8, 
11-13). Although fat could become the ideal soft tissue filler, it is plagued by its
tremendous variability in long-term graft retention, with volume survival rates of 20-
80%, resulting in suboptimal outcomes and repetitive procedures (14).   
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The mechanisms contributing to long-term fat graft survival and resorption are not well 
understood. The recent discovery of multipotent mesenchymal adipose tissue-derived 
stem cells (ASCs) in subcutaneous adipose tissue has encouraged the study of their role 
in enhancing fat grafts for applications in tissue engineering, wound healing, soft tissue 
augmentation and fat graft survival. Avascular fat grafts initially rely on diffusion for 
survival until revascularization occurs. Revascularization of the free fat graft is essential 
to graft survival and is influenced by ASCs, which are more resistant to hypoxic 
conditions when compared to adipocytes. ASCs are observed to survive after grafting, 
and in fact play a major role in adipocyte survival and differentiation. These ASCs 
survive for up to 3 days and regenerate adipose tissue through adipogenesis and paracrine 
effects. ASCs also promote revascularization of ischemic free fat grafts through the 
release of proangiogenic paracrine growth factors, including vascular endothelial growth 
factor (VEGF). In fact, lipoaspirate supplemented with ASCs has been shown to improve 
angiogenesis and long-term graft retention through the release of these factors. Several 
adipose graft enrichment strategies encompassing growth factors, platelet-rich plasma, 
adipose-derived and bone marrow stem cells, gene therapy and tissue engineering have 
been attempted to augment and improve the viability of fat grafts.  
While there is tremendous interest in the use of fat grafting for aesthetic and 
reconstructive breast surgery, concerns have been raised from several regulatory bodies, 
including the Food and Drug Administration and professional organizations, regarding 
efficacy and safety in the setting of breast reconstruction. ASCs have been postulated to 
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create an inflammatory tumor microenvironment, to encourage angiogenesis, and to 
possibly differentiate into carcinoma associated fibroblasts, potentially contributing to 
tumorigenesis. However, concerns regarding the practice of fat grafting are not limited 
solely to the propagation of oncological transformation. 
In 1987, the American Society of Plastic Surgeons (ASPS) issued a report condemning 
the practice of fat grafting to breast tissue due to the lack of long-term clinical trials and 
the possibility that scarring and calcification resulting from the procedure could interfere 
with breast cancer diagnosis. Research in the field has resulted in a reversal of the 
previously recommended moratorium with an investigation by the ASPS Task Force 
revealing no evidence of fat grafting impeding cancer detection or any indication that the 
procedure stimulates cancer recurrence. In light of the recent FDA regulatory changes 
regarding the processing of fat, a systematic review was undertaken to determine the 
safety, efficacy, satisfaction, and oncological outcomes of fat grafting to the breast.  
Due to the significant variability in fat grafting outcomes and tremendous interest of 
ASCs graft retention, the final study attempts to describe the impact of a specific donor 
physiological condition, obesity, on ASC functionality. Obesity (BMI > 30 kg/m
2
) is a
growing epidemic in the United States, affecting more than 33% of adults. Obesity is 
characterized by chronic low-grade systemic inflammation; however, the effects of 
obesity on the intrinsic cellular properties of ASCs are largely unknown. The objective of 
this final study is to characterize the effects of obesity on ASC functionality and fat graft 
retention in breast reconstruction patients. ASCs isolated and cultured from the 
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lipoaspirate of lean and obese women undergoing fat grafting for breast reconstruction 
were compared by ASC yield, viability, growth kinetics, capacity for multi-lineage 
differentiation into adipogenic and osteogenic lineages, and growth factor expression in 
vitro. Understanding how obesity affects ASC function may help to elucidate why lean 
patients anecdotally have better fat graft retention compared to obese patients.  
Collectively, the objectives and specific aims of this dissertation are to generate and 
critically appraise evidence for the safety, efficacy and outcomes of fat grafting in the 
setting of breast reconstruction. Chapter 2 of this dissertation begins with a general 
introduction to adipose and breast tissue and the role of ASCs. Chapter 3 discusses the 
FDA regulatory issues regarding fat grafting. Chapter 4 identifies and appraises 
systematic evidence for autologous fat grafting to the breast, which includes a review of 
the safety, efficacy, satisfaction, and oncological outcomes. Chapter 5 continues this 
theme with a local review of the same variables. Chapter 6 is a review article on the 
impact of ASCs in fat grafting. Chapter 7 is a systematic review of the effects of obesity 
on ASC function. Chapter 8 is an experimental study exploring the effects of obesity on 
ASC functionality and its relationship to fat graft retention in breast reconstruction 
patients. Chapter 9 is a systematic review of adipose graft enrichment strategies. Finally, 
Chapter 10 summarizes the evidence and discusses the clinical implications and 
limitations, and recommends specific direction for future research.  
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Chapter 2: Adipose and Breast Tissue and
Adipose-Derived Stem Cells  
Chapter 2 provides a primer and discussion of the literature on adipose and breast tissue 
and the role of adipose-derived stem cells. Adipose tissue is not only the primary site of 
storage for excess energy, but is also a metabolically active and dynamic endocrine organ 
that is capable of synthesizing many biologically active compounds. This tissue is not 
only composed of adipocytes, but also of other cell types that make up the stromal 
vascular fraction. In order to understand fat grafting in breast reconstruction, it is 
important to understand adipose tissue, breast tissue and the role of adipose-derived stem 
cells. The following subsections describe the function of adipose tissue, the isolation and 
identification of adipose-derived stem cells, the development and regenerative potential 
of these cells, and ongoing clinical trials involving them. Finally, the cell types 
composing breast tissue is briefly discussed. 
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2.1 Adipose: Cell Types Composing the Tissue 
This section is based on an article published in The SAGE Encyclopedia of Stem Cell
Research, Second Edition and reproduced here with permission of SAGE Publications 
Inc. 
Vyas K, Jawahir N. (2015). Adipose, Cell Types Composing the Tissue. In E Bouhassira, 
Vyas KS (Ed.), The SAGE Encyclopedia of Stem Cell Research, Second Edition. Vol 1, 
pp 3-6. Thousand Oaks, CA: SAGE Publications, Inc. 
http://dx.doi.org/10.4135/9781483347660.n3 
10.4135/9781483347660.n3 
Adipose tissue is a loose connective tissue with the primary function of storing lipids that 
can be harvested for energy. This function is performed by adipocytes, which comprise 
the vast majority of cells in adipose tissue. However, multiple other cell types can be 
found in adipose tissue; these cells are grouped under the category of the stromal vascular 
fraction (SVF). Cells of the SVF include preadipocytes, fibroblasts, vascular endothelial 
and smooth muscle cells, mesenchymal stem cells, endothelial progenitor cells, and 
immune cells such as anti-inflammatory M2 macrophages and T regulatory cells. An 
understanding of the cell types in adipose tissue is crucial for many relevant clinical 
applications, such as approaches to dealing with obesity and also potential therapeutic 
uses of adipose stem cells for various disease processes. 
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Function of Adipocytes 
“Adipose tissue” often refers to white adipose tissue, which generally comprises around 
20 percent (with great variation) of human body mass. In many mammals, including 
human infants, brown adipose tissue is also present for thermogenic function in the 
absence of shivering. Human adults also have remnants of brown adipose tissue, 
generally in the neck or upper chest region, but white adipose tissue is the most prevalent 
and clinically relevant. 
White adipocytes. The majority of white adipose tissue is located either subcutaneously 
or viscerally, although small deposits can be found in a variety of locations, from within 
the bone marrow to around the epicardium, within joints and in craniofacial pads. 
Subcutaneous adipose tissue is located in the hypodermis throughout the body and 
especially in regions such as the hips, abdomen, or thighs. Visceral adipose tissue is 
packed in between organs of the abdomen, and is thought to be the most clinically 
relevant for disease processes such as obesity and type 2 diabetes mellitus. The primary 
cell type in white adipose tissue is the white adipocyte. 
White adipocytes have a distinctive histological appearance of a single (unilocular) large 
lipid droplet surrounded by a thin layer of cytoplasm with a flattened peripheral nucleus. 
Multiple hormone and other receptors are present on the surface of white adipocytes; this, 
coupled with endogenous adipocyte hormone production, gives white adipose tissue 
tremendous endocrine function in addition to its storage capacities. In particular, white 
adipocytes play key endocrine roles in energy metabolism and sex hormone levels. 
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One way that energy metabolism is regulated is through white adipocytes’ synthesis and 
secretion of leptin, a peptide hormone that inhibits appetite in the hypothalamus. 
Circulating levels of leptin are proportional to the amount of white adipose tissue in the 
body, and leptin resistance has been implicated in obesity. Energy metabolism is also 
regulated by the presence of insulin receptors on white adipocytes, which inhibit lipolysis 
in the presence of sufficient glucose in the bloodstream. 
Sex hormone levels in the body are influenced by white adipocytes’ ability to synthesize 
estradiol, via their production of the enzyme aromatase that converts androgens into 
estrogen. However, the primary function of the white adipocyte overall is to store lipid. 
Lipid content of adipose tissue overall increases with age, due to hypertrophy of white 
adipocytes. Although excess energy intake can result in the formation of new adipocytes, 
weight loss results in merely shrinkage of existing adipocytes rather than a decrease in 
number. 
Brown adipocytes 
Brown adipocytes have a greater ratio of cytoplasm to lipid content, and multiple smaller 
lipid droplets (multilocular) when compared to white adipocytes. The cytoplasm contains 
multiple mitochondria, which lend to the brown color of the cell and work to generate 
heat via lipid oxidation. Unlike white adipocytes, brown adipocytes express uncoupling-
protein 1 (UCP-1), which drives the generation of heat by dissipating the mitochondrial 
proton gradient (leading to direct heat production rather than ATP production and 
storage). Brown adipose tissue in general also exhibits greater vascularization, due to a 
9 
greater need for oxygen by the mitochondria. Recent research has looked into the 
possible expression of UCP-1 by white adipose tissue as a method of combating obesity. 
Function of Stromal Vascular Fraction 
Preadipocytes 
Preadipocytes are fibroblast-like cells derived from mesenchymal stem cells. 
Preadipocytes are committed to the adipocyte lineage and are regularly present in adipose 
tissue in small quantities, where they serve both to replenish dying adipocytes (adipocyte 
turnover is around 10 percent per year) and to increase existing adipocyte numbers when 
energy stores are plentiful. Preadipocytes often reside in close proximity to the 
vasculature of adipose tissue and express the transcription factor PPAR, which has been 
identified as essential to adipogenesis. Preadipocytes require a specific, high-lipid 
microenvironment in order to differentiate into adipocytes; however, in the case of 
obesity, preadipocyte numbers actually decrease, perhaps as a compensatory mechanism 
to prevent excess irreversible adipocyte formation. 
One of the factors that allow preadipocytes to maintain stable reservoirs of adipogenesis 
is their expression of telomere reverse transcriptase, which prevents the shortening of 
telomeres and subsequent DNA degradation over generations of replication. Differing 
populations of preadipocytes give rise to brown and white adipocytes, and within white 
adipocytes, there are regional differences as well. For example, visceral preadipocytes 
take much longer than their subcutaneous counterparts to differentiate and mature into 
adipocytes; this may explain the hypertrophy and greater lipid accumulation of visceral 
adipocytes. 
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A greater amount of lipids in each adipocyte in turn influences the adipokines (signaling 
proteins from adipose tissue) that are secreted, which can have profound clinical effects. 
For example, visceral adipocytes secrete much less of the adipokine adiponectin, and this 
has been shown to decrease insulin sensitivity and ramp up pro-inflammatory processes 
in visceral adipose tissue compared to subcutaneous. Research on how to alter 
preadipocyte gene expression, and thereby change adipocyte characteristics, has been 
relevant both for obesity and also in potential approaches to treating lipodystrophic 
disorders. 
Mesenchymal stem cells 
From mesodermal origin, mesenchymal stem cells (MSCs) are present in many different 
connective tissues, such as within the bone marrow. In the microenvironment of adipose 
tissue, MSCs generally differentiate into preadipocytes. However, MSCs can still be 
induced to develop into osteogenic, chondrogenic, myogenic, and other lineages, and 
have been heralded for their great research potential. Harvested via liposuction, in vitro 
studies of processed lipoaspirate (PLA) have yielded MSCs that are being studied for 
their use in autologous stem cell transplant. Human adipose tissue shows great potential 
for potential stem cell use due to its availability, quantity, and ease of obtainment. 
Endothelial progenitor cells 
Separate from mesenchymal stem cells, endothelial progenitor cells (EPCs) have been 
identified that give rise to adipose tissue vasculature. These EPCs are free-circulating and 
bone marrow derived, and usually present in the SVF in small quantities. They contain 
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angiogenic and/or hematopoietic cell markers. It has been postulated that in obesity, there 
are greater numbers of EPCs trapped in the adipose tissue rather than free to circulate, 
and thus angiogenic ability overall is reduced in obese patients. EPCs have also been the 
subject of much research recently involving potential transplantation to rebuild vessels 
damaged by atherosclerosis and stenosis. 
Immune cells 
Both T-regulatory immune cells and macrophages are resident to the SVF. The T-
regulatory cells (T-regs) are immune suppressive cells formed from the activation of T 
cells in the absence of costimulatory signals, and their presence in adipose tissue has 
shown to be induced by markers generated from MSCs in adipose. T-regs in turn help 
promote the presence of macrophages. The macrophages present in adipose tissue are 
interesting in that they possess markers for both pro- and anti-inflammatory processes. 
On a surface level, adipose tissue macrophages (ATMs) express markers and receptors 
similar to M2-type macrophages, which promote tissue repair. ATMs, like M2 
macrophages, can also be induced to secrete anti-inflammatory proteins like IL-10 and 
IL-1 receptor antagonist. 
However, these same ATMs also secrete inflammatory proteins such as TNF-α, IL-1, and 
IL-6 in quantities high enough to offset any anti-inflammatory activity by both the ATMs 
and T-regs. It is postulated that the ATM protein secretion is under the regulation of 
adipocytes, which also secrete these inflammatory proteins themselves, and both of these 
processes contribute to the low-grade inflammatory state often present in obesity. 
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Other cells 
Vascular and extracellular matrix cells that are present throughout the body are also 
found in adipose tissue. Similar to vasculature throughout the body, the vessels of 
adipose tissue consist of endothelial and smooth muscle cells. These endothelial cells 
include both ordinary endothelial cells like those found elsewhere and also specialized 
endothelial cells that appear to be able to induce preadipocyte generation. Fibroblasts also 
help secrete collagen and other extracellular matrix components that help form the 
structure of adipose tissue. 
Overall, many different cells in adipose tissue have vast potential for further research 
investigation. Especially with the rise of obesity, there has been a much greater 
international interest in learning more about the components of adipose tissue and how 
they can be altered. In particular, MSCs and preadipocytes show promise for future use 
both in treating obesity and a plethora of other disorders. 
Both adipocytes and components of the stromal vascular function are integral parts of 
adipose tissue, and understanding their functions will be a critical cornerstone of future 
learning. 
Further Readings 
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2.2 Adipose: Tissue Function 
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The parenchyma of adipose tissue consists of adipocytes suspended in a connective tissue 
matrix, which functions as both a crucial endocrine organ as well as a site for metabolic 
activity. Two types of adipose tissue have been identified: brown and white. Brown 
adipose tissue (BAT) in humans is present at birth and provides non-shivering heat 
generation, while white adipose tissue (WAT) is present in adults and is a highly 
metabolic, endocrine organ. Pathology can occur both from adipose tissue deficiency as 
well as excess. 
Brown Adipose Tissue (BAT) 
Non-shivering thermogenesis. Brown adipocytes utilize oxygen and lipids as substrates to 
produce heat. The functional thermogenic unit consists of a brown adipocyte maintained 
within a structural network of connective tissue with access to a rich blood supply and 
innervation. The vascular network serves the BAT by both delivering substrate and 
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signaling molecules to the organ as well as carrying away the heat product to the body. 
Therefore, access to an ample vascular network is necessary in order to achieve maximal 
generation and distribution of the BAT-generated heat. Heat generation is achieved by a 
mitochondrial protein known as uncoupling protein-1 (UCP1) or thermogenin. It allows 
for combustion of fatty acids in the respiratory chain without the production of ATP; 
instead, heat is the form of energy that is released. 
Signal transmission. The ventromedial (VML) hypothalamic nucleus of the brain 
coordinates information regarding body energy reserves and body temperature. When a 
thermogenic demand is sensed by the VML, the information is relayed via the 
sympathetic nervous system. The neurotransmitter norepinephrine (NE) is released and 
binds β-3 adrenergic receptors in the BAT to trigger an intracellular cascade that 
eventually leads to the generation of heat and an increased body temperature. 
Thermogenic demand. Pre-adipocytes represent a rapidly accessible stem cell population 
that can replicate and differentiate into mature BAT under situations of increased 
thermogenic demand. 
White Adipose Tissue (WAT) 
Steroid hormone metabolism. Adipose tissue serves a crucial role in processing steroid 
hormones produced in the adrenal glands and gonads. This processing is referred to as 
“tissue-specific pre-receptor steroid hormone metabolism” and is necessary for full 
activation or inactivation of the circulating steroid hormones. The enzymes required to 
perform this process are extensive and include cytochrome P450-dependent aromatase, 
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3β-hydroxysteroid dehydrogenase (HSD), 3αHSD, 11βHSD1, 17βHSD, 17α-
hydroxylase, 5α-reductase, and UDP-glucuronosyltransferase 2B15. 
Aromatase is an especially important adipose enzyme in that it converts androgens into 
estrogens. In postmenopausal women, gonadal synthesis of estrogens becomes 
diminished and adipose tissue accounts for all of the circulating estrogen. 
Reservoir for energy storage. Despite the large capacity of adipose tissue to secrete 
proteins and metabolize steroid hormones, the major secretory product of WAT is fatty 
acids. Adipocytes store triglycerides internally as a lipid droplet through an enzymatic 
process. First, triacylglycerides absorbed from the diet or synthesized in the liver reach 
their storage site (adipose tissue) and are converted into fatty acids via the enzyme 
lipoprotein lipase (LPL). They are then combined with the metabolic glucose product 
glycerol phosphate to reform triacylglyceride inside the adipocyte. When the cell receives 
signals that the body requires use of the free fatty acids for energy, they are then broken 
down via an enzyme called hormone sensitive lipase (HSL) that breaks apart the stored 
triglycerides to release free fatty acids. HSL responds to hormones such as 
catecholamines and glucagon to increase the free fatty acid concentration in the plasma 
so that it can be utilized for energy. Therefore, the sympathetic nervous system is a 
primary modulator of triacylglycerol breakdown. 
Endocrine functions. Adipose tissue as an organ consists of several different tissue types 
including adipocytes, connective tissue, nerves, stromovascular cells, and immune cells. 
These tissues function in synchrony to express and secrete several hormonal and non-
hormonal products including leptin, angiotensinogen, adipsin, acylation-stimulating 
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protein, retinol-binding protein, tumor necrosis factor alpha (TNFα), interlukin-6, 
plasminogen activator inhibitor-1, adiponectin, complement components, and resistin. 
Several of these mediators are discussed below. 
Secreted proteins
 Leptin is a polypeptide (16-kDa) containing 167 amino acids and has a structural
configuration similar to that of cytokines. Although leptin can be synthesized in
several sites of the body including the stomach, placenta, and mammary glands,
the predominant site of its synthesis is in WAT. The primary role of leptin is to
serve as a messenger to the body that the level of energy is at a sufficient state.
Therefore, adipose tissue mass and nutritional status are the main mediators of
leptin and directly correlate to circulating levels. These levels rapidly decline with
caloric restriction and weight loss. Leptin can also be modulated by other
chemical mediators: it is increased by insulin, steroids, and TNFα, and is
decreased by β3-adrenergic activity, androgens, free fatty acids, growth hormone
(GH), and peroxisome proliferator-activated receptor-γ agonists. Genetically
modified mice that have a recessive knockout of the leptin gene are referred to as
ob/ob mice and are profoundly obese. The lack of circulating leptin leads to an
absent detection of energy sufficiency and causes the mice to eat to excess.
Therefore these mice are often applied as research models for type 2 diabetes.
 TNFα is a transmembrane protein (26-kDa) that becomes biologically active after
cleavage. Levels of TNFα positively correlate with obesity and insulin resistance.
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Induction of insulin resistance can be achieved in vitro and in vivo via chronic 
TNFα exposure. 
 Interleukin-6 (IL-6) is similar to TNFα in that it is a cytokine produced by
adipose tissue that also is associated with obesity and insulin resistance, and
circulating levels have been shown to decrease with weight loss. It also serves as
a predictor of type 2 diabetes as well as cardiovascular disease.
Adipose tissue excess (obesity). Associations of obesity are referred to as metabolic 
syndrome and are characterized by insulin resistance, hyperglycemia, dyslipidemia, 
hypertension, and prothrombotic and proinflammatory states. 
Adipose tissue deficiency (lipodystrophy). A deficiency of adipose is also associated with 
characteristics of metabolic syndrome. 
Further Readings 
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2.3 Adipose: Stem and Progenitor Cells in Adults 
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Adipose tissues play major roles in storage and active regulation of metabolism. In 
addition to these functions, adipose tissue has properties that give it potential application 
for tissue regeneration or transfer. Adipose may be a source of unique, pluripotent 
(possessing the ability to form into cells originating from any of the three germ layers: 
ectoderm, mesoderm, endoderm) stem cells. The utilization of stem cells and cytokines 
can lead to tissue repair and the regeneration of damaged tissues. Other multipotent 
(possessing the ability to differentiate into multiple but limited cell types) progenitor cells 
can be drawn in an undifferentiated state. Progenitor cells are considered to have already 
committed to differentiation on a specific cellular pathway. There may be fewer political, 
legal, and ethical issues with adipose stem and progenitor cells as compared to embryonic 
stem cell use.
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Multi-Lineage Potential 
Stem cells must have the ability to continually divide (self-renewal), maintain viability 
long term, and have the potential to differentiate. Stem cells extracted from bone marrow 
(mesenchymal stem cells) have shown multi-lineage potential through extensive study 
and have been suggested as alternatives to embryonic stem cells in mesodermal defect 
repair and disease management. However, issues with pain, morbidity, and low cell 
number during extraction impede the practical use of bone marrow stem cells. 
Like stems cells derived from bone marrow, adipose tissue is of mesodermal origin. 
Adipose-derived stem cells (ADSCs) can differentiate in vitro (isolated studies in 
experimental biology) toward osteogenic (bone), adipogenic (fat), myogenic (muscle), 
and chondrogenic (connective tissue) lineages when treated with established lineage-
specific factors. Studies have shown that ADSCs show lineage-specific genes to 
distinctive cell lines such as osteocytes or myocytes when stimulated to develop into 
different cells. 
ADSCs can differentiate into adipocytes, chondrocytes, and osteoblasts, a feature known 
as multipotency. A single ADSC is also capable of cloning itself and then further 
differentiating into multiple lineages, a capacity known as clonogenicity. For example, 
human ADSCs show in vitro evidence of differentiation along myocyte lineage pathways. 
When cultured with myocyte lineage factors, adipocytes fuse and express protein markers 
of skeletal myocyte lineage. This suggests that these cells have the potential to repair 
damaged skeletal muscle. ADSCs can also differentiate into osteoblast-like cells by 
depositing calcium phosphate mineral into their extracellular matrix and expressing 
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osteogenic genes and proteins. Evidence suggests that these cells have the potential to 
accelerate repair at fracture sites. 
The range of differentiation that ADSCs possess extends beyond bone, muscle, and 
connective tissue. There may be possibility of repairing gastrointestinal and urinary tract 
smooth muscle defects with ADSCs. Factors can also differentiate these cells along the 
cardiac myocyte pathway and may be a source of regeneration for cardiac tissues 
damaged from infarction or ischemic injury. Preliminary studies have also implicated 
ADSCs in the regeneration of the central and peripheral nervous system following 
traumatic injury. 
Adhesion proteins associated with hematopoietic stem cells can form on ADSCs, which 
can also secrete cytokines (substances secreted by cells of the immune system) and 
promote differentiation along the B-cell, T-cell, and myeloid (white blood cell) lineages. 
This possible application can extend to conditions that weaken patients’ immune systems 
such as those patients undergoing high-dose chemotherapy or suffering from inborn 
errors of metabolisms. 
Harvesting Adipose-Derived Stem Cells 
Adipose tissue is an exciting resource for tissue regeneration and soft tissue repair 
because it houses one of the richest reservoirs of stem cells in the human body. Thus, 
stem cells collected from adipose tissue do not need to be cultured in order to obtain a 
therapeutically vital number of cells. Well-nourished humans store excess calories in 
adipose tissue that increase cell volume and expansion of the number of differentiated 
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adipose cells, suggesting that adipose tissue progenitor cells exist within adult fat tissue. 
ADSCs can also be harvested easily with little harm to the patient through the process of 
liposuction, making adipose stem and progenitor cells much more accessible than bone 
marrow cells. ADSCs cultured in vitro have shown consistent profiles of cell-surface 
proteins, which include adhesion proteins, receptor molecules, surface enzymes, extra-
cellular matrix proteins and glycoproteins, skeletal proteins, hematopoietic (involved in 
blood formation) cell markers, complement regulatory proteins, and histocompatibility 
antigens (immune system components). 
The immunophenotype of ADSCs resemble other adult stem cells from bone marrow and 
skeletal muscle. Methods of harvesting the tissue have dramatic effects on the ability of 
the cells to proliferate and differentiate in culture. Several studies report a negative 
correlation between patient age and the yield of donor cells and proliferation. Many 
concerns remain for the standardization and optimization of methods for cell isolation, 
culture, and application. 
Future Development 
ADSCs may prove to be an ideal option for tissue engineering in regenerative medicine 
since they are self-renewable, plentiful, and easily accessible through minimally invasive 
procedures. Studies suggest that ADSCs can be used in the treatment of type 1 diabetes 
mellitus, obesity, cardiovascular disease, lipodystrophy, and neurodegenerative diseases. 
For example, ADSCs have the ability to be carriers for gene delivery vehicles through 
transduction, the process by which foreign DNA is introduced into another cell through a 
viral vector. In surgical application, ADSCs can aid with neovascularization of free fat 
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grafts (transplanted adipose tissue). Much more preclinical research and development 
must be dedicated to ADSCs before they can be used in treatment. Optimizing methods 
to harvest and preserve viable adipose tissue is of vital importance, but patient safety 
must be the priority. 
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Adipose-derived stem cells, or ASCs, are a unique population of stem cells isolated from 
adipose tissue. These multipotent stem cells present an alternative to the widely used 
embryonic and hematopoietic stem cell lineages for laboratory and clinical applications 
in regenerative medicine. Adipose tissue is abundant in the body and exists in several 
forms, including bone marrow, mammary tissue, and mechanical, brown (multilocular), 
and white (unilocular) adipose tissues. 
Traditional methods of gathering stem cells include the controversial isolation of 
embryonic stem cells and the painful process of procuring stem cells from bone marrow. 
In contrast to these methods, an efficient manner of isolating and producing reliable stem 
cell populations from abundant, easily accessible adipose tissue presents an appealing 
alternative for clinical therapeutic applications. Thus far, adipose stem cells have been 
shown capable of multipotent mesodermal differentiation, as well as potential 
endodermal and ectodermal lineages in vitro. 
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Evidence for Adipocyte Precursor Cells 
Progressive osseous heteroplasia (POH), a pathologic condition that leads to heterotopic 
bone formation within subcutaneous adipose and, eventually, muscle tissue, demonstrates 
the presence of adipocytes, osteoblasts, and chondrocytes upon histologic examination of 
the resultant lesions. Pathologic evidence from this rare, autosomal-dominant, inherited 
genetic defect suggests that ADCs are at least capable of differentiation into the 
aforementioned mesodermal lineages. Along with POH, lupus and Paget disease are also 
known to present with calcification of subcutaneous adipose, providing further evidence 
for the presence of multipotent ASCs within adipose tissue. Additionally, research using 
ligand-induced adipogenesis for the chemotherapeutic treatment of liposarcomas suggests 
that these cancers may derive from a stem cell progenitor; stimulation by both long-chain 
fatty acids and synthetic steroid compounds induces adipocyte formation from 
liposarcoma-derived cells. Furthermore, radioactive tracing to measure adipocyte 
turnover rates in obese patients indicates a lifespan of six to 15 months for these fully 
differentiated adult adipocytes, a value that seems to indicate the presence of a controlled 
replacement mechanism of mature cells by resident stem cell–adipocyte precursors. 
Evaluation of individuals who have undergone rapid weight loss through either metabolic 
or procedural means also supports this concept: Not only do existing adipocytes increase 
in volume but new adipocytes emerge in a homeostatic process to maintain a relatively 
constant level of adipose tissue within the organism. 
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Origin of ASCs 
Adipose tissue is abundant in the body and exists in several forms, including bone 
marrow, mammary tissue, and mechanical, brown, and white adipose tissues. It is 
speculated that ASCs arrive in adipose tissue via distribution of circulating fibroblasts 
derived from the bone marrow that then colonize the respective adipose tissues 
throughout the body. Transplanted bone marrow-derived fibroblasts similar to the ones 
already discussed have been shown capable of differentiating into adipocytes upon proper 
chemical stimulation and in the presence of a lipid-rich diet; however, the exact origin 
and distribution of ASC populations remains unknown. Regarding the relative abundance 
of stem cell populations within the body’s various adipose depots, current evidence 
suggests that richer concentrations of progenitor cells exist in the arm and abdomen 
relative to samples taken from the thigh or breast. Further studies, along with effective 
isolation techniques, are still needed to optimize processes for procuring ASCs in the 
most efficient manner from donors. 
Cell Isolation From Adipose Tissue 
Older methods of isolating cells from adipose tissue involved thoroughly rinsing minced 
animal fat pads, digestion with collagenases, and centrifugation to separate the desired 
stromal vascular fraction (SVF) that contained the processed lipoaspirate cells within a 
heterogeneous mixture. Finally, the plastic-adherent cells within the isolated SVF were 
selectively purified on the surface of tissue-culture flasks to enrich the concentration of 
adipocyte precursors. 
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Researchers are developing more efficient isolation methods that use advances in 
liposuction and reconstructive plastic surgery; in this process, plastic surgeons use a 
cannula to infuse subcutaneous adipose tissue with an anesthetic-containing saline 
solution. The procedure produces aspirations of adipose-tissue fragments containing 
viable adipocyte precursors within the SVF. Following collection of tissue samples, 
centrifugation at 1,200 G optimizes the ASC fraction recovered from the liposuction 
aspirate. However, surgical procedures involving ultrasound-assisted liposuction have 
shown adverse effects on the quantity of viable cells abstracted via the procedure. Once 
isolated, ASCs double in vitro within two to four days. Since massive quantities of tissue 
must be handled to isolate significant quantities of desired cells, methods such as 
rotating, temperature-controlled collagenase incubators, and bag-within-a-bag sieves are 
being tested to assist in procuring the desired cellular fraction from liposuction aspirate 
samples. Thanks to the development of these novel techniques for efficiently isolating 
ASCs, larger-scale commercial isolation methods are in development and becoming a 
realistic possibility for clinical application. 
Purification and Identification 
To identify a stem cell, researchers evaluate the presence and absence of various surface 
marker proteins, or antigens, which are important for immune recognition by leukocytes. 
Studies analyzing the immunophenotype of cells abstracted from liposuction aspirate find 
much consistency in the surface markers of these adipose-derived cells, indicating that 
there is, in fact, a unique population of adipocyte precursors present within the aspirate. 
Among the antigens used to identify stem cell populations, ASCs have been identified as 
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positive for CD29, CD34, CD54, CD90, CD105, CD166, and human leukocyte antigen 
(HLA)-ABC markers; they are negative for CD31, CD45, CD106, CD146, and HLA-DR 
markers. Additionally, ASCs may be purified from the heterogeneous subcutaneous 
adipose and vascular fraction SC+VF by exploiting their plastic-adherent characteristic 
and their multipotent differentiation potential. 
Multipotency of ASCs 
It is now well known that adipose-derived stem cells can differentiate into adipocytes, 
chondrocytes, and osteoblasts. Not only are they capable of this multipotency, but their 
clonogenicity has been established as well. That is, a single ASC has been shown capable 
of cloning itself and then further differentiating into multiple lineages, eliminating the 
possibility of multiple precursors producing the respective observed lineages. Beyond the 
mesodermal tripotency seen in conditions of pathologic calcification, researchers have 
more recently successfully induced in vivo ASC differentiation into neurogenic 
ectodermal cells consistent with neurons, oligodendrocytes, and Schwann cells. Other 
confirmatory studies have elicited ASC commitment to hepatogenic, pancreaticogenic, 
myogenic, hematopoietic supporting, and endodermal lineages by targeting various 
chemical inductive factors to the cells. 
Both endogenous and synthetic chemicals have successfully induced differentiation into 
determinate cell lineages. Cardiomyocytes have been induced using the iron transporter, 
transferrin, interleukins 3 and 6, as well as vascular endothelial growth factor. 
Endothelial cells, on the other hand, result from ASC exposure to basic fibroblast growth 
factor, and epidermal growth factor. Differentiation into many cell lineages indicates that 
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ASCs contain vast potential, perhaps far wider than that initially suggested by 
pathological evidence; it is even theorized that these cells are pluripotent, much like 
embryonic stem cells. 
Clinical Trials With Therapeutic ASCs 
Compared to hematopoietic stem cells, ASCs exhibit greater long-term genetic stability 
and are more immunoprivileged (i.e., evidence suggests they are effective at preventing 
severe graft-versus-host disease). Therefore, presently, these cells seem potentially safer 
and more effective than their adult stem cell counterparts. Currently, dozens of clinical 
trials are underway to evaluate their efficacy in various regenerative treatments. 
Immunosuppressive studies have shown that ASCs suppress T-cell–mediated immunity 
and inflammation while activating regulatory T cells, which downregulate inflammatory 
mediators and reduce the tissue response of inflammatory cells. Other clinical trials are 
investigating applications in cardiovascular and hepatic disease, type 1 and 2 diabetes, 
amyotrophic lateral sclerosis, multiple sclerosis, immunosuppression, limb ischemia, and 
bone reconstruction. 
Regenerative capacities for lumpectomy patients and perianal fistulas are also being 
investigated. Current theories on the mechanism of action for ASCs include the paracrine 
secretion of signaling molecules like cytokines or growth factors that would guide the 
differentiation of local cells to the necessary type to speed recovery; in the treatment of 
ischemia, ASCs may help remove toxins by producing antioxidants and free-radical 
scavengers to aid in tissue recovery. 
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While many clinical trials are underway to address the safety and efficacy of ASCs, much 
remains to be seen regarding the potential these versatile cells have in therapeutic and 
regenerative settings. The vast array of possible treatments being explored will 
undoubtedly continue to revolutionize the management of disease. 
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Human adipose tissue serves as an important endocrine and metabolic organ. Adipose 
tissue is a complex tissue composed mainly of mature adipocytes surrounded by a 
connective tissue matrix, in addition to stromovascular cells, nerve tissue, and immune 
cells. Together, these components play an important role in insulating the body, storing 
energy as lipids, and producing and metabolizing hormones. By secreting factors such as 
leptin, resistin, estrogen, and cytokines, adipocytes act as the major component of a 
highly active endocrine organ that targets various tissues in the body to maintain 
homeostasis. A lack or complete absence of adipose tissue (lipodystrophy) or 
overproduction of adipose tissue (obesity) can result in metabolic complications such as 
type 2 diabetes, insulin resistance, hepatic steatosis, and hypertriglyceridemia. The plastic 
nature of adipose tissue, with its regenerative properties and ability to expand and 
contract in response to shifts in energy balance, is most evident in the obesity epidemic. 
For many years, scientists and clinicians have investigated the development of adipose 
tissue at the cellular level; however, with modern biotechnological advances in stem cell 
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research, the study of adipogenesis has been focused on the discovery and function of 
adipose-derived stem cells (ASCs). Capable of differentiating into cells of 
nonmesodermal and mesodermal origin, ASCs serve as an important target for adipose 
tissue engineering and regenerative medicine. 
Adipose Tissue: A Source of Multipotent Stem Cells 
Stems cells are cell populations that possess multilineage potential, self-renewing 
capacity, and long-term viability. Originating from the stroma of bone marrow, 
mesenchymal stem cells (MSCs) have been widely studied as an example of adult stem 
cells that are capable of differentiating into chondrocytes, osteoblasts, adipocytes, and 
myoblasts in vivo and in vitro. While MSCs are promising candidates for disease 
management and mesenchymal defect repair, the use of MSCs in the clinic has been 
limited due to complications associated with morbidity, pain, and low cell count/tissue 
volume upon harvest. 
In recent years, researchers have focused attention to adipose tissue as an alternative 
source of adult stem cells. Much like bone marrow, adipose tissue is derived from 
mesenchymal origin and contains an easily isolated stroma. ASCs exhibit stable 
proliferation and growth kinetics in culture and in the presence of specific inducing 
factors can differentiate into chondrogenic, osteogenic, adipogenic, and myogenic 
lineages. Due to the ubiquitous nature of human adipose tissue, large quantities of ASCs 
can be easily obtained with little patient discomfort or donor site morbidity. 
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The multipotent nature of ASCs is evident in various human pathologies. In children with 
progressive osseous heteroplasia (POH), an autosomal dominant genetic defect that 
causes ectopic bone formation within subcutaneous adipose depots, chondrocytes and 
osteoblasts can be found within colonies of adipocytes. Histologic analysis implies a 
tripotent capacity of ASCs to differentiate into cells of chondrogenic, osteogenic, and 
adipogenic origin. Obesity also presents additional evidence supporting the presence of 
stem cells in adipose tissue. Adipocytes have a turnover rate ranging between 6 and 15 
months. While various behavioral, genetic, and epigenetic factors can contribute to 
obesity, in vivo studies have demonstrated the existence of stem cell populations that 
replace mature adipocytes throughout the lifetime of humans. 
Adipose-Derived Stem Cell Isolation 
Humans contain five major types of adipose tissue: bone marrow, mammary, mechanical, 
brown, and white. Each type of adipose depot serves a unique biological function and 
contains a distinct stem cell profile. White adipose tissue contains higher amounts of 
multipotent stem cells compared to brown adipose tissue, with subcutaneous depots 
providing higher yields of ASCs compared to visceral fat. Within subcutaneous white 
adipose tissue, greater numbers of stem cells have been harvested from arm regions 
compared to the abdomen, thigh, and breast. ASCs recovered from superficial abdominal 
regions were found to be the most resistant to apoptosis. Furthermore, ASCs from 
younger donors have demonstrated greater cell adhesion and proliferation compared to 
older donors. It has yet to be determined which adipose tissue depot serves as the optimal 
location for stem cell recovery. 
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Samples of subcutaneous adipose tissue are often obtained from subjects under local 
anesthesia. Current methods for isolating ASCs depend on collagenase digestion of tissue 
followed by centrifugation to isolate primary adipocytes from the stromal vascular 
fraction (SVF). ASCs display morphology similar to fibroblasts, which makes phenotypic 
identification difficult, and do not exhibit the intercellular lipid droplets that are found in 
adipocytes. Isolated ASCs are grown in monolayer culture utilizing specific cell culture 
techniques. 
Regeneration, Repair, and Tissue Engineering 
Traditionally, rehabilitation of injured or diseased organs and tissues has required tissue 
replacement through the use of autologous tissues since the body rejects tissue transplants 
with foreign antigen. With advances in modern biotechnology, researchers have placed 
an emphasis on developing tissue-engineered substitutes that are better suited in 
restoring, maintaining, and improving tissue function. The technology of tissue 
engineering involves an interdisciplinary field of physicians, engineers, and scientists 
who utilize adult stem cells to be directly implanted into the host or expanded in culture. 
In the latter technique, stem cells are differentiated and combined with tissue-engineered 
scaffolds and growth factors to develop tissue and organ systems. Tissue engineering can 
be used as a tool for transplantation, rehabilitation, and reconstructive surgery. 
ASCs have the potential to regenerate and repair different types of tissues through a 
variety of mechanisms. ASCs can provide a beneficial impact on diseased or injured 
tissues/organs by producing and secreting soluble factors. Some of the growth factors and 
cytokines secreted by ASCs include hepatocyte growth factor (HGF), insulin-like growth 
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factor (IGF-1), vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF-
α), fibroblast growth factor (FGF), adiponectin, transforming growth factor-β (TGF-β) 
and other angiogenic, anti-apoptotic, and anti-inflammatory factors. Certain soluble 
factors can also promote tissue repair and wound healing by recruiting endogenous stem 
cells. This newly formed stem cell population acts in a paracrine manner that can be 
stimulated to differentiate along the lineage pathway required for tissue repair. 
ASCs can act as a viable source of free-radical scavengers, antioxidant chemicals, and 
chaperone/heat shock proteins. In injured regions such as ischemic sites, ASCs act in 
such a manner to clear the local environment of toxic substances, thereby improving 
recovery of surviving cells. Recent studies have demonstrated the capacity for bone 
marrow–derived MSCs to deliver mitochondria to injured cells and rescue aerobic 
metabolism. Comparable studies on ASCs may uncover a similar potential to contribute 
mitochondria. 
Therapeutic benefits of ASCs also differ between autologous (derived from the same 
individual’s body) and allogenic (derived from genetically dissimilar individual) 
transplantation. While autologous ASCs can be beneficial from histocompatibility, 
infectious, and regulatory perspectives, it is rare for patients to provide their own 
therapeutic cells. Researchers have determined that a human’s ASCs that are passaged in 
cell culture, compared to freshly isolated cells, have reduced surface histocompatibility 
antigen expression and suppressed immune reactivity when cultured together with 
allogenic cells. While this implies that passaged ASCs may not produce a cytotoxic T-
cell response when transplanted in vivo, comprehensive testing is required before clinical 
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implementation. If proven correct, the use of allogenic ASCs in regenerative medicine 
holds the potential to lower costs of cell therapies, to improve availability of stem cells, 
and to reduce complications associated with organ and tissue failure. 
The Future of ASCs 
Deriving stem cells from adipose tissue has proven to be an efficacious, safe, and simple 
process with little donor site morbidity. Furthermore, stem cell yields from adipose tissue 
are far greater than most stem cell reservoirs in the human body. While they may be 
suitable candidates in regenerative medicine, various limitations still remain. One of the 
major concerns with the use of ASCs is that very few in vivo clinical trials have been 
conducted compared to the large number of in vitro preclinical studies. In addition, many 
scientific questions remain unclear. Firstly, the specific transcription factors and key 
molecular events that allocate ASCs to a particular lineage have not been identified. 
Secondly, evidence implies that the ability for ASCs to differentiate may depend on the 
anatomic source and the donor’s age and gender. Furthermore, methods for large-scale 
manufacturing with appropriate quality control and quality assurance have yet to be 
developed. To fulfill expectations and to determine if ASC-based therapies can be 
successfully implemented in treatment, further investigation is required. 
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2.6 Adipose: Existing or Potential Regenerative Medicine Strategies 
This section is based on an article published in The SAGE Encyclopedia of Stem Cell
Research, Second Edition and reproduced here with permission of SAGE Publications 
Inc. 
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A stem cell is a cell that has the ability to self-renew and differentiate into one or more 
types of cells. Therefore, stem cells hold great promise for regeneration and repair of 
tissues. Recent study has focused on their use for the treatment of Parkinson disease, 
Alzheimer disease, cancer, myocardial infarction injuries, breast reconstruction, diabetes 
mellitus, autoimmune diseases, and much more. Unlike the embryologic stem cells that 
aroused much controversy, adipose-derived stem cells (ASCs) are derived from adults 
and are noncontroversial. Furthermore, research suggests ASCs are a better stem cell 
source than the conventional mesenchymal stem cells—the bone marrow stem cells 
(BMSCs). 
Shift From BMSCs to the ASCs 
Historically, BMSCs were the most frequently used mesenchymal stem cell pool. 
However, ASCs are more advantageous in several respects. The pool of ASCs is larger 
than that of BMSCs. They can be collected by liposuction with local anesthesia, whereas 
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bone marrow acquisition is more invasive, requires general anesthesia, and carries a 
greater risk for mortality. Furthermore, clinical data show that ASCs have a higher 
proliferation rate than BMSCs. ASCs can grow to 90 percent confluence within three 
days compared to BMSCs, which can take a week to reach the same mark. 
Potential of ASCs 
ASCs are multipotent and mesenchymal in origin. Initially, ASCs were studied for 
differentiation into chondrogenic, myogenic, and osteogenic cell types. However, further 
research showed transdifferentiation capacity extending beyond the traditional 
mesenchymal lineage. ASCs are now known to be capable of skeletal myogenesis, 
cardiac myogenesis, neurogenesis, and angiogenesis. 
ASC use in regenerative therapy involves redirection from normal reparative function to 
generation of new tissue in areas that are diseased or received trauma. In addition to their 
proliferative capacity, ASCs also decrease inflammation and release growth factors, 
allowing focused healing. Their anti-inflammatory nature suggests potential for treating 
autoimmune and inflammatory diseases, such as rheumatoid arthritis, inflammatory 
bowel disease, and graft-versus-host disease. 
Clinical Applications and Published Clinical Trials 
ASC therapy is gaining popularity. Most studies report no adverse effects and the 
majority of outcomes were beneficial. However, rigorous trials are lacking and most 
publications are case reports and noncontrolled studies. 
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The clinical applications of ASCs discussed in this article are spinal cord injury; diabetes 
mellitus; breast reconstruction and augmentation; facial lipoatrophy; rheumatoid arthritis; 
multiple sclerosis; hematologic and immunologic disorders; complex perianal or 
enterocutaneous fistulas and tracheomediastinal fistula; bone tissue repair; cardiovascular 
disease; cancer; and musculoskeletal regeneration. 
Spinal Cord Injury 
Stem cells have been studied intensely for spinal cord injury because the damaged axons 
and neurotransmitter-producing neurons cannot be regenerated by the human body. As a 
result, individuals with spinal cord injury suffer loss of sensory and motor function below 
the site of injury. Scientists started working with stem cells with the hope that they would 
promote new regeneration of neurons to promote healing. Indeed, in 2011, eight patients 
with spinal cord injury who were treated with intravenous infusions of autologous ASCs 
were shown to have improved motor function after 12 weeks. 
Type 1 Diabetes Mellitus 
Type 1 diabetes mellitus occurs because of autoimmune attack on pancreatic cells. The 
number of beta islet cells is reduced as a result, leading to decrease in insulin and C-
peptide production. ASCs were studied for their ability to regenerate pancreatic beta islet 
cells. In a study of ASC therapy administered to five patients with diabetes, results 
showed a 30% to 50% decrease in insulin requirements and increase in serum C-peptide 
levels during a follow-up period of 2.9 months. No adverse effects were noted. 
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Breast Reconstruction and Augmentation and Facial Lipoatrophy 
It should come as no surprise that ASCs have the potential for adipose tissue 
regeneration. In 2008, ASCs were used successfully for breast augmentation. Normally, 
the body resorbs injections of unprocessed adipose tissues. However, when patients were 
injected with a mixture of ASCs and unprocessed adipose tissue, they retained the 
volume over the next 12 months. Similar success was shown in facial lipoatrophy. 
Autoimmune Diseases 
ASCs have potential for treatment of autoimmune diseases. In 2010, there was a case 
report of ASC use in a 67-year-old woman with rheumatoid arthritis. She was treated 
with autologous ASCs isolated from liposuction; subsequently, she reported reduced joint 
pain and stiffness. Additionally, authors measured the levels of rheumatoid factor as a 
more objective measurement and noted a decrease after treatment. The patient had no 
side effects. 
ASCs have also been used for the treatment of multiple sclerosis, another autoimmune 
disease. Three patients with multiple sclerosis received intravenous infusions of ASCs, 
allogeneic CD34+ cells, and mesenchymal cells. Patients reported significant 
improvement of symptoms. 
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Hematologic and Immunologic Disorders 
Researchers have also studied ASCs for the treatment of graft-versus-host disease, 
idiopathic thrombocytopenic purpura, and pure red-cell aplasia. Patients were given 
intravenous infusion of allogeneic ASCs. Treatment was successful in graft-versus-host 
disease and pure red-cell aplasia; in idiopathic thrombocytopenic purpura, remission was 
achieved. However, the effect of ASCs on alloreactivity in patients who have undergone 
solid-organ transplantation is not yet known. 
Fistulas 
Potential use of ASCs for fistulas has been demonstrated in treatment of perianal, 
enterocutaneous, and tracheomediastinal fistulas. To study the effect of ASCs on perianal 
and enterocutaneous fistulas, the fistulas of the patients were injected with autologous 
ASCs mixed with proteinaceous fibrin glue. Results of phase 1 and 2 clinical trials 
showed four times the healing compared to the control group. Again, no adverse effects 
were reported. 
To study the effect of ASCs on a patient with lung cancer-induced tracheomediastinal 
fistula, the patient’s fistula was injected with autologous ASCs mixed with fibrin glue. 
Epithelialization of the fistula was observed three months later and was completely 
closed one year after treatment. This case is particularly encouraging, as fistula 
progression into blood vessels occurs frequently and is often fatal. No side effect was 
noted. 
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Bone Tissue Repair 
In 2004, there was a case report on a seven-year-old girl who had a calvarial defect from 
a severe head injury. The first attempt at treatment, fixation of calvarial fragments via 
titanium miniplates, was unsuccessful. She was then treated with a mixture of autologous 
ASCs and autologous bone from the iliac crest. Three months after the surgery, computed 
tomography scan confirmed successful calvarial bone formation. 
Cardiovascular Diseases and Cancer 
Not all studies with ASCs have shown positive results. Study of ASCs for treatment of 
acute myocardial infarction and cancer are two examples where results have been 
inconsistent. 
Musculoskeletal Regeneration (Clinical Study on Animal Models) 
Musculoskeletal regeneration is an area of intense research because there is a limited pool 
of muscle progenitor cells, called satellite cells. Therefore, ASCs were used as a potential 
therapy for muscular disorders. In 2006, intravenous injection of allogeneic ASCs was 
shown to restore muscle function in murine muscular dystrophy. Successful use of ASCs 
in intervertebral disc regeneration has been also reported. In addition, topical 
administration of adipose stem cells on rabbits’ tendons accelerated tendon repair rate 
and tensile strength was increased, supporting the transdifferentiation potential of the 
ASCs in vivo and in vitro. 
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Conclusion 
Though their effectiveness is still unproven, treatment with ASCs in regenerative 
medicine appears promising. However, their benefit in the treatment of cancer is 
particularly weak and presents a major concern, since ASCs secrete cytokines that may 
affect cancer metastases. More research is needed for conclusive evidence, and further 
work will be required to determine the safety of ASCs. 
Likewise, standard protocols for ASC studies do not exist yet. The ideal procedure for 
acquiring ASCs, the optimal number of stem cells that should be used for each procedure, 
and the safe number of stem cells that can be injected into different organs will have to be 
determined. 
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2.7 Breast: Cell Types Composing the Tissue 
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This article provides a brief introduction to the cell types that compose human breast 
tissue. It focuses on the anatomy of the human breast, the major types of tissues and cells 
in breast tissue, and the role stem cells play in normal breast tissue and pathologies. 
The human breast is located on the upper ventral region on the body and is a 
distinguishing feature of mammals. The breast is part of the skin and, therefore, part of 
the integumentary system. Breast tissue is composed of three main types of tissue: 
glandular tissue, connective tissue, and adipose tissue. The breast contains no muscle 
tissue. These components have various functions in the breast, which will be discussed 
further. The breast contains many lobes, which are composed of lobules. The lobules are 
composed of the aforementioned adipose tissue. These lobules give the breast its size and 
shape. All of these tissues are made up of various cell types that have different functions. 
The importance of stem cells in breast tissue is enormous. Breast cancer is the second 
leading cause of death for women in the United States, and it is a great concern among 
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health care professionals. Therefore, understanding how stem cells operate is critical for 
how some breast pathologies are treated. The use of stem cells in regenerative medicine 
has become more realistic in the past several years. 
Anatomy of Breast Tissue 
The base of the breast is attached to the thoracic cavity by the pectoralis muscles. The 
space located between the pectoralis muscle and the breast is referred to as the 
retromammary space. This space is responsible for providing mobility to the breast. The 
next layer of tissue is a layer of fat called adipose tissue, which forms the majority of the 
breast. Then the suspensory Cooper’s ligaments extend from the superficial fascia, which 
is located on top of the layer of adipose tissue, into the breast to provide support. The 
lobules composed of adipose tissue form into a cone shape, which converge into the 
nipple. The areola, a dark pigmented area, surrounds the nipple. There are four major 
types of tissue in the human breast: epithelium, stroma, adipose tissue, and glandular 
tissue. The epithelium lines the surfaces and cavities throughout the body. The stroma is 
the connective tissue in the body. Adipose tissue makes up the majority of breast tissue 
and is composed of adipocytes (fat cells), preadipocytes, fibroblasts, endothelial cells, 
and various immune cells. There are two main types of adipose tissue: white adipose 
tissue and brown adipose tissue. The breast is also composed of glandular tissue. The 
breast is an apocrine gland that contains many sebaceous glands, which secrete sebum to 
waterproof the skin. Another apocrine function of the breast is to produce milk for 
infants. 
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Introduction to Stem Cells 
A stem cell is an undifferentiated cell that is capable of giving rise to more cells of the 
same type indefinitely, and from which other types of cells can arise through 
differentiation. There are two main types of stem cells: pluripotent stem cells and 
multipotent stem cells. Pluripotent stem cells have the ability to differentiate into any of 
the three types of germ layers: endoderm, mesoderm, and ectoderm. Multipotent stem 
cells have the ability to differentiate into multiple, yet limited cell types. An example of 
this is a blood stem cell that can differentiate into lymphocytes, monocytes, or 
neutrophils but cannot differentiate into bone cells or heart cells. 
Cell Types in Breast Tissue 
There are three major epithelial cell types in breast tissue. The epithelial cell types are 
basal cells, luminal cells, and myoepithelial cells. The epithelium is composed of luminal 
cells and myoepithelial cells. These major cell types express different patterns of keratin 
that helps distinguish between them. 
Luminal cells
These inner cells are surrounded by myoepithelial cells, which help expel secretions and 
assist in the movement of fluid. The luminal cells consist of differentiated cells and also 
many types of cells that are in between luminal cells and stem cells. 
Basal cells
These outer cells consist mostly of differentiated cells with several mammary stem cells. 
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Myoepithelial cells
These cells are sandwiched between the stroma and luminal cells in breast tissue. They 
are frequently found in the glandular epithelium and are involved in expelling secretions 
from the exocrine glands. 
Adipose-Derived Stem Cells (ASCs) 
As discussed earlier, adipose tissue is composed of adipocytes, or fat cells. ASCs have 
remarkable plasticity and have the ability to differentiate into several different cell types, 
including adipocytes, cardiomyocytes, chondrocytes, epidermal cells, endothelial cells, 
hepatocytes, myocytes, osteoblasts, cells similar to glial cells, and cells similar to 
neurons. 
These characteristics make ASCs a very useful type of stem cell. Furthermore, ASCs 
have shown the ability to differentiate into cells with angiogenic characteristics since they 
are derived from the stromal vascular fraction. The stromal vascular fraction of adipose 
tissue is the important portion because it contains a significant amount of preadipocytes, 
mesenchymal stem cells, endothelial progenitor cells, and immune cells such as T-cells, 
B-cells, mast cells, and macrophages. Also, ASCs have been identified as cells that
secrete growth factors such as insulin-like growth factor (IGF), hepatocyte growth factor 
(HGF), pro-angiogenic growth factor, and vascular endothelial growth factor (VEGF). 
These characteristics of ASCs make them extremely valuable tools for regenerative 
medicine. 
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Mesenchymal Stem Cells (MSCs) 
Mesenchymal stem cells have the ability to differentiate into osteoblasts, chondrocytes, 
myocytes, neurons, and adipocytes. MSCs are derived from mesoderm, which forms 
connective tissue in the body. However, the MSCs in breast tissue are derived from breast 
adipose tissue. These MSCs work to stimulate the growth of tumor cells in breast cancer, 
and can make the disease metastasize. MSCs play a role in basal-type cancer by 
degrading the extracellular matrix and facilitating the invasion of basal-like cancer cells. 
Further research on the role of MSCs in breast cancer progression should be performed. 
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Chapter 3: Regulatory Issues Regarding Fat Grafting 
This section is based on an article published in Plastic Surgery Pulse and reproduced here
with permission of © 2009 Quality Medical Publishing, Inc. 
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Autologous fat grafting or lipotransfer is a dynamic and widely accepted modality to 
improve functional and aesthetic form for volume loss or deformity due to aging, facial 
and body lipodystrophies, congenital anomalies, breast augmentation and reconstruction, 
wound healing, and other soft tissue deficiencies. Fat grafting has been praised as the 
ideal soft tissue filler due to its abundant supply, low donor site morbidity, versatility, 
and biocompatibility. A recent survey of American Society of Plastic Surgery (ASPS) 
members reported that 85% of facial aesthetic surgeons used the technique in face-lift 
procedures.
1
 Adipose-derived stem cells (ASCs) within adipose tissue have also 
demonstrated efficacy in wound healing and tissue engineering.
2
 Although fat grafting 
has been utilized for over a century, its popularity has markedly increased in recent times. 
Notable deviations and abuses from accepted practice have also become more common.  
In December 2014, the Food and Drug Administration (FDA) released three guidance 
documents that would change the regulation of human cells, tissues, and cellular- or 
tissue-based products (HCT/Ps) from adipose tissue, effectively restricting fat grafting 
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procedures to a study environment and requiring registration and report manufacturers (in 
this case, surgeons). These documents addressed same surgical procedure 
exception,
3
 minimal manipulation of HCT/Ps,
4
 and HCT/Ps derived from adipose
tissue.
5
 In the case of fat grafting in breast reconstruction and the use of stromal vascular
fraction (SVF) and adipose-derived stem cells (ASCs), HCT/Ps from adipose tissue 
would be considered as biologic drugs, and surgeons would need to apply for premarket 
FDA approval and a license.  
While the draft guidance is not yet finalized, it does provide the latest report to date of the 
FDA's perspective on the use of fat injections in breast reconstruction and the use of 
ASCs. A team of ASPS experts has reviewed the guidance documents and drafted a 
response to elucidate why these FDA interpretations are misguided.  
HCT/Ps 
The FDA regulates human cells and tissues to control the spread of communicable 
diseases. HCT/Ps are defined as products containing human cells or tissues intended for 
implantation, transplantation, infusion, or transfer into a human recipient. Notably, 
organs and blood products are regulated through other mechanisms. There are two types 
of HCT/P depending on the risk category: 361 (lower-risk) and 351 (higher-risk) 
HCT/Ps.  
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361 HCT/Ps 
A subset of category 361 includes procedures that take place in the same operative 
session, which are exempt from FDA regulation, but are guided by laws established by 
state medical boards and professional societies. 361 HCT/Ps require registration and 
product listing with the FDA. Products fall under this category with the following 
conditions. This lower-risk category:  
 is minimally manipulated (for cells and nonstructural tissue, processing does not
alter the relevant biologic characteristics; for structural tissue, processing does not
alter the original characteristics of the tissue related to the tissue's utility for
reconstruction, repair, or replacement).
 is intended for homologous use (that is, the HCT/P performs the same function in
the recipient and the donor).
 does not combine cells, tissues, drugs, or devices.
 does not have systemic effect or does not depend on metabolic activity of other
living cells for its primary function (or if metabolic, is autologous and for use in a
first- or second-degree relative).
351 HCT/Ps 
351 HCT/Ps include drugs and biologics that are under the jurisdiction of FDA regulation 
and require a biologic license from the FDA.  
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Minimal Manipulation 
Defining "minimal manipulation" is an important consideration because regulatory 
pathways differ; if the product is more than "minimally manipulated," then the product 
must go through the therapeutic "351 HCT/P" category of FDA regulation. Exceptions to 
the rule include removal of an HCT/P from an individual and implant of the HCT/P to the 
same individual during the same surgical procedure (such as an autologous skin graft 
harvested and utilized for burn reconstruction), or licensed products. 
The primary function of HCT/Ps in the donor is used to determine whether the function is 
structural or nonstructural, and therefore how HCT/Ps should be regulated. The structural 
components of adipose tissue include adipocytes and the extracellular matrix. 
Decellularized fat tissue-derived extracellular matrix is considered more than minimally 
manipulated because processing alters the ability of the tissue to provide structural 
function. Manipulation of cells or tissues includes enzymatic digestion, separation of cell 
populations, cell culture and expansion, introduction of drugs or growth factors, and 
cryopreservation. Processing steps such as rinsing, cleansing, or sizing of the tissue are 
exempt.  
ASPS has requested that the FDA expand the scope of exemptions to include 
centrifugation of lipoaspirate in preparation for fat grafting, morselized cartilage for 
grafting, and dilation of a vessel graft using a solution containing a pharmacologic agent, 
for example, in free tissue transfer. ASPS has also drafted a response to redefine adipose 
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tissue as serving both structural and nonstructural functions, including endocrine, 
immune, and regenerative functions, such as in the treatment of radiation dermatitis. 
According to the current guidance statements, ASCs derived from the SVF for 
reconstruction and repair in the same operative session constitute a biologic drug and 
must be approved by the FDA in advance and tested in clinical trials before routine use in 
patients. The classification of ASCs as drugs by the FDA would add costs, resources, and 
time for surgeons who perform therapies with ASCs.  
Homologous Use  
Another issue is the definition of "homologous use." Although fat has many functions, 
including endocrine, metabolic, and immunologic, the FDA considers fat solely as a 
structural tissue that functions to cushion and support other subcutaneous tissues and 
defines the breast as having a sole function of lactation. Therefore, decellularizing 
adipose tissue eliminates its structural capacity, makes it more than minimally 
manipulated, and represents a nonhomologous use when applied to the breast. 
Furthermore, any surgeon who wishes to utilize SVF and isolate cells from a structural 
tissue must now submit an Investigational New Drug Application (IND) to the FDA and 
have an approved Institutional Review Board (IRB) application.  
ASPS Response 
The ASPS has proposed replacing the concept of "main donor function" to "intended 
use." The FDA defines skin with relationship to its external function (as a barrier to 
retain moisture and protection from the external environment); however, acellular dermal 
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matrix (ADM) is used internally in breast reconstruction. The structural function is 
preserved in ADM and should represent homologous use.  
ASPS has proposed that the definition of adipose tissue be expanded from solely 
structural to both structural and nonstructural, depending on intended use. The breast 
should be considered as a structural tissue with important functions in both lactation and 
sexual function. ASPS has proposed that fat grafting for breast reconstruction should be 
considered for homologous structural use that is only minimally manipulated. 
Furthermore, isolation and digestion of SVF from adipose tissue does not alter the 
relevant biologic characteristics of individual cells and therefore should be considered 
minimal manipulation. 
ASPS is also working to secure a meeting with the FDA's Center for Biologics 
Evaluation and Research and has addressed the draft guidance documents. The General 
Registry of Autologous Fat Transfer (GRAFT) of the Plastic Surgery Foundation (PSF) is 
a quality improvement initiative to establish a nationwide web-based registry of fat 
grafting for aesthetic and reconstructive breast surgery. Data collection will begin in 
October 2015 and will include patient demographics, procedural variables, complications, 
and the incidence of new or recurrent breast cancers. This data will be used to clarify the 
safety of fat grafting and to establish best practice guidelines.  
Plastic surgery leadership, including ASPS and PSF among others, is working to preserve 
the future of fat grafting and of our specialty.  
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Chapter 4: Autologous Fat Grafting to the Breast: A Systematic Review of Safety, 
Efficacy, Satisfaction, and Oncological Outcomes 
Summary
Background: There is tremendous interest in the use of autologous fat grafting (AFG) 
for aesthetic and reconstructive breast surgery. However, concerns have been raised 
regarding its safety and efficacy. The primary objective of this systematic review was to 
determine the safety, efficacy, satisfaction, and oncological outcomes of AFG to the 
breast. 
Methods: A systematic review was undertaken in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. 
Electronic databases searched included PubMed, MEDLINE, EMBASE, SCOPUS, 
Cochrane Library, and clinical trial registries on autologous fat grafting to breast tissue. 
Title and abstract screening and full text assessment undertaken separately by two 
independent researchers. Data was extracted and organized in a database. Random effects 
models were used to estimate pooled complication rates, breast cancer recurrence rates, 
and patient satisfaction. Meta-regression was performed using a random effects model to 
determine factors that predicted the outcomes of interest. 
Results: A total of 100 articles involving 7,817 patients with a mean follow-up period of 
25.8 months (1-156 months) were included. No randomized controlled studies were 
found. 2.77 percent of the patients undergoing fat grafting to healthy breast tissue 
experienced major complications requiring a surgical intervention or hospitalization. Fat 
necrosis was the commonest reported complication (48.16%), biopsy of a subsequent 
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breast lump was required in 140 cases. Two patients with breast cancer (0.11%) after 
AFG for cosmetic purposes were reported. 137 patients with breast cancer (2.26%) after 
AFG for reconstructive purposes were reported. Average breast volume gain ranged from 
27.1% to 106% relative to the grafted fat volume. 
Conclusions: AFG is a potentially useful aesthetic and reconstructive tool with a 
relatively low complication rate.  The majority of patients and clinicians are satisfied or 
very satisfied with the results. Long term clinical and radiological follow-up is required. 
Background 
The technique of autologous lipotransfer for cosmetic indications has long been 
employed in the field of plastic and reconstructive surgery. Gustav Neuber was amongst 
the first to introduce the concept of fat transplantation in 1893 through his work in the 
treatment of facial defects with lipofilling [1]. This technique was first adapted for the 
breast in 1895 by Czerny for the reconstruction of post-mastectomy defects through the 
transplant of an autologous lipoma [2]. In 1987, Bircoll and Novack further improved 
upon the practice of fat grafting through the use of autologous lipoaspirate for 
transplantation [3]. The procedure is now being used quite frequently for numerous 
indications. However, this evolution and rise in employment of the technique through the 
years has spawned concerns for safety by practitioners in the field. One such issue is the 
concern that autologous adipose stem cells are tumorigenic. Studies have shown, in both 
animal and human models, that adipose cells exert a positive regulatory effect on the 
proliferation of tumor cell lines [4, 5]. It was suggested by Freese et al., in their 
systematic review of the oncological impact of adipose derived stem cells, that these 
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adipose cells create an inflammatory tumor microenvironment, encourage angiogenesis, 
and possibly differentiate into carcinoma associated fibroblasts [6]. Concerns regarding 
the practice of fat grafting were initially not limited solely to the propagation of 
oncological transformation. In 1987, the American Society of Plastic Surgeons (ASPS) 
issued a report condemning the practice of fat grafting to breast tissue due to the lack of 
long-term clinical trials and the possibility that scarring and calcification resulting from 
the procedure could interfere with breast cancer diagnosis [7]. Continued research in the 
field has resulted in a reversal of the previously recommended moratorium with an 
investigation by the ASPS Task Force revealing no evidence of fat grafting impeding 
cancer detection or any indication that the procedure stimulates cancer recurrence [8]. 
However, though this report by the ASPS departed from the previous stance that fat 
grafting should be avoided, the task force was unable to make a confident 
recommendation due to a paucity of available data. Instead, the authors stated that the 
technique is a “promising and clinically relevant research topic” with the need for further 
study and investigation.   
Due to the requirement for further insight into this procedure, our study was undertaken 
to systematically review the literature in order to investigate autologous fat grafting 
(AFG) for both reconstructive and cosmetic breast procedures. In order to further 
elucidate the efficacy and safety of AFG indicated for both cosmetic breast augmentation 
and reconstruction post-mastectomy/breast conserving therapy the rate of complication 
occurrence, oncological occurrence, and patient satisfaction resulting from AFG was 
analyzed.  
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Methods 
A Literature search was undertaken in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Electronic databases 
searched included PubMed, MEDLINE, Cochrane Library, and clinical trial registries on 
autologous fat grafting to breast tissue. Title and abstract screening and full text 
assessment was undertaken separately by independent researchers. Data was extracted by 
two researchers and organized in a database. Random effects models were used to 
estimate pooled complication rates, breast cancer recurrence rates, and patient 
satisfaction. Meta-regression was performed using a random effects model to determine 
factors that predicted the outcomes of interest. 
Variables of Interest 
The outcomes of interest in this study were complication events (grouped into those 
requiring hospitalization or surgery and those not requiring hospitalization or surgery), 
breast cancer recurrence, and patient satisfaction. Satisfaction was determined from 
articles explicitly noting subjective patient reports of “good” or “excellent.” Numerical 
satisfaction surveys were not included in the analysis. Independent variables extracted for 
the analysis were procedure indication (cosmetic or oncological), follow-up time 
(months), and mean volume of autologous fat injected (mL). 
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Statistical Analysis 
The data analysis was divided into two phases. First, random effects models (selected due 
to the heterogeneity of study populations) were used to estimate pooled complication 
rates, breast cancer recurrence rates, and patient satisfaction rates. A total rate and 
individual rates for either cosmetic or oncological subgroups were calculated. Studies 
with a sample size of 1 were excluded from the meta-analysis (n=21). Second, meta-
regression with a random effects model was performed for our outcomes of interest. 
Predictor variables included in the model were the independent variables extracted and 
any relevant other outcomes, such as complication rates as factors predicting patient 
satisfaction. Data were analyzed using Comprehensive Meta-Analysis version 3.0 
(Biostat Inc., Englewood, New Jersey, USA). 
Results 
Out of 100 articles, 7,817 patients with a mean follow-up period of 25.8 months (1-156 
months) were analyzed. A mean volume of 166.0 mL of autologous fat per breast was 
injected, and average breast volume gain ranged from 27.1% to 106% relative to the 
grafted fat volume. 
Through meta-analysis, the pooled rate of complications requiring surgical intervention 
or hospitalization was 2.62% (n=52 studies, p<0.001). The rate of complications not 
requiring hospitalization determined was 8.40% (n=60 studies, p<0.001). Fat necrosis 
was the commonest reported complication (48.16%), and biopsy of a subsequent breast 
lump was required in 140 cases. The pooled rate of breast cancer complication was 
62 
2.54% (p<0.001), with an estimated rate in the cosmetic and oncological cohorts of 
1.70% and 3.04%, respectively (n=64 studies, p<0.0001). Two patients with breast cancer 
(0.11%) after AFG for cosmetic purposes were reported. 137 patients with breast cancer 
(2.26%) after AFG for reconstructive purposes were reported. Patient satisfaction rate 
determined by meta-analysis was 88.93% for the cosmetic cohort, 80.88% for the 
oncological cohort, and 84.72% overall (n=21 studies, p<0.001). 
For the meta-regression results, multiple factors were significantly associated with an 
effect on complications requiring hospitalization (n=35 studies). Mean volume injected 
predicted a slightly higher rate (b=0.005, p=0.010), while post-operative cancer 
recurrence (b=-0.094, p=0.006) and cosmetic indication (b=-0.579, p=0.033) predicted a 
significantly lower complication rate. None of these factors were significantly associated 
with complications not requiring hospitalization or surgical intervention. In the analysis 
for patient satisfaction rate (n=16), cosmetic indication was significantly associated with 
a lower satisfaction rate (b=-1.515, p=0.044). Mean volume injected and complications, 
both requiring and not requiring hospitalization, were not associated with satisfaction 
rate. Post-operative cancer recurrence (n=35 studies) was negatively associated with 
cosmetic indication (b=-1.673, p=0.001) and complications requiring hospitalization (b=-
0.109, p=<0.001), while number of follow-up months was a predictor for breast cancer 
recurrence (b=0.025, p=0.025). Mean volume of fat injected and complications not 
requiring hospitalization were not associated with cancer recurrence. 
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Discussion 
Many options exist for breast reconstruction after breast cancer therapy and cosmetic 
breast augmentation. One of the most popular options for elective breast augmentation in 
the past has been implant-based technique. In 2015, the ASPS reported that 279,143 
breast augmentations were carried out with the use of these implants. Though a popular 
and decidedly common procedure, this technique is not without its own risks and 
complications. In a report published by the FDA in 2011, twenty to forty percent of 
patients receiving primary augmentation and forty to seventy percent of patients 
receiving breast reconstruction via implant procedures required reoperation upon the 
breast in the first eight to ten years after the initial operation [9]. In one study of Allergen 
silicone implants, rupture was experienced in 10.1% of cases in breast augmentation and 
in 27.2% of reconstructions post cancer treatment. Additionally, significant rates of side 
effects such as capsular contracture were also reported by the study.  Upon analysis of the 
data obtained by our review, the overall complication rates for breast augmentation and 
breast reconstruction with fat grafting appear to compare favorably with complication 
incidences experienced with breast implantation. Our study determined the rate of serious 
complications requiring surgery or hospitalization to be 2.62% and the rate of minor 
complications to be 8.40%. This result suggests superiority to other reconstruction 
methods when compared to a study by Alderman et al. investigating breast reconstruction 
complication rates of TRAM and implant based procedures. This study found that 
complications occurred in 45.4% of their study population with 31.6% of patients 
experiencing major complications [10]. When compared to this study and the reoperation 
rates for silicone implant placement cited by the FDA, the use of fat grafting in breast 
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augmentation and reconstruction appears to not only be an equivalently safe alternative 
technique, but possibly a superior method for these procedures in terms of surgical 
complications.   
Beyond the surgical and perioperative complications of fat grafting, a major focus of 
concern by the medical community has been upon the oncological safety of grafting 
adipose tissue to the breast.  Numerous studies have indicated a link between adipose 
derived stem cells and oncological promotion.  One such study found that adipose tissue 
contained multiple progenitor cells that encouraged metastasis and cancer growth [11]. 
Many clinical trials have also been undertaken to investigate this link of autologous 
lipotransfer to oncological stimulation in breast tissue. One such study carried out by 
Petit et al. investigated the rate of breast cancer recurrence in 59 patients with 
intraepithelial neoplasia after undergoing reconstruction with lipofilling [12]. This study 
determined that patients undergoing fat grafting experienced an 18% five-year 
locoregional recurrence rate compared to a 3% recurrence rate in those patients not 
undergoing a lipofilling procedure. While this result did not bode well for the prospects 
of fat grafting in breast procedures, other studies have indicated more encouraging 
findings. In a study by Kronowitz et al. of 719 breasts reconstructed with lipofilling and 
670 without following segmental or total mastectomy indicated for breast cancer 
treatment, locoregional recurrence was observed in 1.3% of the cases undergoing 
lipofilling and 2.4% of breasts reconstructed without fat grafting [13]. This equated to a 
five-year locoregional recurrence rate of 1.6% and 4.1% for the lipofilling and non-
lipofilling reconstruction cohorts, respectively. The data compiled by our analysis 
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indicated a similar oncologic safety profile with a pooled breast cancer complication rate 
of 2.54%, 1.70% in the cosmetic augmentation cohort and 3.04% in the oncological 
reconstruction cohort. In contrast to the study by Petit et al., these rates are indicative of a 
very low occurrence of malignant stimulation by the transplanted fat grafted to both 
healthy and previously cancerous tissue. Based upon these results, it appears that fat 
grafting can be employed for breast reconstruction and augmentation purposes without 
placing the patient at an overtly elevated risk for the development or recurrence of breast 
malignancy.   
In addition to exhibiting an acceptable complication and oncological incidence rate, fat 
grafting to breast was also shown to result in excellent patient satisfaction based upon our 
analysis. Of the patients receiving lipofilling for reconstructive and cosmetic purposes, 
satisfaction rates of 80.8% and 88.93% were observed respectively. The pooled 
satisfaction rate amongst all patient cohorts was determined to be 84.72% overall (n=21 
studies, p<0.001). This level of satisfaction compares favorably to the level of 
contentment achieved through the use of implant based procedures. One study of 1529 
women receiving breast implants for both cosmetic and reconstructive purposes by 
Handel et al. revealed an average satisfaction level of 4.4 out of 5 resulting from breast 
augmentation and 4.0 out of 5 for those undergoing reconstruction with implants [14]. 
Another study of 450 patients receiving saline implants carried out by Cunningham et al. 
revealed 93% of patients were satisfied or very satisfied with the result of their breast 
augmentation [15]. Based upon these comparisons, fat grafting appears to be nearly as 
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efficacious in achieving patient satisfaction following breast augmentation and 
reconstruction as implant based techniques.   
Conclusions 
Based upon the results of the analysis, it appears that autologous fat grafting for the 
purposes of breast augmentation and reconstruction is both efficacious and safe. 
Oncological and surgical complication rates determined by this study indicate favorable 
results when compared to studies of other reconstructive methods. Additionally, patient 
satisfaction appears to be non-inferior when compared to implant based techniques. 
Currently, it appears the technique of autologous fat grafting is a viable tool for breast 
procedures both in the cosmetic and reconstructive setting.     
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Table 4-1: Fat grafting for cosmetic augmentation. 
Author, Date n Mean volume 
injected/breast (mL) 
Surgeries 
required 
Minor 
Complications 
Major 
Complications 
Cancer 
Occurrence 
Reported 
Follow-up time 
(months) 
Cheng Li et 
al. 2014[16] 105 205 (120 to 250) 1.28 3  0 0 18 (6-72) 
Derder et al. 
2014[17] 10 285 (200-500) 2 (1-4) 1 0 0 68 (60-77) 
Klit et al. 
2014[18] 11 210 (95-370) 1 (1-3) 0 0 0 13 (7-63) 
Peltoniemi et 
al. 2013[19] 18 292 (180-438) 1 3 0 0 18-24
Auclair et al. 
2013[20] 197 NR 1 2 1 0 
5 (1 month to 3.25 
years) 
Bulgin et al. 
2013[21] 1 185 1 0 0 0 12 
Khouri et al. 
2012[22] 71 282 (90-600) 1 12 1 0 44 
Kim et al. 
2012 [23] 1 NR NR 0 1 0 42 
Del Vecchio 
2012[24] 12 625 1 0 0 0 12 
Del Vecchio 
and Bucky 
2011[25] 25 220-550 1 0 0 0 6 
Kamakura et 
al. 2011[26] 20 
244.9 right breast, 
235.1 left NR 2 0 0 9 
7
3
 
Veber et al. 
2011[27] 31 200.8 +/-64.8 NR 8 0 0 16 
Lee et al. 
2011[28] 1 250 NR 0 1 0 9 
Wang et al. 
2011[29] 48 50-170 1-4 13 0 0 NR 
Yang and lee 
2010[30] 1 972 4 1 0 0 53 
Delay et al. 
2010 [31] 1 161.8 5 0 0 0 12 
Talbot et al. 
2010[32] 1 100 1 0 1 0 1 
Yoshimura et 
al. 2010[33] 15 
R: 268+/-29, L: 259 
+/- 39 1 0 0 0 12 
Uberreiter et 
al. 2010[34] 52 184 (120-293) 
2 in 85% 
cases 2 0 0 6 
Herold et al. 
2010[35] 10 (150-293) 1 0 0 0 6 
Mu et al. 
2009[36] 157 90-360 NR 0 9 0 15 
Illouz and 
sterodimas 
2009[37] 439 145 (25-180) 3 (1-5) 129 13 0 12 
Lazzarettie et 
al. 2009[38] 1 NR NR 0 1 0 120 
Hyakusoku et 
al. 2009[39] 12 NR NR 2 12 0 39 
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Delay et al. 
2009[40] 136 NR NR 10 1 0 12 
Wang et al. 
2008[41] 33 50-60 3 (1-5) 1 0 0 NR 
Zocchi and 
Zuliani 
2008[42] 181 375 (160-745) NR 19 0 0 12 
Pinsolle et al. 
2008[43] 8 96 (25-200) 2.1 (1-5) 0 1 0 NR 
Zheng et al. 
2008[44] 66 
101 (60-120) into 
subq 73 (60-90) into 
subglandular tissue 1.83 9 2 0 37(13-61) 
Yoshimura et 
al. 2008[45] 40 
total: 270 mean R: 
277+/- 39, L: 268 
+/- 48 1 2 0 0 6 
Carvajal and 
Patino 
2008[46] 20 NR NR 0 0 0 34.5 
Coleman and 
Sabeiro 
2007[47] 15 278.6 NR 4 0 2 67 
Pulagam et al. 
2006[48] 1 NR NR 1 0 0 156 
Kwak et al. 
2004[49] 1 NR NR 0 1 0 NR 
Valdatta et al. 
2001[50] 1 NR NR 0 1 0 NR 
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Castello et al. 
1999[51] 1 NR NR 0 1 0 10 
Maillard 
1994[52] 1 NR NR 0 1 0 36 
Horl et al. 
1989[53] 1 NR NR 0 1 0 1 
Matsudo and 
Toledo 
1988[54] 21 NR NR 8 0 0 18 
Bircoll and 
Novack 
1987[3] 1 100 1 0 0 0 36 
Bircoll 
1987[55] 1 90 1 0 0 0 30 
Major complications described as those requiring hospitalization or additional surgical treatment.   
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Table 4-2. Fat grafting for reconstruction post surgical breast cancer intervention. 
Author, 
Date 
n Mean volume 
Injected/breast (mL) 
Surgeries 
required 
Minor 
Complications 
Major 
Complications 
Cancer 
Occurrence       
Follow-up time 
(months) 
Kaoutzanis 
et al. 
2016[56] 108 50 (15-180) 1.3 (1-4) 1 0 0 20.2 (6.3-57.4) 
Kim et al. 
2014[57] 102 49.3 (10-183) 1-3 18 0 1 NR 
Silva-
Vergara et 
al. 2016[58] 195 160 (20-480) 1.6 23 3 10 31 
Pinell-
White at al. 
2015[59] 46 29 (10-90) 3.57 NR NR 3 50.4 
Weichman 
et al. 
2013[60] 100 147.8 (22-564) 1.12 0 1 0 18 (12-41) 
Al-Kalla et 
al 2014[61] 1 
70, 141, 20 mL in 
successive procedures 3 0 0 0 6 
Biazus et al. 
2015[62] 20 121 (68-228) 1 6 0 0 20.75 (13-29) 
Brenelli et 
al. 2014[63] 59 
52.3 first, (32.8, 52.8 
for second and third 
defects) 1.3 3 0 3 34.4 +/-15.3 
Uda et al. 
2014[64] 14 256 (150-400) 2.3 0 2 0 21 (6-54 
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Bonomi et 
al. 2013[65] 31 247 (80-455) 1.4 (1-2) 3 0 1 21 (6-36) 
Chaput et al. 
2013 [66] 1 NR NR NR NR 1 4 
Ihrai et al. 
2013[67] 64 
38 (10-80) 1st session, 
60 for 2nd and third 
1.57 (1-
5) 1 0 2 46.4 SD 21.4 
Le Brun et 
al. 2013 
[68] 42 80 1.3 NR NR 0 24.5 (12-192) 
Petit et al. 
2013[12] 59 NR NR NR NR 6 38 
Beck et al. 
2012 [69] 10 76.5 1 NR NR 0 36 
Cigna et al. 
2012[70] 20 NR NR 1 0 0 6 
Doren et al 
2012[71] 278 50 (5-200) 2 45 0 9 28 (0.56-168) 
Mestak and 
zimovjanov
a 2012[72] 14 NR 1.4 (1-3) NR NR 0 3 to 12 
Parikh et al. 
2012[73] 37 42.8+/- 26.0 2.2 39 0 1 12 minimum 
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Perez-cano 
et al. 
2012[74] 67 
1st session 91 (23-
163), 6 months 81 (22-
143). Median defect 
volume was 100 (35-
150) 1.35 10 0 0 12 
Petit et al. 
2012[75] 
321 
AFG 
group 
(642 
control NR NR NR NR 8 26 
Petit et al. 
2011[76] 513 107.3 (5-400) 1.3 17 1 29 19.2 (1-107) 
Rietjens eta 
al. 2011[77] 
155 
oncologi
cal 
patients 48 (6-183) 1.2 7 0 1 18.3 (6-49) 
Rigotti et al. 
2010[78] 137 NR NR NR NR 14 
91.2 (37.2-
229.2) 
Sinna et al. 
2010[79] 200 176 (35-405) 1.22 2 6 0 14.5 (4-52) 
Delaporte et 
al. 2009[80] 15 600 3 (2-5) NR NR 0 28 (7-49) 
Delay et al. 
2009[40] 734 NR NR 29 0 0 
12 clinical, 120 
for oncology  
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Fitoussi et 
al. 2009[81] 1 NR NR NR NR NR 12 
Iannace et 
al. 2009[82] 15 100 4.1 NR NR 0 12 
Illouz and 
Sterodimas 
2009[37] 381 
145 (25-180)/ session. 
Total mean =540 (25-
900)  3 (1-5) NR NR 0 12 
Kanchwala 
et al. 
2009[83] 110 31 (18-48) 2 NR NR 0 21 (6-84) 
Panettiere et 
al. 2009 
[84] 20 24.5 (8-50) 3.4 (1-7) 0 0 0 17.6 +/-6.7 
Amar et al. 
2008[85] 15 62.3 (30-100) 1 5 0 0 9 
Cotrufo et 
al. 2008[86] 42 NR NR 1 0 0 7 
Delay et al. 
2008[87] 42 154 (43-227) 1.3 NR NR 6 20.5 
Missana et 
al. 2007 
[88] 69 
prosthesis 107, LD 
and prosthesis 147.2, 
LD 142.5, TRAM 
142.1, conservative 
treatment 75 1.1 NR NR 0 11.7 (1-38.4) 
Pierrefeu-
lagrange et 
al. 2006 
[89] 30 164.7 (34-290) 1.1 NR NR 0 NR 
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Pulagam et 
al. 2006[48] 1 NR 1 1 0 0 NR 
Spear et al. 
2005[90] 37 116 1.1 4 0 0 
15 (3 weeks - 7 
years) 
Sarfati et al. 
2011[91] 28 115 (70-275) 
3 (2-3) 
prior to 
implant 
placemen
t 3 1 0 17 (4 to 34) 
Losken et 
al. 2011[92] 107 40 (5-150) 1.32 12 0 0 
8 (1 - 2.5 
years) 
Serra-
Renom et al. 
2010[93] 65 
150+/-25 1st stage, 
150+/-30  
2 fat 
grafts (6 
cases 
required 
3rd stage 
75 mL) 0 0 0 1 year 
de Blacam 
et al. 
2011[94] 49 67 1.63 3 4 0 
2.4 years (5 
months-4.1 
years) 
Salgarello et 
al. 2011[95] 42 
120 (25 to 231) for 
platelet enriched, 115 
(21-169) 
1.88 fat 
alone, 
1.82 
platelet 
group 
Total: 
1.86 8 0 0 9 months 
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Choi et al. 
2013[96] 90 
Group A (40 breasts): 
151 (111-216) Group 
B (42): 51 (12-72) 
Group C (41) 93 (75-
108) 0 0 0 140 days 
Costantini et 
al. 2013[97] 24 114.8+/-55 2.2 8 0 1 1 year 
Hoppe et al. 
2013[98] 28 159+/-61 
4 to 6 
(4.15) 6 1 1 
2.6 years (6 
months to 3.7 
years) 
Howes et al. 
2014[99] 1 400 1 0 0 0 1 year 
Khouri et al. 
2015[100] 488 225 (100 to 400) 3.2 5 25 6 
2.5 years (6 
months to 7 
years) 
Kronowitz 
et al. 
2016[13] 719 
1-100 (688 70.3%),
101-200 (210 21.5%),
201-300 (55 5.6%),
301-400 18 (1.8%),
401-500 (2 0.2%),
>500 (5 0.3%)
1:761 
(74.3%), 
2: 181 
(7.7%),3: 
36 
(3.5%) NR NR 26 60 
Laporta et 
al. 
2015[101] 20 211 (169-260) Mean 1.1 0 0 0 23 (12-34) 
Longo et al. 
2014[102] 21 
137 (90-175) non 
irradiated per session, 
108 (40-160) 
irradiated per session 
3 non 
irradiated
, 5.4 
irradiated 0 0 0 
34.8 (23-52) 
non, 17.2 (6-3) 
radiation  
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Mestak et 
al. 
2013[103] 1 
840 total to right, 790 
left (1: 260, 
210/2:280,280/3:300,3
00) 3 0 0 0 4 
Garcia et al. 
2016[104] 37 50 (20-80) 1 11 0 0 12 
Riggio et al. 
2013[105] 60 
47.13, 38.28 2nd sess, 
55.12 3rd 1.37 NR NR 6 92.2 (5-132) 
Schultz et 
al. 
2012[106] 43 40 (6-200) 
1.55 (1-
3) 2 0 0 
6 months or 
longer 
Seth et al. 
2012[107] 69 
20 to 50 (absolute 
range 20 -200) 1.1 (1-4) 1 0 0 
24.8+/-5.9 fg 
group 
Tissiani and 
Alonso 
2016[108] 19 NR NR 1 3 0 
16 month 
control, 36 SG 
Mestak et 
al. 2016 
[109] 32 NR NR NR NR 2 27 (14-88) 
NR: not reported. Major complications described as those requiring hospitalization or additional surgical treatment. 
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Chapter 5: Autologous Fat Grafting to the Breast: An Institutional Review of 
Safety and Oncological Outcomes 
Summary:
Background: Autologous fat grafting has been widely used for more than two 
decades during breast reconstruction for postmastectomy patients. However, few 
studies evaluate clinical outcomes in this patient population. The purpose of this 
study was to assess complications, radiographic changes and locoregional cancer 
recurrence outcomes in patients undergoing autologous fat grafting after breast 
reconstruction in postmastectomy patients. 
Methods: We retrospectively reviewed the records of consecutive postmastectomy 
patients who underwent autologous fat grafting after breast reconstruction at a 
university center over a 10-year period. Patients with at least 3 months of follow-up 
were included. Medical records were reviewed for demographics, operative details, 
complications, incidence of palpable masses, and/or suspicious breast imaging 
findings, and locoregional cancer recurrence. Descriptive statistics were generated. 
Results: The records of 124 patients undergoing lipofilling procedures from January 
2006 to January 2016 were reviewed. Their ages ranged from 23 to 79 years (mean, 
45.77 years). Fat grafts were harvested, processed, and injected using the Coleman 
technique. The mean number of fat grafting procedures was 1.50 (range, 1-6) per 
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breast, receiving 97.2 mL of autologous adipose on average during each session. The 
most common indication for reconstruction in this study was found to be for aesthetic 
correction following mastectomy (90.6 % of patients). Fat grafting was most 
commonly used as an adjunctive therapy following initial implant (54.9% of patients) 
and flap (43.4% of patients) reconstruction. The time from first oncological surgery to 
fat grafting occurred after a mean of 27.51 months and median of 14 months. 
Following the completion of fat grafting, patients were followed by a plastic surgeon 
for an average of 1.054 months. Twenty-six complications were found to have 
occurred, resulting in a complication rate of 21.3% in this population of patients. The 
most commonly reported complications were liponecrosis (19.2% of complications) 
and infection (15.3% of complications). During oncologic follow up, six patients 
were reported to have experienced breast cancer recurrence following autologous fat 
grafting for reconstruction resulting in a recurrence rate of 4.8%. Additionally, of the 
59 patients with reported radiologic follow up, seven patients exhibited radiological 
abnormalities in the post-operative period (11.9%).       
Conclusions: In this population of breast cancer patients who had mastectomy with 
reconstruction, fat transfer was not associated with a higher risk of cancer recurrence. 
Based on these preliminary findings, autologous fat grafting appears to be a relatively 
safe procedure for refinement of the reconstructed breast in postmastectomy patients.  
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Background: 
Mastectomy and breast-conserving surgery are important tools employed in the 
treatment of breast cancer. While they are life saving measures for many patients, 
these procedures often result in poor aesthetic outcomes. Many methods exist for 
post-surgical breast reconstruction to correct defects of oncologic therapy. One such 
method is that of autologous fat grafting (AFG). The technique of AFG was first 
reportedly utilized in post-mastectomy breast reconstruction by Czerny in 1895 
through the use of an autologous lipoma for aesthetic repair [1]. In 1987, Bricoll and 
Novack revolutionized the technique through the use of lipoaspiration for the 
acquisition of the autologous adipose tissue for radical post-mastectomy 
reconstruction [2]. Since this advancement, the practice has increased in popularity 
and employment in the field of reconstructive surgery. To this end, AFG often serves 
as an adjunctive procedure for the refinement of breast implant and flap-based 
reconstructions to improve residual contour and volume deficits [3]. Adipose tissue 
itself is ideal for such means as it is soft, formable, autologous, readily available, and 
easily harvested [4]. Furthermore, there exists a high level of satisfaction after AFG 
among both patients and providers (93.4% and 90.1%, respectively according to a 
review by Groen et al.) in part due to the relatively straightforward surgical process, 
low complication rate, and aesthetic outcomes associated with the procedure [5]. All 
of these factors have contributed to the widespread use of AFG. In fact, a 2013 survey 
of members of the American Society of Plastic Surgeons found that 62% of all 
respondents commonly used AFG for reconstructive breast surgery [6]. 
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Despite its popularity, AFG has not always been accepted as an acceptable treatment 
option for breast reconstruction. In 1987, the American Society of Plastic and 
Reconstructive Surgeons (ASPRS) advised against AFG due to concerns of potential 
adverse effects on breast imaging, specifically in screening for breast cancer and 
recurrence [7].  
Since this original ruling, several studies have shown that AFG is a reasonably safe 
option for refinement of breast reconstruction in this patient population. Complication 
rates, for example, remain on average between 0.9% and 8% per patient and include 
relatively benign occurrences such as donor and recipient site infection, hematoma, 
and palpable masses [8-10]. 
 
In 2012, the same organization issued a new position 
statement, indicating that AFG in postmastectomy breast reconstruction “yields 
aesthetic improvement and significant patient satisfaction,” with “relatively low” 
complication rates [11]. Despite this new stance, questions still remain about the 
overall safety of the technique and impact upon radiological surveillance.     
The purpose of this study was to address these concerns and the efficacy of the 
procedure through the analysis of clinical complications, radiographic imaging results 
and cancer recurrence in postmastectomy patients who underwent AFG after breast 
reconstruction. 
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Methods: 
We retrospectively reviewed the records of consecutive postmastectomy patients who 
underwent autologous fat grafting after breast reconstruction at a university center 
over a 10-year period (January 2006 to January 2016). Postmastectomy patients who 
underwent autologous fat grafting after breast reconstruction with 3 months of 
follow-up were identified using the Current Procedural Terminology (CPT) codes 
15770, 19361, 19364, 19366, 19367, 19368, 19369, 19380, 20926, S2066, S2067, 
and S2068. Medical records (operative reports for oncology and plastic surgery notes, 
and follow-up notes from clinic) were reviewed for demographic characteristics, 
breast cancer diagnosis and reconstructive and fat grafting operative details. The 
indications, location and volume for grafting were also recorded. Data on oncologic 
follow-up, fat grafting complications, incidence of palpable masses, and/or suspicious 
breast imaging findings, and locoregional cancer recurrence were recorded.  
The clinical and demographic characteristics included age (years) at time of breast 
reconstruction, indication (cancer or cosmetic), location of cancer (right, left, 
bilateral), treatment (immediate, mastectomy, or breast conservative treatment), 
histopathology (ductal intraepithelial neoplasia, lobular intraepithelial neoplasia, 
invasive ductal carcinoma, invasive lobular carcinoma, other), histologic Grade, pT, 
pN, receptors (estrogen, progesterone, Her-2, triple negative), adjuvant therapy 
(lymphadenectomy, radiotherapy, chemotherapy, hormonal therapy), and follow up to 
oncologist (months). 
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The oncologic follow-up and lipofilling operative data included the procedure, type of 
breast reconstruction (implant, type of flap, etc), date of AFG case, number of fat 
grafting sessions, volume injected in mL (specified left or right and if more than one 
time), follow up to plastic surgeon after AFG case (months), time from oncologic 
surgery to AFG (months), and if an inpatient or outpatient. 
The lipofilling complications included presence and type of complication, 
(liponecrosis/oil cyst, prosthesis rupture, hematoma, infection, donor site 
complication), breast cancer recurrence and radiographic changes.  
Lipofilling technique: 
Autologous fat grafting was performed under general anesthesia. Fat was prepared 
and grafted according to the standard Coleman technique. After harvest from the 
abdomen or flanks, the fat was centrifuged with the resulting oil and serous 
components decanted. The processed fat was transferred to 3-mL syringes and 
injected using blunt infiltration cannulas, placing a small aliquot of fat with each 
withdrawal of the cannula. All 4 surgeons' technique remained consistent throughout 
the period of the study.  
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Results: 
For the purposes of this study, the records of 124 patients undergoing lipofilling 
procedures from January 2006 to January 2016 were reviewed. The median age of the 
patients at the time of first lipofilling procedure was 45.77 (range 23 to 79 years). 
Patients included in this study population received a mean number of 1.5 fat grafting 
sessions per breast, receiving 97.2 mL of autologous adipose on average during each 
session. The most common indication for reconstruction in this study was found to be 
for aesthetic correction following mastectomy (90.6 % of patients). Fat grafting was 
most commonly used as an adjunctive therapy following initial implant (54.9% of 
patients) and flap (43.4% of patients) reconstruction. The time from first oncological 
surgery to fat grafting occurred after a mean of 27.51 months (median=14 months). 
Additional clinical and lipofilling data are indicated in Tables 1 and 2, respectively.     
Following the completion of fat grafting, patients were followed by a plastic surgeon 
for an average of 1.054 months. Twenty-six complications were found to have 
occurred, resulting in a complication rate of 21.3% in this population of patients. The 
most commonly reported complications were liponecrosis (19.2% of complications) 
and infection (15.3% of complications). During oncologic follow up, ten patients 
were reported to have experienced breast cancer recurrence following autologous fat 
grafting for reconstruction resulting in a recurrence rate of 10.5%. Additionally, of 
the 59 patients with reported radiologic follow up, seven patients exhibited 
radiological abnormalities in the post-operative period (11.9%).      
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Table 5-1 Clinical and Demographic Characteristics 
n % 
Location 
   Left  52  47.3 
   Right  45  40.9 
   Bilateral  13  11.8 
Indication 
   Cancer  118  92.9 
   Cosmetic  9  7.1 
Treatment 
   Mastectomy  60  50.8 
   Bilateral mastectomy  47  39.8 
   Lumpectomy 4 3.4 
   Other / not specified  7  5.9 
Histopathology 
   Ductal intraepithelial neoplasia  28  30.8 
   Lobular intraepithelial neoplasia  1  1.1 
   Invasive ductal carcinoma  48  52.7 
   Invasive lobular carcinoma  5  5.5 
   Other  9  9.9 
Histologic Grade 
   I  10 23.2 
   II  11 25.6 
   III  22 51.2 
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pT 
   1  35  57.4 
   2  23  37.7 
   3  1  1.6 
   4  2  3.3 
pN 
   Positive lymph nodes  30  37.0 
   Negative lymph nodes  51  63.0 
Receptors 
   Estrogen  56  65.1 
   Progesterone  42  48.8 
   Her-2  18  20.9 
   Triple Negative  12  14.0 
Adjuvant therapy 
   Lymphadenectomy  2  2.3 
   Radiotherapy  30  34.5 
   Chemotherapy  65  74.7 
   Hormonal therapy  28  32.3 
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Table 5-2 Oncologic follow-up and lipofilling data 
n % 
Type of Breast Reconstruction 
   Implant  67  54.9 
   Flap  53  43.4 
   Other  2  1.6 
Number of fat grafting session (mean)  1.50 
Total volume Injected (mean, mL)  97.2 
Follow-up to plastic surgeon after FG case (mean, 
months) 
 1.054 
Time from oncologic surgery to FG (mean, months)  27.51 
(median=14 
months) 
Inpatient  10  8.1 
Outpatient  114 91.9 
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Table 5-3 Lipofilling complications 
n % 
Complication 
   Yes  26 21.3 
   No  96 78.7 
If yes, type 
   Liponecrosis  5  4.1 
   Oil Cyst  1 0.08 
   Prosthesis rupture  2  1.6 
   Hematoma  1  0.08 
   Infection  4  3.3 
   Donor site complication  4  3.3 
Breast cancer recurrence 
   Yes  10 (6 
specifically 
after AFG) 
 10.5 
   No  85  89.5 
Radiographic changes 
   Yes  7 11.9 
   No  52  88.1 
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Discussion: 
In recent years, fat grafting has become an oft-used tool for reconstructive procedures 
indicated in the repair of defects secondary to oncological breast surgery. Since the 
reversal of the previous admonishment of the practice by the ASPS, the technique 
greatly increased in frequency of use [11]. The procedure is often employed, as was 
the case in this study, as an adjunctive aesthetic procedure following implant or flap 
repair to correct residual defects. Due to the popularity and utility of this procedure, 
several studies have investigated the safety of this procedure in terms of surgical 
complications. In a systematic review of AFG in post mastectomy breast 
reconstruction by Agha et al., it was determined that the overall complication rate 
observed following AFG procedures was 7.3% [12]. Furthermore, 62% of the 
complications in the 35 studies reviewed were found to be due to the relatively benign 
condition of liponecrosis. Compared to the complication rate determined by Agha et 
al., the complication rate exhibited by the cohort of this study was significantly higher 
at 21.3%. Despite this inferior complication rate, the results of our study are 
encouraging as a great deal of the complications reported were not significant. In fact, 
23.1% of all complications were due to liponecrosis or oil cysts discovered in the 
post-operative period. Therefore, this procedure can still be considered to have a 
relatively favorable safety profile based upon the data.   
In addition to surgical complications, many questions have arisen concerning the 
oncological safety of lipofilling. Adipose tissue has previously been discovered to 
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promote angiogenesis and create an inflammatory microenvironment, two actions that 
are feared to promote tumorogenesis [13]. A recent study of adipose tissue harvested 
from healthy human donors found that adipose derived stem cells stimulated the 
metastasis of a tumor cell in a mouse host when compared to injection of tumor cells 
only [14]. Due to these concerns and discoveries, multiple investigations have been 
directed towards the oncological effects of fat grafting to breast tissue.  In the review 
by Agha et al., the incidence of new or recurrent breast cancer was determined to be 
4.4% [12]. A recent study of 195 patients undergoing AFG for breast reconstruction 
indicated a similar rate of oncologic occurrence of 5.1% [15]. The occurrence rate 
determined in our patient population was found to be 10.5%. The oncological 
occurrence determined in this study may be elevated due to the cohort investigated. 
Of the patients included in this investigation 34.9% were afflicted with HER-2 
positive or triple negative breast cancers, both poor prognostic indicators. 
Additionally, 22 patients were found to have grade III carcinomas. Additionally, in 
one large study focusing upon the oncological recurrence of breast cancer in 1027 
patients with stage I and II disease, the locoregional recurrence rate was found to be 
8% [16]. This recurrence rate is similar to that determined in our study, indicating an 
acceptable oncological outcome for lipofilling in post-mastectomy patients.    
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Chapter 6: Do Stem Cells Have an Effect When We Fat Graft? 
Fat Versus Fiction 
This section is based on an article published in Annals of Plastic Surgery and reproduced 
here with permission of Wolters Kluwer Health Lippincott Williams & Wilkins© 
Rinker BD, Vyas KS. Do Stem Cells Have an Effect When We Fat Graft? Ann Plast  
Surg. 2016 Jun;76 Suppl 4:S359-63. 
Summary: Fat grafting has become a widely accepted modality of soft tissue restoration 
and has found applications in many areas of aesthetic and reconstructive plastic surgery. 
Numerous claims have been made regarding the regenerative effects of fat grafting on the 
recipient bed. The purpose of this paper is to survey the available literature to answer the 
question of whether fat grafting has a positive effect on the surrounding tissues. It has 
been convincingly demonstrated that fat grafts contain viable adipose-derived stem cells 
(ASCs). The fate of these cells is determined by the microenvironment of the recipient 
bed, but animal studies have shown that a large fraction of ASCs survive engraftment. 
Numerous clinical studies have demonstrated the positive effects of fat grafting on 
recipient tissues. Improvement in validated scar scores as well as scar stiffness 
measurements have been documented after fat grafting of burn scars. Fat grafting has also 
been convincingly demonstrated to improve the quality of irradiated tissues, as measured 
by validated clinical scales and staged histology. It is ultimately unclear whether ASCs 
are responsible for these effects, but the circumstantial evidence is weighty. Fat grafting 
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is effective for volumizing and improving skin quality in the setting of radiation, burns, 
and other scars. The observed effects are likely due to ASCs, but the evidence does not 
support the routine use of ASC-enriched fat grafts. 
Introduction: Autologous fat grafting has become a widely accepted method used by
plastic surgeons to correct soft tissue defects due to its simplicity, versatility, low donor 
site morbidity, and biocompatibility. Fat grafts have been used as soft tissue filler to 
improve function and aesthetic form after trauma (1), thermal or radiation damage (2), 
the correction of congenital anomalies (3) or aging (4). In the aesthetic surgery arena, 
they have been used for body and facial contouring (5,6) and breast augmentation. 
However, the applicability of autologous fat grafting has been limited by variability in 
long-term graft retention, with estimates of the survival rate by volume ranging from 20% 
to 80% (7–10).   
The recent discovery of multipotent mesenchymal adipose tissue-derived stem cells 
(ASCs) in subcutaneous adipose tissue has encouraged the study of their role in 
enhancing fat grafts for applications in soft tissue augmentation, tissue engineering, and 
wound healing (11). The objective of this review is to evaluate the role of ASCs in 
clinical applications of fat grafting, to answer the question, “Do stem cells have an effect 
when we perform fat grafting?” Applying the deductive nomological model of logicians, 
this question can be addressed by reducing it to its 3 component parts, which are: (1) 
Does fat grafting transfer viable stem cells? (2) Does fat grafting induce tissue 
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regeneration? (3) Are the stem cells responsible for the observed regenerative effects? 
Does Fat Grafting Transfer Viable Stem Cells?  
In 2000, Halvorsen et al (12) described the osteogenic differentiation of ASCs, and in 
2001, Zuk et al (13) demonstrated adipose tissue as an easily accessible and abundant 
source of adult mesenchymal stem cells with multilineage potential. Although ASCs 
share many of the characteristics of other mesenchymal stem cells (14), including self-
renewal and multipotency, they can be obtained much more easily and with higher 
cellular yield. The ASCs are isolated from the stromal vascular fraction (SVF) of 
collagenase-digested adipose tissue. Adipose harvested through direct excision or with 
the Coleman technique with centrifugation has been shown to yield the most SVF cells 
and ASCs (15). The SVF is a heterogenous population of cells and rich source of ASCs, 
preadipocytes, vascular progenitors, fibroblasts, pericytes, macrophages, mast cells, and 
lymphocytes (16). Culture of SVF on a tissue culture surface with growth media yields an 
adherent and more homogenous population of ASCs that can be expanded in vitro and 
differentiated into cells of ectodermal and endodermal lineages, including adipocytes, 
osteoblasts, chondrocytes, endothelial cells, neuron-like cells, myocytes, and 
cardiomyocytes (12, 17–19).   
Factors influencing ASC populations include donor age (20), sex, harvesting and 
processing technique, harvest site (21), and other variables; this contributes to 
heterogeneity among results and influences complicates direct comparison of studies. The 
studies of ASCs in fat grafting must take into consideration patient variability, volume of 
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lipoaspirate and recipient site, and the number of SVF and ASCs in the lipoaspirate, 
which may account for the differences observed among studies. Some studies conclude 
that the lower abdomen or inner thigh are the preferable donor sites for adipose tissue 
harvesting due to the relative ease of access and high yield of ASCs (22), although the 
current literature does not support a significant difference in the volume or weight of 
grafted fat among donor sites (23). A recent systemic review of the literature revealed no 
significant difference in outcomes of grafted fat obtained from different donor sites, 
donor site preparations, harvesting technique, harvesting cannula size, centrifugation 
speed, or when tumescent technique was used. Clinical studies favored fat processed by 
centrifugation compared to sedimentation and higher retention was observed with slower 
reinjection in less mobile areas (24).   
Fat grafting has been used clinically for over 100 years, but the underlying cellular and 
molecular mechanisms of the engraftment process remain to be elucidated. Avascular fat 
grafts rely on diffusion for survival until revascularization occurs; this results in cell 
death with subsequent volume loss, fibrosis, and the development of oil cysts. The cell 
survival theory (25) and host replacement theory were the predominant hypotheses of the 
engraftment process until Eto et al (26) described the fate of adipocytes based on 3 zones 
defined by the local microenvironment and distance from the surface. Within the 
peripheral/regenerating zone, adipocytes and ASCs within 300 μM from the surface 
survive. Although viability may be preserved in the intermediate/ inflammatory zone, 
adipocytes in the central/necrotic zone die within the first 24 hours due to lack of 
nutritional diffusion, severe ischemia, necrosis, and graft resorption. The ASCs are more 
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resistant to hypoxic conditions (27), however, and survive for up to 3 days to regenerate 
the adipose tissue through adipogenesis, angiogenesis, and paracrine effects. More recent 
models suggest that recipient adipocytes may be more significant in replacing the 
necrotic adipocytes (28). A study using green fluorescent protein mice reveal that 
regenerated adipocytes mostly originate from ASCs within the grafted tissue, although 
only ASCs located adjacent to the necrotic adipocytes differentiated directly into 
adipocytes (29). In contrast, a recent transcriptional analysis of ASCs within grafted fat 
transplants demonstrated no changes in adipogenic differentiation, challenging the belief 
that ASCs contribute to regenerating adipocytes (30).  
Revascularization of the free fat graft is essential to graft survival and is influenced by 
ASCs. The ASCs differentiate into endothelial cells in vitro and were once thought to 
directly contribute to vasculogenesis after fat transfer (31). Studies of transgenic mice 
demonstrate that the neovasculature of fat grafts is derived from the recipient animal, 
refuting the direct contribution of ASCs in revascularization (28). The current 
predominant hypothesis is that ASCs promote revascularization of ischemic free fat 
grafts through the release of proangiogenic paracrine growth factors, including vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor, hepatocyte growth 
factor, and insulin-like growth factor-1 (32,33). Lipoaspirate supplemented with ASCs 
has been shown to improve angiogenesis and long-term graft retention through the 
release of these factors (34,35). Thus, ASCs are observed to survive after grafting, and in 
fact play a major role in adipocyte survival and differentiation. 
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Does Fat Grafting Induce Tissue Regeneration?  
Fat grafting was pioneered by Neuber and Czerny, working separately in Germany in the 
1890s (36,37). It was used enthusiastically by Gillies, who observed that the 
subcutaneous application of “fat parcels” improved the quality of scars. Autologous fat 
grafting fell from favor until the 1990s, when Coleman38 developed the technology of 
structured fat grafting and observed positive effects on the skin, even in the presence of 
severe atrophy and scarring.  
Wound repair is a process of inflammation, angiogenesis, tissue development, and 
remodeling. Fat grafting has been used as a treatment modality for complex wounds, 
burns, and scars due to its influence on the wound healing process, including stimulation 
of angiogenesis (39), release of cytokines and growth factors such as transforming 
growth factor-β, granulocyte colony-stimulating factor, and VEGF, recruitment of 
endogenous stem cells to thewound bed, and by direct differentiation into cells. Fat 
grafting has been shown to reduce inflammation and fibrosis, decrease hypertrophic 
scarring, and decrease healing time (40–42). Several applications of autologous fat 
grafting provide direct evidence for the regenerative effects of the technique. 
Scars 
Adult stem cells are important for the mobilization and coordination of cells during the 
healing process (43). The discovery of ASCs and refinement of the fat grafting and cell-
based therapy processes permitted the introduction of large numbers of ASCs into 
104 
targeted treatment areas to improve healing. Local injection of ASCs in a pig model has 
been shown to decrease scar size and pliability and improve color through the inhibition 
of TGF-β against fibroblasts, decrease activity of mast cells, and increase expression of 
matrix metalloproteinases that all contribute to scar remodeling (44). Pallua et al (45) 
reported decreased pain, improved scar color, quality, pigmentation, stiffness, and 
pliability in patients with facial scars treated with lipofilling. 
Radiation-Induced Injury 
Fat grafting can reverse chronic skin changes secondary to radiation, and these effects are 
likely mediated by ASCs. In an irradiated mouse model, human fat grafts were injected 
into the subcutaneous plane of the scalp, resulting in attenuated dermal thickness and 
collagen deposition and increased vascularity in the irradiated tissue compared to the 
non-irradiated tissue (46). In 2007, Rigotti et al (47) demonstrated improved tissue 
wound healing with neovessel formation and significant clinical improvement in breast 
cancer patients undergoing repeated transplantation of purified autologous lipoaspirates 
for radiationinduced wounds. In 2009, Panettiere et al (48) investigated the effects of fat 
grafting on the functional and aesthetic aspects of irradiated reconstructed breasts 
compared to control. A significant improvement in all clinical symptoms and aesthetic 
scores was achieved in the fat grafting group compared with the control group. 
Burns 
Fat grafting has also been successful in the management of thermal injury (49) and burn 
scars (41). Bruno et al (50) treated half of a scar area with processed lipoaspirate and 
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collected biopsies before treatment and at 3 and 6 months after the treatment. 
Immunohistochemical evaluation revealed a marked improvement in vascularity, dermal 
papillae, and increased collagen organization and elastic fibers with lipofilling. Klinger et 
al (51) reported on lipoaspirate treatment in 3 adult patients with hemifacial hypertrophic 
scars and keloids from severe burns. The scar was examined through punch biopsy before 
and after treatment and at 6-month follow-up revealed new collagen deposition, local 
hypervascularity, and dermal hyperplasia with a significant improvement in skin texture 
and thickness. Several other clinical studies have reported similar success with the use of 
lipoaspirate in the management of burn scars for not only filling soft tissue voids (52) but 
also for the resolution of pain and functional improvement. In a study by Klinger et al 
(42) of 20 patients with retractile and painful burn scars restricting normal daily activity
and joint mobility, autologous fat graft led to a significant improvement in joint mobility 
and scar appearance. Baptista et al (53) described the benefits of autologous fat grafting 
for the management of painful burn scars and noted improvement of symptoms in the 
majority of patients with no reported complications. Patients with severe burns may 
require serial transplantation to overcome underlying structural defects of the fibrotic 
tissue. 
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Figure 6-1. SVF in cell assisted lipotransfer or tissue culture. Liposuction of 
subcutaneous adipose tissue followed by centrifugation yields lipoaspirate. The oil layer 
is discarded to reduce the incidence of oil cysts. The SVF, which contains cells such as 
pre-adipocytes and adipose-derived stem cells, can be obtained through collagenase 
digestion and centrifugation of lipoaspirate. The SVF can be utilized in cell-assisted 
lipotransfer or can be cultured in vitro. Adipose-derived stem cells are multipotent and 
demonstrate plasticity in culture; these cells can be induced to differentiate into 
adipocytes, myocytes, osteoblasts, chondrocytes, endothelial cells, hepatocytes, 
hematopoietic cells, and other cell types by exposure to growth factors. 
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Figure 6-2. Conventional lipotransfer compared to cell-assisted transfer. In conventional 
lipotransfer, preinjection processing is limited to cleansing and centrifugation. In cell-
assisted lipotransfer, a portion of the lipoaspirate is subjected to enzymatic digestion and 
centrifugation to isolate the stromal vascular fraction, which contains adipose-derived 
stem cells and other cells thought to improve graft retention. These cells are added to 
lipoaspirate to yield a stem cell enriched lipograft. 
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Are the Stem Cells Responsible for the Observed Regenerative Effects? 
It has not been definitively proven that ASCs are the causative agent for the observed 
regenerative effects after fat grafting, rather than the trauma of injection or inflammatory 
mediators. However, the circumstantial evidence for ASCs is compelling. The ASCs have 
been shown to support tissue regeneration by differentiating to replace defective cells or 
through the release of paracrine factors that directly accelerate tissue repair via host-
derived cells (54). For example, ASCs secrete several growth factors in response to 
hypoxia, including the proangiogenic factor VEGF and anti-inflammatory cytokine 
interleukin (IL)-10 (54). The growth factors brain-derived growth factor, glial-derived 
growth factor, and nerve growth factor have been shown to augment nerve regeneration. 
The secretion of growth factors, such as VEGF, hepatocyte growth factor, insulin-like 
growth factor-1, granulocyte colony-stimulating factor, IL-6, and IL-8 can affect 
processes such as angiogenesis, wound healing, and/or immunomodulation. These 
paracrine effects of ASCs are likely responsible for the observed tissue regeneration after 
fat grafting for complex wounds, burns, scars, and radiation-induced skin injury.  
Additional circumstantial evidence for ASCs as the regenerative agent in fat grafting is 
provided by the observed effects of cell-assisted lipotransfer (CAL) (Fig. 1). Enrichment 
of fat grafts with concentrated ASCs through CAL significantly enhances volume 
retention (55) and neovascularization and reduces the adverse effects of lipoinjection, 
such as fibrosis and cyst formation (31). The CAL been heralded by some as superior to 
conventional lipoinjection (31, 56, 57). The specific mechanisms contributing to 
improved fat graft volume retention with CAL are not well understood, but it is debated 
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thatASCs can differentiate directly into adipocytes and contribute to tissue regeneration 
and secrete antiapoptotic factors to reduce the loss of adipocytes (Fig. 2). A more 
evidence based hypothesis affirms the role of ASCs in the release of angiogenic growth 
factors that promote improved graft vascularization in the hypoxic graft environment 
(30). This process has been successful in cosmetic breast augmentation and soft tissue 
reconstruction (56, 58–61), facial contouring (62,63) and facial lipoatrophy (56,57,64).  
In a clinical trial of patients with craniofacial microsomia, CAL enhanced fat volume 
retention for facial recontouring compared with conventional lipoinjection (65). Kølle et 
al (66) conducted the first clinical study to assess the effect of lipofilling with fat grafts 
enriched with ex vivo expanded ASCs. This triple-blinded placebo-controlled clinical 
trial of 10 healthy adults demonstrated improved volume retention in fat grafts enriched 
with ex-vivo expanded ASCs compared to conventional fat grafts. However, not all 
clinical studies have reported improved graft survival rates with CAL. In 2 studies of 
women undergoing breast augmentation with CAL, there was no significant advantage of 
CAL over conventional techniques when measured by magnetic resonance imaging at 6 
months postoperatively (59,67).  
Conclusions 
Autologous free fat grafting is a safe and dynamic procedure used by plastic surgeons to 
improve functional and aesthetic form for volume loss or deformity for a variety of 
indications, including trauma, burn or radiation damage, scars and complex wounds, 
congenital anomalies, aging, body and facial contouring, and breast augmentation and 
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reconstruction. Current practice for autologous fat grafting for soft tissue reconstruction 
or augmentation has been limited by variability in long-term graft retention, resulting in 
suboptimal outcomes and repetitive procedures. Evidence-based research suggests that 
the SVF and ASCs may improve fat graft survival, largely through angiogenic properties, 
although superiority of cell-assisted lipotransfer over conventional lipotransfer has not 
been unequivocally demonstrated. The tissue regenerative properties of fat grafts in the 
setting of radiation, burns, and scars are likely due to ASCs. High-quality clinical trials to 
demonstrate safety and efficacy are necessary to guide the development of protocols for 
clinical practice. 
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Chapter 7: Profile of Adipose Derived Stem Cells in Obese and Lean Environments: 
A Review 
Summary
Introduction: Due to the demand of stem cells for applications in regenerative medicine, 
new methods of isolating these cells are highly sought. Adipose tissue is a readily 
available and non controversial source of multipotent stem cells with low risk to potential 
donors. However, donor Body Mass Index (BMI) over 25 has been associated with 
altered cellular microenvironment and thus has implications for stem cell efficacy in 
recipients. This systematic review explores the existing literature on adipose-derived 
stem cells (ASCs) and the effect of donor obesity on cellular function. 
Methods: The search term “obesity on adipose derived stem cells” was used to search 
Pubmed database. 243 papers were retrieved. Of those, 4 were meta-analyses and 31 were 
reviews. 
Results: There is agreement on reduced ASC function in response to obesity in terms of 
angiogenic differentiation, proliferation, migration, viability and on an altered and 
inflammatory transcriptome. Osteogenic differentiation and cell yield do not show 
reasonable agreement. Finally, weight loss partially rescues some of the aforementioned 
features. 
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Conclusions: Generally, obesity reduces ASC stem cell qualities and may have an effect 
on their therapeutic value. As weight loss and some biomolecules have been shown to 
rescue these qualities, further research should be conducted on methods to return obese 
derived ASCs to baseline. 
Introduction 
The growing field of modern regenerative medicine requires the development of a 
reliable source of stem cells for tissue engineering and other medical applications. Stem 
cells are characterized by the ability to self-regenerate and also to form multiple types of 
terminally differentiated cells. While embryonic stem cells are totipotent in their 
differentiation potential, adult stem cells have been found to be multipotent and much 
less controversial in their origin. In fact, adipose tissue, which is commonly discarded 
after procedures such as liposuction, is an easily accessible and cost effective source of 
adult stem cells. These adipose-derived stem cells (ASCs) can then be used in multiple 
therapeutic avenues, including healing bone defects, organ repair, vascular regeneration 
and increasing fat tissue survival rate [1, 2].  
The exploration of adipose derived stem cells (ASCs) as a source of material in 
regenerative medicine has raised concerns as to the optimal donor environment. Studies 
have shown previously that age adversely affects ASC proliferation and differentiation 
potential [3-7]. In addition, gender and anatomic location of extraction play a role in 
differentiation capability [6-8]. However, it is important to note that the viability of 
adipocytes does not differ between obese and lean individuals in fat taken from the flank, 
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inner thigh and lower abdomen [9]. ASCs from fat taken from the omentum also showed 
no difference in proliferation as compared with those taken from subcutaneous fat in one 
study [7]. However, Cleveland-Donovan et al.
10
 suggests that subcutaneous ASCs have a
greater capacity for proliferation, differentiation and survival as compared with omental 
ASCs due to impairment of the AKT pathway. In addition, according to three studies, 
body mass index (BMI) does not influence the concentration of processed lipoaspirate 
cells [2, 11, 12]. However, Yu et al [13] suggest a positive correlation between BMI and 
yield while van Harmelen et al [14] and Aust et al [15] suggest a negative correlation. 
The variable results could partially be explained by the error prone, high subject 
variability and protocol dependent nature of quantifying ASCs, as noted by Bakker et al. 
[16]. Clinically, the totality of these results suggests age is a strong prognostic factor of 
ASC graft usefulness while donor site and gender may also play a role. However, the 
effect of BMI on graft utility is clearly an area of contention, especially with respect to 
lipoaspirate yield. 
Given the fact that many ASCs are extracted from the excess adipose tissue of 
overweight (BMI > 25) or obese (BMI > 30) donors, the potential influence of this 
microenvironment has become an area of clinical relevance. Healthy adipose tissue is 
increasingly seen not only as an energy reservoir, but also as an endocrine organ with a 
role in normal metabolic regulation. On the other hand, adipocytes in obese patients have 
been proven ‘dysfunctional’ due to their induction of a hypoxic and mildly inflammatory 
cellular microenvironment [17, 18]. 
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The WHO estimates over one billion overweight (BMI > 25) and 300 million obese (BMI 
> 30) individuals worldwide. In addition, the prevalence of obesity is increasing, with
over 20% of the United States already falling under that category [19]. With a significant 
part of the prospective donor population ASCs experiencing the environment produced 
by obesity, substantial efforts have been made to characterize that environment’s effects. 
Altered Environment 
An important first step in understanding obesity’s effects on ASCs is characterizing the 
obesity microenvironment. Obesity is one of the conditions, along with diabetes and 
aging, that induces cellular stress in the form of low-level inflammation and storage of 
excess lipids [17]. Generally, this is through adipocyte hypertrophy, coinciding with 
decreased angiogenesis and lipogenesis [20]. Interestingly, ASCs have been found to not 
only promote the generation of inflammatory macrophages, but also to directly 
differentiate into these cells [21]. Therefore, the presence of inflammatory cells and 
cytokines in the adipose tissue of obese patients may be in large part due to site-specific 
mesenchymal ASCs [22, 23]. In addition, obesity increases the level of local and 
systemic circulating inflammatory cytokines which encourages migration of macrophages 
into the subcutaneous adipose tissue, adding another source to the inflammatory cells 
[24]. One of the upregulated cytokines potentially thought to increase this localization of 
inflammatory cells is osteopontin [25]. NFkB is shown to be heavily upregulated in obese 
ASCs responding to hypoxia, providing another mechanism for the increased 
inflammatory response [26]. 
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Hypoxia has been noted in the white adipose tissue of obese mice, indicated by a 1.7 fold 
increase in lactate and an increase in bound pimonidazole, which forms adducts with thiol 
in hypoxic environments [18]. The hypoxia is partly due to a decrease in perfusion. 
Expectedly, as HIF1A is thought to be a key mediator in the hypoxia response, affecting 
cell survival and metabolism, it is decreased in obese ASCs [27].  
One study showed that even after bariatric surgery-induced weight loss, the ASCs 
isolated from a formerly obese individual’s adipose tissue still showed negative effects on 
mitochondrial function. These formerly obese ASCs also remained more pro-adipogenic 
despite normal BMI, potentially through epigenetic mechanisms, which may explain the 
reason why weight loss is difficult to maintain for many obese patients [20].  
Altered Transcriptome Profile 
Superficially, many of the surface markers on obese-derived vs lean-derived ASCs are 
similar, such as CD29, CD44, CD90 and CD105 [28]. Upon further investigation, 
obesity-induced inflammation can in fact cause lasting functional differences in ASCs 
from obese donors. One study showed increased mRNA expression of pro-inflammatory 
cytokines such as TNF-alpha and IL-6 by obese ASCs, which further caused no clinical 
improvement when used in murine models of multiple sclerosis [29]. Additionally, a 
study showed strong upregulation of NFkB in response to hypoxia [26].  
These results were bolstered by another study in domestic pigs fed an atherogenic diet vs 
normally fed controls for 16 weeks. At the end of the study, ASCs in the obese pigs 
expressed higher amounts of TNF-alpha, which further correlated in vitro with enhanced 
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adipogenic and osteogenic differentiation [30]. Lee et al [31] also showed the 
overexpression of chemokines MCP-1 and MIP-1 alpha, and adhesion molecules 
fibronectin that respectively attract and retain macrophages to tissue. Further, Nair et al. 
showed an upregulation of various inflammatory genes, including IL-8 and CD53 in 
ASCs isolated from obese Pima Indian individuals [32]. Finally, several microRNAs 
implicated in differentiation and cell senescence are upregulated in obese ASCs [33]. It is 
important to note that IL-6, mentioned previously, and IL-8 in high levels are also a cause 
of cell senescence [34]. Thus, the preponderance of evidence points to ASCs not only 
being influenced by, but contributing to the low grade inflammatory environment 
observed in obesity.  
Differentiation Potential 
ASC, as multipotent cells, have the potential to revolutionize reconstructive surgery by 
increasing availability of high demand tissue types. For example, the reconstruction of 
craniomaxillofacial defects, whether inherited or acquired, is often limited by the scarcity 
of available bone tissue. In one study, ASCs derived from lean human subjects showed an 
increased propensity towards osteogenic differentiation as compared to those derived 
from obese individuals, both in vitro and in vivo [35]. When the obese ASCs were 
supplemented with estradiol, they regained their osteogenic propensity. This contradicts 
the previously mentioned Zhu et al study using porcine models of obesity, which showed 
increased osteogenic differentiation in obese-derived ASCs that correlated with increased 
TNF-alpha expression [30].  The finding also contradicts Yang et al., which showed an 
121 
increase in osteogenic differentiation potency with increasing BMI in human derived 
ASCs [12]. 
Obese-derived ASCs also showed reduced overall differentiation and angiogenic 
differentiation potential compared to their lean-derived counterparts, limiting their 
efficacy as regenerative tools. [14, 36, 37]. Roldan et al showed that this reduction in 
differentiation capacity was associated with dysregulation of Sonic Hedgehog, Wnt and 
Notch signaling pathways [33]. Isakson et al. [38] also showed dysregulation of Wnt and 
increased TNF-a led to a proinflammatory, macrophage-like phenotype which limited the 
normal differentiation capacity of ASCs. Studies also show that obese-derived ASCs 
exhibit decreased expression of genes essential to embryogenesis, wound repair and 
angiogenesis such as the HOX and T-box genes [28].   
Migration Potential 
In order to effectively aid wound healing and other regenerative processes, ASCs must be 
able to migrate to injured tissue with the aid of chemotactic factors such as SDF-1, 
CXCL16 and CXCR4 [39]. Reliably reproducible chemotaxis would potentially even 
allow the intravenous delivery of ASCs to distant injury sites within the body [40]. Oñate 
et al showed that obese-derived ASCs had significantly lower expression of SDF1 as 
compared to lean controls, indicating that obesity may affect the delivery of ASCs to 
injured tissue [28]. In contrast, a study showed that when responding to stimuli like 
MCP1 and HMGB1, obese human derived ASCs doubled their migration capacity. 
However, it was also found that under basal conditions that population has a reduced 
122 
migration capacity as there is no dose dependent response in migration to chemotactic 
factors like TNF-A, SDF-1 or IL-8 [37].  
Proliferation Potential 
The preponderance of studies show ASCs from obese populations display impaired 
proliferation potential and decreased cell survival [26, 27, 41]. One study however 
showed no significant correlation between BMI and proliferation [2]. Perez at al found a 
significantly increased population doubling time in obese derived ASCs as opposed to 
lean ASCs in mice and humans [27]. The study also found an increased fraction of pre-
apoptotic cells in obese ASC populations. This could potentially be due to the reduced 
telomerase activity and upregulation of p21, increasing DNA instability and apoptosis, 
respectively [27]. 
Obese individuals do not all have the same microenvironment in their tissues; but the 
presence of metabolic syndrome is indicative of a certain subset of cells. Oñate et al 
reported that only ASCs from patients with metabolic syndrome had a significantly 
higher population doubling time than ASCs from normal weight or metabolically healthy 
obese patients [36]. Another study by the same group was able to differentiate increasing 
degrees of impairment between healthy lean, healthy obese and metabolic syndrome 
obese individuals [28]. Metabolic derangement also limits the lifespan of ASCs derived 
from obese subjects; in a porcine model of obesity, ASCs showed increased senescence 
compared to ASCs from lean pigs [30].   
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Weight Loss 
As mentioned previously, ASCs isolated from previously obese individuals have been 
reported to be pro-adipogenic and maintain negative mitochondrial function. Thus, as 
previously obese individuals may be an important source of ASCs, it is important to 
characterize ASCs isolated from this environment. Some studies have shown a significant 
decrease in inflammatory cytokines [42] and inflammatory cell infiltration [43] in 
subcutaneous adipose tissue following weight loss. However, effects on ASCs themselves 
have been less encouraging. Mitterberger et al [44] found no change in ASCs isolated 
from previously obese populations. Indeed, ASCs from the previously obese group 
achieved an adipocytic phenotype faster than those isolated from lean patients [44, 45]. 
However, Petrangeli et al. [26] noted obese ASCs recover differentiation potential 
features after hypoxia and Perez et al. noted that ASCs from formerly obese mice 
partially recovered viability [46]. A study also showed ASCs from previously obese 
patients had the same osteogenic potential as those from controls [45]. In Perez et al., 
formerly obese ASCs showed partial recoveries to non-obese baseline in proliferation, 
cell morphology and migration potential but not live cell fraction or angiogenic potential 
[46]. More generally, in a study examining the effects of bariatric surgery in women, 
ASCs from previously obese individuals showed the most lipid accumulation and 
secreted more MCP-1, an inflammatory cytokine [47]. The data would suggest that 
though inflammation is generally reduced following weight loss, ASC differentiation 
potential and transcriptome profile do not completely return to baseline. 
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Discussion 
Metabolic health seems to play a larger role in predicting the performance of ASCs than a 
strict BMI cutoff. The presence of this metabolic derangement due to obesity results in an 
inflammatory cellular microenvironment, which reduces the proliferation potential of 
ASCs. In terms of angiogenic differentiation potential, obesity appears to play a negative 
role while in osteogenic potential there is less of a clear relation. This may be an 
important distinction for ASCs used in scaffolds and other bone grafts. Additionally, 
studies show that obesity may decrease ASC therapeutic value by altering the cell 
transcriptome, impairing migration, slowing doubling time and hastening senescence.  
Many of these studies rely heavily on animal models of diet-based obesity for a set 
amount of weeks. Further research should attempt to more accurately model human 
obesity, which is also dependent on stress level, genetics and amount of exercise. This 
would more accurately predict the effect of donor obesity on ASCs and thus, the efficacy 
of using these cells in regenerative medicine. Further research should also further 
elucidate methods by which obese-derived ASCs may be returned to their healthy state, 
as some studies found using estradiol, TNF-alpha and weight loss. Based on the current 
body of knowledge, it can be assumed that ASCs derived from obese, metabolically 
unhealthy donors do not exhibit the same properties and are potentially less 
therapeutically valuable as those derived from lean, healthy donors. This should be taken 
into account when the ASCs are used for clinical purposes. 
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Chapter 8: The Effect of Obesity on Adipose Stem Cell Functionality and Fat Graft 
Retention 
ABBREVIATIONS:  
ADQ: adiponectin 
ARS: Alizarin red staining 
ASC: Adipose tissue-derived stem cell 
BMI: Body mass index 
BMSC: Bone marrow-derived stem cell 
CFU: Colony-forming unit 
DMEM: Dulbecco’s modified Eagle’s medium 
FACs: Fluorescence-activated cell sorting 
FBS: Fetal bovine serum 
HIF-1α: hypoxia inducible factor 
LPL: lipoprotein lipase 
MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) 
ORO: Oil-red-O 
P/S: penicillin/streptomycin 
RT-PCR: real time polymerase chain reaction  
RUNX-2: runt-related-transcription factor 2 
SVF: stromal vascular fraction 
TIE2: tyrosine kinase 2  
VEGF: vascular endothelial growth factor 
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Summary
Purpose: Fat grafting has become a widely accepted modality of soft tissue restoration 
and has found applications in many areas of plastic surgery, such as in breast 
reconstruction; however, current practice is plagued by tremendous variability in long-
term retention, resulting in suboptimal outcomes and repetitive procedures. Anecdotally, 
we have experienced reduced graft retention in obese patients when compared to lean 
patients. Adipose-derived stem cells (ASCs) within adipose tissue are thought to 
contribute to fat graft survival; this has led to questions about donor conditions, such as 
obesity, on ASC function. Our study will determine the impact of obesity on ASC 
function as it relates to fat graft retention. 
Methods: ASCs were isolated and cultured from the lipoaspirate of female patients who 
were undergoing autologous fat grafting at the time of secondary breast reconstruction 
and grouped into lean (BMI<30) and obese (BMI>30). ASC yield, viability, growth 
kinetics, and capacity for multi-lineage differentiation into adipogenic and osteogenic 
lineages were compared in vitro. Adipogenic differentiation was assessed at 1 week of 
differentiation with Oil Red O staining and photometric quantification. Early osteogenic 
differentiation was assessed at 1 week of differentiation with alkaline phosphatase 
staining and quantification. Late osteogenic differentiation was assessed at 2 weeks of 
differentiation with Alizarin Red stain in with photometric quantification and 
quantification of calcium content. Clinical correlation with serial photographs and 
questionnaires from the patients and surgeons were performed to assess retention over 
time. 
Results: ASCs derived from obese donors exhibited a significantly decreased ability to 
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proliferate when compared to ASCs derived from non-obese subjects. Obese patients 
were more likely to have graft resorption at the 3 month (p=0.046), 6 month (p=0.003) 
and 12 month (p=0.002) visits when compared to non-obese patients. Fat graft retention 
also positively correlated to ASC proliferation (r=0.49, p=0.03).   
Conclusion: Altered ASC behavior of the obese subcutaneous adipose depot may 
contribute to reduced long-term graft retention in obese patients due to diminished 
proliferation potential. In addition to other ASC properties, the compromised ability of 
ASCs to proliferate in obese subjects should be considered in applications of cell-based 
technologies and therapies such as tissue engineering, stem cell banking and fat grafting. 
Introduction 
Autologous fat grafting is a dynamic and widely accepted modality of soft tissue 
restoration in plastic and reconstructive surgery that is used to improve functional and 
aesthetic form (1-3) due to its easy accessibility, abundance, and benefits of non-
immunogenicity. Fat grafting refers to the procedure in which fat is harvested by 
liposuction from a part of the body where it is unwanted and injected into an area where 
it can be used to add volume or correct a contour deformity. Advantages of the technique 
include using autologous fatty tissue rather than a foreign body (such as a filler or 
implant) and the added benefit of having liposuction to remove fat from an undesirable 
location. The concept of fat grafting has been of interest since the inception of whole-fat 
grafts in 1893 and became more popular with the advent of liposuction in the 1980s (4), 
which enabled the recovery of significant volumes of fat that could be reintroduced into 
patients as grafts (5). Since then, hundreds of reports have highlighted the benefits of fat 
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transfer for the management of soft tissue defects and contour deformities from trauma 
(4), disease (5), congenital defects (6), wound and scars (7), breast reconstruction (8, 9), 
and other reconstructive and aesthetic purposes. 
In the year 2013 alone, over 95,000 reconstructive breast procedures were performed and 
the number of patients seeking breast reconstruction is greatly increasing (1, 10-13). 
From 1998 to 2008, the Nationwide Inpatient Sample database registered 178,603 
mastectomies and 51,410 immediate breast reconstructions. Breast reconstruction 
following mastectomy has benefits on body image, sexuality, self-esteem and quality of 
life. Along with implants, fat grafting is a widely utilized modality in breast 
augmentation and reconstruction (Figure 8-1). In a recent national survey of plastic 
surgeons, 88% who performed fat grafting to the breast reported using it in breast 
reconstruction. Autologous fat grafting can modify the size, shape and contour of the 
breasts (10, 11), improve the quality of irradiated breast skin (12), and alleviate post-
mastectomy pain syndrome (13). Fat grafting is a valuable adjunct to other methods of 
tissue augmentation and reconstruction, such as implants or complex microvascular tissue 
flap procedures (14-17). Ideally, fat grafting could become an alternative to implants in 
breast reconstruction (11-13).  
Despite the long history of fat grafting, the adoption of autologous fat as the ideal soft 
tissue filler is plagued by tremendous variability in long-term graft retention, resulting in 
unpredictable results, suboptimal outcomes and repetitive procedures (14-17). In fact, 
only about 20-80% of grafted fat remains. The mechanisms contributing to long-term fat 
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graft survival and resorption are not well understood. Previous research has attempted to 
identify factors that may contribute to variability in fat grafting outcomes, including the 
role of adipose-derived stem cells (ASCs), which survive after grafting and promote the 
regeneration of adipocytes (Figure 8-2). Several ongoing clinical trials are exploring the 
potential of enriching fat grafts with ASCs to promote long-term graft survival, 
particularly to the breast. While there is significant interest to understand the role of 
ASCs in fat grafting, little is known about the impact of obesity on ASC functionality. 
Understanding how obesity affects ASC function may help us to understand why 
anecdotally that lean patients have better fat graft retention compared to obese patients.  
Obesity (BMI > 30 kg/m
2
) is a growing epidemic in the United States, affecting more
than 33% of adults. The effects of obesity on the intrinsic cellular properties of ASCs are 
still largely unknown, and no study has correlated these variables to fat graft retention 
(15-24). We aim to determine the effect of obesity on ASC function (yield, proliferation, 
and differentiation) and to correlate in-vitro ASC function with fat graft retention. We 
hypothesize that obesity is associated with compromised ASC function and reduced fat 
graft retention. Our results may help to define which patients will benefit most from fat 
grafting procedures, leading to more predictable fat grafting outcomes and refinement of 
future cell-based therapies and regenerative applications utilizing ASCs. 
Methods 
Donor Selection and Informed Consent 
All protocols were reviewed and approved by the University of Kentucky Institutional 
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Review Board prior to tissue collection and all subjects provided informed consent. 
Patients who had a scheduled consultation for secondary breast reconstruction with fat 
grafting with a University of Kentucky plastic surgeon and who were identified by study 
personnel as candidates for the study were informed of the opportunity to donate 
otherwise discarded lipoaspirate and to participate in the study. Patients were informed 
that participation in the study was completely voluntary and that refusal to participate in 
the study would not affect medical care. Demographic data on each subject was limited to 
age, ethnicity, sex, height, weight, body mass index, medical history and comorbidities, 
history of breast cancer, chemotherapy or radiation, operative technique, fat harvest 
volume and fat graft volume. 
Donor Demographics 
Lipoaspirate was obtained with informed consent from subjects undergoing elective 
liposuction (n=19). Inclusion criteria comprised female patients ranging in age from 18-
65 years with a BMI <30 (non-obese) or BMI >30 (obese) who have scheduled 
autologous fat grafting using subcutaneous abdominal tissue for secondary breast 
reconstruction between January 1, 2012 and January 1, 2016. These criteria were selected 
to minimize variables such as sex, age and depot site that may contribute to lipoaspirate 
variability. Furthermore, harvesting and processing techniques were standardized. Due to 
potential impact on adipose tissue function, we excluded patients with a history of 
diabetes mellitus, those on insulin or immunosuppressive drugs such as corticosteroids, 
with autoimmune disease, connective tissue disease, hematologic abnormalities, prior or 
scheduled chemotherapy and/or radiotherapy, current smokers, pregnant women, and 
those with abnormalities of adipose tissue (e.g., lipodystrophy).  
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Lipoaspirate Harvesting 
Lipoaspirate was harvested by liposuction performed under general anesthesia and sterile 
conditions. In all cases, subcutaneous adipose tissue was harvested from the lower 
abdominal region utilizing the Coleman technique with a standard harvest cannula on a 5-
ml syringe under manual suction. The harvested fat was centrifuged in the operating 
room (G force-1,006g) to obtain approximately 75 cc of purified fat from each patient 
(Figure 8-3). The tissue was sent directly to the research laboratory for stem cell 
isolation following centrifugation.     
ASC Isolation and Culture 
ASCs were processed from fresh human subcutaneous adipose lipoaspirate according to 
previously published methods with minor modifications (19). Briefly, lipoaspirate was 
rinsed with warm sterile phosphate-buffered solution to remove erythrocytes, followed by 
removal of the oil and saline layers. The remaining fat layer was digested with 
Dulbecco's Modified Eagle Medium–Low Glucose (DMEM, Life Technologies, Grand 
Island, NY) containing 0.15% collagenase type I (Worthington Biochemical, Lakewood, 
NJ) for 60 minutes at 37°C on a shaker. After centrifugation (300g) for 5 minutes at room 
temperature, the supernatant was aspirated and discarded. The cellular pellet was 
resuspended in DMEM with 10% fetal bovine serum (FBS, Walkersville, MD), 1% 
Antibiotic/Antimycotic and 1% Penicillin-Streptomycin, then filtered through a 100- and 
40-µm strainer and centrifuged at 300g for another 5 min. The supernatant was again
discarded. The cell pellet was then re-suspended in red cell lysis buffer and centrifuged 
before re-suspending the SVF in complete medium and cultured in plates that were 
maintained in a humid atmosphere of 5% carbon dioxide/95% air at 37°C. Cultures were 
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washed every day with warm PBS and maintained in stromal medium until 90% 
confluent. Primary isolated ASCs derived from each individual donor were compared 
before the first passage. ASCs were evaluated under phase contrast microscopy (Olympus 
CKX41) after primary isolation. The adherent population was then harvested by digestion 
with trypsin (0.05%)/EDTA (1 mM) at 37°C for five minutes, washed in stromal medium 
and replated at 5 × 10
3
 ASCs per sq cm (Passage 1) or cryopreserved for future use.
Cell Yield and Viability 
The trypan blue exclusion assay (Sigma, SA, 200-786-7) was used to count the number of 
viable cells. A fresh solution of 10 uL trypan blue (0.05%) in water was mixed with 10 
uL of each cell suspension for 5 minutes. Non-viable cells stain blue. Non-viable and 
viable cells were counted in a hemocytometer using light microscopy (Olympus CKX41). 
Growth Kinetics and Proliferation Assay 
To measure proliferation, cells were seeded in at a density of 5,000 cells/well and then 
cultured in ASC plating medium for 72 hours at 37°C and 5% CO2. Proliferation was 
measured using the MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide) assay according to manufacturer’s instructions and fluorescence intensity was 
measured using a micro-plate reader. Cell number was calculated and the percentage 
increase in cell proliferation was calculated based on existing and seeding cell count 
number.  
Colony Forming Unit Assay 
To examine differences in ASC growth, colony forming unit (CFU) assays were 
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performed. ASCs were plated in 6 well plates and cultured in a 37°C incubator with 
humidified 5% CO2. After 14 days of culture, the media was removed and the plates were 
washed with 3 mL PBS. 3% crystal violet in 100% methanol was added and the plates 
were incubated for 10 minutes at room temperature. The plates were washed with dH20 
until the background was clear. The stained colonies were examined under a microscope 
and the numbers of colonies greater than 2 mm in diameter were counted. Percent CFU 
was defined as the number of colonies per plate divided by the number of cells plated x 
100.  
Adipogenic Differentiation Assay  
Adipogenic differentiation was assessed at 1 and 2 weeks with Oil Red O (ORO) staining 
and photometric quantification. Briefly, cells were seeded in triplicate into standard tissue 
culture plates at 3 x 10
4
 cells/cm
2
 per well and maintained at 37°C in a 5% carbon
dioxide incubator under 95% humidity, and adipogenic differentiation medium (ADM) 
(consisting of Dulbecco’s Modified Eagle’s (DMEM)-Ham’s F-12 medium, 10% fetal 
bovine serum (FBS), 15 mM HEPES at pH 7.4, 33 µM biotin, 17 µM pantothenate, 100 
nM human recombinant insulin, 1 µM dexamethasone, 0.5 mM isobutylmethylxanthine, 
5 µM rosiglitazone, 1% penicillin/streptomycin, 1% antibiotic/antimycotic) was added 
after cell attachment for three days before being converted to adipocyte maintenance 
medium (identical to adipogenic differentiation medium but without 
isobutylmethylxanthine and rosiglitazone) for the remaining nine days. The medium was 
replaced every other day for up to 14 days before fixation. Cultures were photographed 
under phase contrast microscopy to monitor morphological changes. Adipogenic 
differentiation was identified by the formation of lipid droplets in the cytoplasm. The 
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percentage of differentiated ASCs producing lipid droplets was assessed by percentage of 
intracytoplasmic incorporation of Oil Red O (ORO) into monolayers at day 7 and day 14 
of adipogenesis using phase contrast microscopy at 10x and 40x magnification and then 
extracted with isopropanol and quantified by absorbance spectrophotometry at 520 nm.  
Osteogenic Differentiation Assay  
To measure osteogenic differentiation, the extent of extracellular calcium deposition was 
assessed by Alizarin Red S stain with photometric quantification. Briefly, cells were 
seeded in triplicate into standard tissue culture plates at 3 x 10
4
 cells/cm
2
 per well and
maintained at 37°C in a 5% carbon dioxide incubator under 95% humidity until at least 
80% confluence. Confluent cultures of ASCs were subjected to Osteogenic 
Differentiation Medium (DMEM/Hams F-12, 10% FBS, 1% antibiotic/antimycotic, 1% 
penicillin/streptomycin, 10 mM β-glycerophosphate, 50 µg/ml sodium 2-phosphate 
ascorbate, 10
−8
 M dexamethasone) and maintained in culture for 14 days with medium
changes every third day. The cultures were rinsed three times with 150 mM NaCl, fixed 
in 70% ethanol, and stained with Alizarin Red in order to assay extracellular 
mineralization. Briefly, cells were fixed with 4% paraformaldehyde at room temperature 
for 10 minutes. After washing two times with deionized water, 1 ml of alizarin red S 
solution (2%, pH 4.2) was added to each well. Each well was then washed with deionized 
water four times. The plate was dried at room temperature. The amount of matrix 
mineralization was determined by dissolving the cell-bound Alizarin Red S in 20% 
methanol and 10% acetic acid with gentle shaking for 15 minutes at room temperature 
and quantifying spectrophotometrically at 415 nm. Stains were performed in triplicate 
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and all measurements were normalized to the total protein content of a well seeded at 
equal density.  
RNA isolation and reverse transcriptase polymerase chain reaction (RT-PCR) 
Total RNA was harvested and processed by means of RNeasy Mini Kit (Qiagen; 
Valencia, CA) according to the manufacturer’s instructions. cDNA was synthesized from 
extracted RNA with TaqMan Reverse Transcription Reagents Kit (Invitrogen). An ABI 
Prism 7900HT Sequence Detection System (Applied Biosystems; Foster City, CA, USA) 
was used to perform quantitative real-time polymerase chain reaction (qRT-PCR) with 
Power SYBR Green PCR Master Mix (Applied Biosystems) as the reporter. qRT-PCR 
analysis was conducted to detect gene expression levels of the adipogenic differentiation 
marker lipoprotein lipase (LPL) and adiponectin (ADQ) was determined in a subset of 
samples. Each sample was run in duplicate and the mean values of the duplicates were 
used to calculate the transcript level. Gene expression values were normalized to 18S 
ribosomal RNA as internal control in the corresponding samples and the quantity of 18S 
did not vary between the two groups (p=0.31). Gene expression of early osteogenic 
marker runt-related-transcription factor 2 (RUNX-2) was analyzed and assessed in a 
manner identical to that described above by qRT-PCR in a subset of samples. The mRNA 
expression of vascular endothelial growth factor (VEGF), hypoxia inducible factor (HIF)-
1α, and endothelium-specific receptor tyrosine kinase 2 (TIE2) under normoxic 
conditions were determined with real-time RT-PCR. Specific primers for the genes 
examined are based on their PrimerBank sequences (Table 1).  
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Clinical Evaluation 
Patient photographs were taken serially at 2 weeks, 3, 6 and 12 months to evaluate fat 
graft retention clinically. The serial two-dimensional photographs and clinical evaluation 
were used to objectively evaluate breast contour based on percent fullness. Patients in 
both groups were monitored for the occurrence of adverse events of any type, 
logoregional cancer recurrences, fat necrosis, oil cysts, infection or skin necrosis. The 
patient and two reconstructive breast surgeons were asked to rate the fullness of the fat 
graft at each of the aforementioned time periods, specific issues such as nodularity, 
irregular shape/contour, dimpling, over or underfilling), complications (pain or infection) 
and time to resolution of these issues or complications). Patients were asked to rate their 
satisfaction of the procedure with questions such as whether the results were as expected, 
whether they would have this procedure again, and whether they would recommend this 
procedure to a family member or friend. During each clinic visit or through telephone 
follow-up, the patient reported by what quantity the fat graft had decreased from baseline. 
Statistical Analysis 
Data are shown as mean, median and percentage. Statistical analyses were performed 
using GraphPad Prism software (GraphPad Prism Software v5.01 (GraphPad Software, 
San Diego, CA). Numerical data are presented as means ± SDs. Statistical comparisons 
between the lean and obese groups were made using student’s t-tests. Pearson r and p-
values were obtained through correlation analysis. Regression analysis with least fit 
ordinary squares for proliferation and differentiation and the R
2
 coefficients were
evaluated. Results were reported as a positive or negative correlation depending on the 
relationship of R
2
 to 0 (weakest correlation) or 1 (strongest correlation). The statistical
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significance was set at p< 0.05. 
Results 
This prospective study included 19 women who underwent fat grafting for secondary 
breast reconstruction. The two groups were significantly different in body mass index 
(mean lean=26.4, mean obese=33.7; p<0.0001). Analysis of the satisfaction assessment 
questionnaire revealed that both groups were satisfied with the aesthetic result of the fat 
grafting procedure. In both groups, the majority of patients would undergo the fat 
grafting procedure again and would recommend the fat grafting procedure to a friend. At 
12-month follow-up, the obese group had less fat graft retention than lean group as
determined by self (p=0.04) and surgeon (p=0.01) questionnaires and clinical evaluations 
(Figure 8-4). The interrater reliability for the raters was found to be Kappa = 0.68, 95% 
CI (0.50, 0.89). Obese patients were more likely to have graft resorption at each follow-
up at the final (12 month) outcome when compared to lean patients (Figure 8-5). There 
was no difference in the rates of complications such as fat necrosis or oil cysts between 
the two groups (p=0.32). No patients reported locoregional cancer recurrence following 
AFG during the follow-up period.  
Obesity does not impact cell yield 
Obesity had no impact on cell yield (Figure 8-6). The mean yield achieved was 364 ± 
126 x 10
3 
cells/mL of lipoaspirate. No significant difference was found when comparing
the mean cell yield ratios between the lean (0.331 [0.07-0.575]) and obese (0.420 [0.233-
0.679]) groups (p>0.05).  
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Obesity impacts ASC kinetics 
Non-obese ASCs displayed significantly faster growth kinetics (Figure 8-7) and 
proliferation (Figure 8-8) than those from obese environments. Obese subjects (0.3834 ± 
0.0265) demonstrated reduced proliferative potential when compared to lean subjects 
(0.2665 ± 0.04195); p<0.003 as measured by MTT assays.  
Obesity reduced CFU potential in vitro  
Lean ASCs formed a significantly higher percentage of colonies (33.2 ± 2.93) than obese 
ASCs (23.2 ± 2.67), p=0.04 (Figure 8-9). 
Obese ASCs demonstrated reduced adipogenic differentiation potential in vitro 
After one week of adipogenic differentiation, Oil Red O staining was performed. Less 
lipid droplet formation was observed in obese ASCs compared to lean ASCs (Figure 8-
10 and 8-11, p=0.04). However, the expression levels of LPL and ADQ were not 
significantly different between the lean and obese cohorts (Figure 8-12 and Table 8-1). 
Obese ASCs demonstrated reduced osteogenic differentiation potential in vitro 
To measure osteogenic differentiation, the extent of extracellular calcium deposition was 
assessed by Alizarin Red S stain at 14 and 21 days. Obesity reduced early and late 
osteogenic differentiation potential (Figure 8-13, p=0.04). However, the expression 
levels of the early osteogenic gene RUNX2 were not significantly different between the 
lean and obese cohorts (Figure 8-12).  
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Correlation with retention 
Fat graft retention varied between lean and obese phenotypes (p<0.01) at each visit and at 
the 12-month follow-up (Figure 8-4 and 8-5). Correlation analysis of age, satisfaction, 
proliferation, colony formation, and adipogenic differentiation between lean and obese 
donors was performed. No statistically significant difference in graft retention for age 
(p=0.8) or satisfaction (p=0.2) was identified. There was a positive trend for retention and 
satisfaction (Figure 8-14). There was a statistically significant relationship between 
proliferation and retention (p=0.03, r=0.4996). There was an upward trend toward colony 
formation and retention, but this did not reach statistical significance (p=0.12, r=0.4363). 
There was no relationship between adipogenic differentiation and retention as assessed 
by oil red O stain and retention (p=0.51, r=-0.109) (Figure 8-15). 
Discussion 
ASCs are prominent tools in regenerative medicine due to their abundance, ease of 
isolation and multipotent capacity. Due to the dynamic use of fat grafting across clinical 
applications, much effort has been taken to understand the impact of patient 
characteristics on fat graft viability. In this study, we demonstrate that an obese 
environment modulates in vitro properties of ASCs. There is accumulating evidence of 
decreased proliferation and differentiation potential with increased age, radiotherapy, and 
diabetes, although this is not consistent among all studies. In this study, ASCs derived 
from obese donors exhibited compromised properties. In this study, cell yield did not 
differ between the lean and obese groups. However, non-obese ASCs displayed 
significantly faster growth kinetics and proliferation compared to obese ASCs and had 
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increased proliferation when measured by the MTT assays. Clonogenic ability as 
measured by colony forming potential was also significantly reduced in obese subjects. 
When measuring adipogenic differentiation of ASCs by Oil Red O staining with 
spectrophotometric quantification, the obese cohort had a significantly lower rate of 
adipogenesis when compared to the non-obese group. Adiponectin, a protein hormone 
and anti-inflammatory cytokine that modulates glucose and lipid metabolism, was not 
statistically significant between the lean and obese cohorts, but inversely correlated to 
BMI and had a weak upward trend toward increased retention. Obesity also reduced early 
and late osteogenic differentiation potential as measured by alizarin red staining. 
RUNX2, a marker for early osteogenic differentiation, demonstrated a weak downward 
trend with BMI, suggesting impaired osteogenic potential for the obese. ASC 
proliferation potential and fat graft retention were significantly reduced in the obese. 
Therefore, it is possible that the ability of ASCs to proliferate may impact graft retention. 
Although our adipogenic staining revealed a statistically significant difference between 
the lean and obese cohorts, there was no statistically significant difference when related 
to retention. Adiponecin, a protein hormone and anti-inflammatory cytokine that 
modulates glucose and lipid metabolism, was inversely correlated to BMI. RUNX2, a 
marker of early osteogenic differentiation, showed a weak downward trend with BMI and 
retention. Hypoxia-inducible factor-1 (HIF1a) is a transcription factor that accumulates 
during hypoxia and increases the mRNA expression of several variety of genes that 
stimulate angiogenesis and other pathways. HIF1a showed a slight trend upwards with 
increased retention. The major inducer of angiogenesis is vascular endothelial growth 
factor (VEGF) and ASCs secrete this cytokine that contributes to their angiogenic 
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properties. There was a downward trend for VEGF products with increasing BMI and no 
trend with retention. The TEK tyrosine kinase (TIE2) is an angiopoietin 1 receptor that is 
involved in the pathway for angiogenesis and vascular maturation. The data show an 
upward trend of TIE2 with increased BMI and increased retention.  
Our results are in agreement with that of groups who previously reported that ASCs from 
obese individuals were compromised differentiation potential (20). Perez et al. reported 
reduced proliferative abilities of obese ASCs and also changes in telomerase activity and 
DNA telomere length, suggesting decreased self-renewal capacity. In addition, metabolic 
analysis demonstrated impaired mitochondrial content and function in obese ASCs (21). 
This same group has also demonstrated impaired differentiation and migration properties 
in ASCs derived from obese patients (22, 23). Perez reported decreased cell proliferation, 
viability, and adipogenic capacity in obese mice (24). Roldan noted that human omental 
ASCs derived from morbidly obese individuals were capable of initiating the adipogenic 
differentiation process, but maturation was impaired after two weeks; the group also 
observed decreased cell proliferation, premature senescence, and increased cytokine 
secretion (25). The plasticity of preadipocytes and inverse relationship between lipid 
storage and proinflammatory capacity have also been noted (26). Van Harmelen et al 
found that the adipogenic differentiation capacity of subcutaneous mammary adipose 
tissue is decreased in obese women (27). Furthermore, Onate et al. showed diminished 
adipogenic and angiogenic differentiation (28) and an upregulation of inflammatory 
genes in ASCs derived from obese patients (29). ASCs are currently being used in cell-
assisted lipotransfer techniques in breast reconstruction. Notably, if ASCs derived from 
ex-obese patients have adipogenic memory of the obesity phenotype, then it reasonable to 
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assume that an altered inflammatory memory also exists, thus potentially worsening 
tumor progression. Obesity is a chronic inflammatory state and therefore future studies 
should evaluate inflammatory genes that may contribute to diminished ASC function. 
While there is much variability in outcomes among studies, this could be partially 
explained by differences in harvesting technique or in vitro methodologies.  
Understanding ASCs after massive weight loss has tremendous implications for 
regenerative medicine. ASCs promote tissue repair and regeneration by indirectly 
producing soluble factors or by directly differentiating into ASCs. For example, if ASCs 
are isolated from ex-obese patients, the regenerative potential may be modified and 
distinct from those derived from non-obese patients. Understanding the impact of obesity 
and other patient characteristics is scarce, but is crucial for surgeons when considering 
the amount of lipoaspirate to inject, to improve patient selection, and to counsel patient 
expectations with regards to outcomes and the need for repeat procedures.     
Limitations 
This study has many limitations; first, the in vitro methodologies may not correspond to 
what occurs in vivo. The cohort of patients included in the study may not be 
representative of the general population, which may limit the generalizability. 
Furthermore, none of our patients were morbidly obese, diabetic, or with metabolic. 
Future research should include subgroup analysis of these populations and consider the 
influence of massive weight loss on ASC memory and function. Furthermore, it will be 
important to assess other properties of the SVF, such as macrophages and T cells, to 
better understand their role in fat graft survival both in vitro and in vivo.  
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This study is limited by absence of a standardized metric to evaluate graft stability. 
Current evaluation of fat grafts is limited to clinical evaluation, ultrasound (US), 
magnetic resonance imaging (MRI), computerized tomography (CT), and three-
dimensional (3-D) imaging. Although most of the currently published clinical outcome 
studies rely on patient and surgeon reported outcomes, ideally, graft volume retention 
should be quantified with a more objective and validated assessment tool such as with 3-
D imaging or MRI to monitor fat graft outcomes over time. However, MRI confers both 
cost and risk to the patient and 3-D imaging is not a readily available methodology for 
volumetry. Two-dimensional clinical photographs and clinician assessment with 
questionnaires are standard methods for assessing fat graft retention. The kappa 
coefficient showed substantial agreement among raters; the evaluation of aesthetic results 
was overall positive, suggesting that contour irregularities were improved by the fat 
grafting procedure. Lim et al. utilized 2D photographic analysis in their 2012 study 
assessing patients with craniofacial microsomia and Treacher Collins Syndrome (30). 
Therefore, we utilized serial photographs, clinical evaluations and a questionnaire to 
assess fat graft volume over time.  
Conclusions 
ASCs derived from obese donors (BMI>30) have impaired cell function. This suggests 
ASCs in adipose tissue of obese patients have impaired capacity for spontaneous or 
therapeutic repair than ASCs from non-obese metabolically normal individuals. Although 
many factors contribute to fat graft retention, altered adipose cell behavior of the obese 
subcutaneous adipose depot may contribute to reduced long-term graft retention in obese 
patients. Of all measured variables, ASC proliferation was most related to retention. 
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Nonetheless, the results discussed here should be considered for all applications 
involving ASCs, including in cell-based therapies, tissue engineering and stem cell 
banking.  
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Figure 8-1. Fat harvesting and preparation. (A) Markings on the donor site. (B) 
Markings on the donor site, oblique view. (C) Harvesting with the cannula fitted directly 
on to the 10-mL Luer Lock syringe. (D) Centrifugation of the syringes in batches of 6 
for 20 minutes. (E) Centrifugation separates the fat into 3 layers. Only the middle layer 
of purified fat is retained. (F) Transfer from one syringe to another, using a 3-way tap to 
obtain 10-mL syringes containing pure fat. 
Reprinted from Delay E, Guerid S. The Role of Fat Grafting in Breast Reconstruction. 
Clin Plast Surg. 2015 Jul;42(3):315-23, vii., with permission from Elsevier. 
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Figure 8-2. The fate of nonvascularized fat grafting is controversial. Long-term 
retention of fat graft occurs both due to adipocyte survival within transplanted fat and by 
ASC adipogenesis. Eto et al. found that transplanted fat grafts can be divided into three 
zones. The outer 300 μm forms the peripheral zone and survives through plasma 
imbibition. The central zone represents the innermost zone of the graft where all 
adipocytes and progenitor cells die. In the intermediate zone, adipocytes still die, but 
ASCs are able to survive and regenerate, contributing to long-term tissue remodeling and 
fat retention. Therefore, ASCs are better able to endure ischemic insult and therefore play 
a major role in fat graft survival. 
With permission, from: 
Mashiko T, Yoshimura K. How does fat survive and remodel after grafting? Clin 
Plast Surg. 2015 Apr;42(2):181-90. doi: 10.1016/j.cps.2014.12.008. Epub 2015 Jan 
29. Review. PubMed PMID: 25827562.
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Figure 8-3. Lipoaspirate processing. Lipoaspirate (whole fat tissue derived from 
liposuction) is obtained through a liposuction cannula and centrifuged. The upper (oil) 
and lower (serous) layers are decanted. The middle fatty layer is injected into the patient 
in the process of fat grafting. A portion of the lipoaspirate is saved and is subjected to 
washes, collagenase digestion, and centriguation. The stromal vascular fraction (SVF) is 
separated from the mature adipocytes. The SVF is plated and grown to confluence.  
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Figure 8-4. Surgeon and Patient-Reported Graft Retention Outcomes. At 12-month 
follow-up, the obese group had less fat graft retention than lean group as determined by 
self (p=0.04) and surgeon (p=0.01) questionnaires and clinical evaluations. The interrater 
reliability for the raters was found to be Kappa = 0.68, 95% CI (0.50, 0.89).  
Figure 8-5. Volume retention vs. obesity over time. Obese patients were more likely to 
have graft resorption at the 3 month (t-test, p=0.046), 6 month (t-test, p=0.003) and 12 
month (t-test p=0.002) visits when compared to lean patients.  
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Figure 8-6. Cell yield did not differ between the lean and obese groups. The mean 
yield achieved was 364 ± 126 x 10
3 
cells/mL of lipoaspirate. No significant difference
was found when comparing the mean cell yield ratios between the lean (0.331 [0.07-
0.575]) and obese (0.420 [0.233-0.679]) groups (p>0.05). 
Figure 8-7. Obesity reduces ASC kinetics. Proliferation was measured by cell counting. 
Data represent mean ± SEM. Non-obese ASCs displayed significantly faster growth 
kinetics and proliferation than those from obese environments.  
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Figure 8-8. Obesity affects ASC proliferation as measured by MTT assays. Cell 
growth was measured by MTT assays. Obese subjects (0.3834 ± 0.0265) demonstrated 
reduced proliferative potential when compared to lean subjects (0.2665 ± 0.04195); 
p<0.003. Values are reported as mean ± SEM.  
Figure 8-9. Clonogenic ability as measured by colony forming potential is reduced in 
the obese population. ASCs were plated in 6 well plates and cultured for 14 days, 
washed with PBS, and stained with 3% crystal violet in 100% methanol for 10 minutes. 
The plates were washed with dH20 until the background was clear. The stained colonies 
were examined under an inverted microscope and the numbers of colonies greater than 2 
mm in diameter were counted. %CFU was defined as the number of colonies per plate 
divided by the number of cells plated x 100. When grouped, the lean group formed a 
significantly higher percentage of colonies (33.2 ± 2.93) compared to the obese (23.2 ± 
2.67); p=0.04. Values are reported as mean ± SEM. 
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Figure 8-10. Adipogenic differentiation of ASCs was assessed by in vitro staining with 
Oil Red O and measured by spectrophotometric quantification. Even accounting for 
differences in cell proliferation, the obese cohort had a significantly lower rate of 
adipogenesis compared to the lean cohort; p=0.04. 
Figure 8-11. Unstained (left) and stained (right, with Oil Red O) lipid droplets during 
adipogenesis at 40X magnification. 
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Figure 8-12. Obesity reduces early and late osteogenic differentiation potential as 
measured by alizarin red staining. Higher alizarin red staining intensity represents 
more osteogenic differentiation. More osteogenic differentiation was observed in both 
early (day 14) and late (day 21) osteogenesis in the lean group compared to the obese 
group.   
Table 8-1. Primers used for qRT-PCR. 25 nmole DNA Oligo from IDT 
Gene Primer forward sequence (5’-3’) Primer reverse sequence (3’-5’) 
LPL GCTCGTGCTGACTCTGGCCG TCTTCTTTGGTCGGCGGCGG 
ADQ GGCCGTGATGGCAGAGAT TTTCACCGATGTCTCCCTTAGG 
RUNX2 TGGTTACTGTCATGGCGGGTA TCTCAGATCGTTGAACCTTGCTA 
HIF-1a CAGAGCAGGAAAAGGAGTCA AGTAGCTGCATGATCGTCTG 
VEGF CTCTACCTCCACCATGCCAAG AGACATCCATGAACTTCACCACTTC 
TIE2 CGCATAACCAGTGAAACAGC
ATTGC 
CCCTGTGCTCAGACAGAAATGAGA 
18S AAACGGCTACCACATCCAAG CCTCCAATGGATCCTCGTTA 
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Figure 8-13. Comparison of mRNA expression of LPL, ADQ, RUNX2, HIF1a, 
VEGF and TIE2 in the ASCs of lean and obese donors. When grouped, there was no 
statistically significant difference between these factors assessed by unpaired t-test; LPL, 
p=0.5; ADQ, p=0.9; RUNX2, p=0.6; HIF1a, p=0.8; VEGF, p=0.8 and TIE2, p=0.9. 
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Table 8-2. Correlation analysis of factors LPL, ADQ, RUNX2, HIF1a, VEGF and 
TIE2 between lean and obese donors. There was trend toward lower levels of ADQ and 
VEGF and higher levels of TIE2 with increased BMI, although these did not reach 
statistical significance. There was a trend toward higher levels of LPL, HIF1a, and TIE2 
with increased retention, although these did not reach statistical significance. 
Factor r 
coefficient 
BMI
p-
value 
r 
coefficient 
Retention 
p-
value 
LPL 0.0268 0.9159 0.2368 0.3291 
ADQ -0.2799 0.2605 0.0455 0.8532 
RUNX2 -0.05828 0.8183 -0.05828 0.8183 
HIF1a 0.01722 0.9459 0.1574 0.5198 
VEGF -0.1076 0.6708 0.01962 0.9365 
TIE2 0.433 0.0727 0.2944 0.2212 
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r=0.0505; p=0.84 
r=0.3142; p=0.19 
Figure 8-14. Correlation analysis of age and satisfaction between 
lean and obese donors. There was no statistically significant difference 
in graft retention for age (p=0.8) or satisfaction (p=0.2). There was a 
positive trend for retention and satisfaction.  
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r=0.4996; p=0.03 
r=0.4363; p=0.12 
r=-0.1609; p=0.51 
Figure 8-15. Correlation analysis of proliferation, colony formation and adipogenic 
differentiation between lean and obese donors. There was a statistically significant 
relationship between proliferation and retention (p=0.03, r=0.4996). There was an 
upward trend toward colony formation and retention, but this did not reach statistical 
significance (p=0.12, r=0.4363). There was no relationship between adipogenic 
differentiation as assessed by oil red O stain and retention (p=0.51, r=-0.109).  
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Chapter 9: Adipose Graft Enrichment Strategies: A Systematic Review 
Summary
Purpose: Autologous fat grafting is a dynamic modality used in reconstructive surgery as 
an adjunct to improve functional and aesthetic form. However, current practices in fat 
grafting for soft tissue augmentation are plagued by tremendous variability in long-term 
graft retention, resulting in suboptimal outcomes and repetitive procedures. This 
systematic review identifies and critically appraises the evidence for various enrichment 
strategies that can be used to augment and improve the viability of fat grafts.  
Methods: A comprehensive literature search of the Medline and PubMed databases was 
conducted for animal and human studies published through October 2015 with multiple 
search terms related to adipose graft enrichment agents encompassing growth factors, 
platelet-rich plasma, adipose-derived and bone marrow stem cells, gene therapy, tissue 
engineering, and other strategies. Data on level of evidence, techniques, complications, 
and outcomes were collected.  
Results: A total of 1064 articles were identified of which 132 met inclusion criteria. The 
majority of enrichment strategies demonstrated positive benefit for fat graft survival, 
particularly with growth factors and adipose-derived stem cell enrichment. Platelet-rich 
plasma and adipose-derived stem cells had the strongest evidence to support efficacy in 
human studies and may demonstrate a dose-dependent effect.  
1
6
3
163 
Conclusions: Improved understanding of enrichment strategies contributing to fat graft 
survival can help to optimize safety and outcomes. Controlled clinical studies are lacking, 
and future studies should examine factors influencing graft survival through double-
blinded, randomized controlled clinical trials in order to obtain consistent outcomes and 
to establish recommendations.   
Introduction 
The concept of fat grafting was initially pioneered by Neuber in 1893, and transitioned 
into popularity almost a century later with the advent of liposuction. Lipoplasty enabled 
the recovery of significant volumes of fat that could be reintroduced to patients as grafts 
[1]. Since then, autologous fat grafting has evolved to become a dynamic modality used 
in reconstructive surgery as an adjunct to improve functional and aesthetic form. There is 
tremendous clinical interest in the utilization of fat grafting for soft tissue reconstruction 
and augmentation with thousands of cases performed each year in the treatment of 
patients with volume loss due to trauma, disease, congenital defects, or the natural 
process of aging. However, current practice is plagued by tremendous variability in long-
term graft retention, with some studies estimating a volume survival rate of 20-80%, 
resulting in suboptimal outcomes and repetitive procedures [2-4]. Furthermore, the Food 
and Drug Administration (FDA) released guidelines changing the regulation of human 
cells, tissues, and cellular-or-tissue-based-products in December 2014. These products 
would be considered as biologic drugs by the FDA and surgeons would need to apply for 
premarket FDA approval and licensure prior to their use. The American Society of Plastic 
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Surgery has drafted a response to explicate why these FDA regulations are misguided [5]. 
This systematic review critically appraises the level of evidence for adipose graft 
enrichment agents, including growth factors, platelet-rich plasma, adipose derived and 
bone marrow stem cells, gene therapy, tissue engineering, and other strategies.  
Methods 
A systematic literature review of the PubMed database was performed using the 
following search algorithm:  
(Fat AND ("transplantation" OR "transplantation" OR "grafting" OR "transplantation" 
OR "grafting” AND ((fat AND ("transplantation"[Subheading] OR "transplantation"[All 
Fields] OR "transplantation"[MeSH Terms] OR "transplantation"[All Fields] OR "organ 
transplantation"[MeSH Terms] OR ("organ"[All Fields] AND "transplantation"[All 
Fields]) OR "organ transplantation"[All Fields])) OR lipofilling[All Fields] OR 
lipostructuring[All Fields] OR lipografting[All Fields]) AND (("intercellular signaling 
peptides and proteins"[MeSH Terms] OR ("intercellular"[All Fields] AND 
"signaling"[All Fields] AND "peptides"[All Fields] AND "proteins"[All Fields]) OR 
"intercellular signaling peptides and proteins"[All Fields] OR ("growth"[All Fields] AND 
"factors"[All Fields]) OR "growth factors"[All Fields]) OR ("vascular endothelial growth 
factor a"[MeSH Terms] OR "vascular endothelial growth factor a"[All Fields] OR 
"vegf"[All Fields]) OR FGF[All Fields] OR IGF[All Fields] OR EGF[All Fields] OR 
PDGF[All Fields] OR EPO[All Fields] OR ("platelet-rich plasma"[MeSH Terms] OR 
("platelet-rich"[All Fields] AND "plasma"[All Fields]) OR "platelet-rich plasma"[All 
Fields] OR ("platelet"[All Fields] AND "rich"[All Fields] AND "plasma"[All Fields]) 
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OR "platelet rich plasma"[All Fields]) OR ("Pharmacol Res Perspect"[Journal] OR "prp" 
OR "genetic therapy" OR ("genetic" AND "therapy"[All Fields]) OR "genetic 
therapy"[All Fields] OR ("gene"[All Fields] AND "therapy"[All Fields]) OR "gene 
therapy"[All Fields]) OR (("adipose tissue"[MeSH Terms] OR ("adipose"[All Fields] 
AND "tissue"[All Fields]) OR "adipose tissue"[All Fields]) AND ("engineering"[MeSH 
Terms] OR "engineering"[All Fields])) OR (("adipose tissue"[MeSH Terms] OR 
("adipose"[All Fields] AND "tissue"[All Fields]) OR "adipose tissue"[All Fields]) AND 
derived[All Fields] AND ("stem cells"[MeSH Terms] OR ("stem"[All Fields] AND 
"cells"[All Fields]) OR "stem cells"[All Fields]))). A total of 1064 studies were identified 
on this preliminary search (Figure 1). Relevant articles were selected through assessment 
of titles and abstract as well as the reference lists of related articles. Pertinent articles 
were selected and reviewed. 932 studies were unrelated to fat grafting enrichment. 
Among the remaining articles, 109 were animal studies and 23 were human studies. With 
regards to human studies, there were no reports on Vascular Endothelial Growth Factors 
(VEGF), Fibroblast Growth Factor (FGF), Insulin-Like Growth Factor (IGF), or 
Epidermal Growth Factor (EGF) in enrichment strategies. There was one study on 
Platelet-Derived Growth Factor (PDGF), one study on erythropoietin (EPO), 11 studies 
on Platelet-Derived Growth Factor (PRP), and ten studies Adipose Tissue-Derived Stem 
Cells (ASCs). With regards to animal or in vitro studies, there were 12 reports on VEGF, 
11 for FGF, one for IGF, one for EGF, one for PDGF, one for EPO, six for PRP, and 33 
for ASC. Other enrichment strategies characterized 43 studies. Neutral, negative, or 
positive results from these studies are summarized in Figures 2 and 3.  
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Figure 9-1. Search Strategy 
A comprehensive literature search of the Medline and PubMed databases was conducted 
for animal and human studies published through October 2015 with multiple search terms 
related to adipose graft enrichment agents encompassing growth factors, platelet-rich 
plasma, adipose-derived and bone marrow stem cells, gene therapy, tissue engineering, 
and other strategies. Data on level of evidence, techniques, complications, and outcomes 
were collected.  
Legend: Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), 
Insulin-like Growth Factor (IGF), Epidermal Growth Factor (EGF), Adipose-derived 
Stem Cells (ASCs), Platelet Derived Growth Factor (PDGF), Erythropoietin (EPO), 
Platelet-Rich Plasma (PRP) 
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Figure 9-2. Systematic Review of Adipose Graft Enrichment in Animal Models. The 
majority of enrichment strategies demonstrated positive benefit for fat graft survival, 
particularly with growth factors and adipose-derived stem cell enrichment.  
*Not included in graphs: 43 studies related to other enrichment factors and methods
Legend: Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), 
Insulin-like Growth Factor (IGF), Epidermal Growth Factor (EGF), Adipose-derived 
Stem Cells (ASCs), Platelet Derived Growth Factor (PDGF), Erythropoietin (EPO), 
Platelet-Rich Plasma (PRP) 
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Figure 3. Systematic Review of Adipose Graft Enrichment in Humans. Platelet-rich 
plasma and adipose-derived stem cells had the strongest evidence to support efficacy in 
human studies and may demonstrate a dose-dependent effect.
*Not included in graphs: 43 studies related to other enrichment factors and methods
Legend: Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), 
Insulin-like Growth Factor (IGF), Epidermal Growth Factor (EGF), Adipose-derived 
Stem Cells (ASCs), Platelet Derived Growth Factor (PDGF), Erythropoietin (EPO), 
Platelet-Rich Plasma (PRP) 
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Factors that influence fat graft survival 
Autologous fat grafting has become a dynamic modality used in reconstructive surgery as 
an adjunct to improve functional and aesthetic form. However, the factors leading to 
successful long-term outcomes in fat grafting are not fully understood. Until fully 
understood, producing consistent results will continue to be a challenge. Kato et al. used 
animal models to show that a process of dynamic tissue remodeling occurs over a period 
of three months following fat grafting [6-9]. During this time, varying degrees of 
adipogenesis and macrophage mediated replacement of fat with scarring and oil cyst 
formation occurs. Several groups have attempted to identify which factors contribute to 
the variability in outcomes in autologous fat grafting. These factors may influence the 
process of dynamic tissue remodeling. One of the initial aspects reviewed was fat donor 
site and volume of fat used for grafting.  
In a recent retrospective study, Small et al. looked at patients who underwent autologous 
fat injection to reconstructed breasts and used three-dimensional imaging to find that the 
choice of donor site (anterior abdomen versus lateral thigh), radiated versus non-radiated 
breast tissue, and volume of fat injected did not play a significant role in volumetric 
retention of the fat graft at 20 weeks post-revision [10], although previously published 
studies described that patients receiving higher volumes of injected fat had slower 
volume loss and greater total volume retention [11].  
Pressure and shear have previously been described as important variables that should be 
taken into consideration during the harvesting and preparation of fat grafts. In order to 
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determine the role of pressure and shear on ultimate fat graft viability, Lee et al. 
performed liposuction on fresh human panniculectomy specimens, subjected the 
lipoaspirates to negative pressure, positive pressure, or shear stress and injected them into 
nude mice and examined the samples at four weeks [12]. Only the samples subjected to 
shear stress via fast injection versus slow injection showed a significant decrease in graft 
weight and unfavorable changes in histology. The authors concluded that shear stress 
plays a more important role in fat graft viability than pressure. In contrast, Cheriyan et al. 
showed that low-pressure abdominal lipoaspiration resulted in greater cell viability at 
seven days post-operation than high-pressure abdominal lipoaspiration. They hypothesize 
that this difference in findings may be attributable to differences in harvesting and 
processing between the two studies, given that multiple factors play a role in the success 
of autologous fat grafting [13].  
A less appreciated yet promising tool in fat grafting is the graft-to-capacity (GC) ratio, 
which looks at the volume of fat injected relative to the volume of the recipient site. 
Using 3D imaging, del Vecchio et al. looked at 30 cases of women who underwent breast 
augmentation with autologous fat grafting and calculated an average GC ratio of 117 
percent +/- 22 percent [14]. They found that there was an inverse relationship between 
the GC ratio and the percentage volume maintenance of fat at 12 months post-
augmentation. If the ratio was more than one standard deviation above the mean, there 
was lower percentage volume maintenance of fat. This can occur if the volume of fat 
injected is excessive, if the volume of the recipient site is not adequate to accommodate 
the volume injected, or a combination of both. In contrast, if the ratio was more than one 
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standard deviation below the mean, there was higher percentage volume maintenance of 
fat. One effective method employed in the study was to use tissue expansion to increase 
the capacity, or volume of the recipient site, to accommodate the desired amount of fat to 
be grafted while still maintaining an appropriate GC ratio. It is interesting to note that the 
correlation coefficient between the GC ratio and percentage volume maintenance was 
0.62, suggesting that other factors also contribute to the long term success of autologous 
fat grafts. For example, a variety of harvesting techniques were used which could have 
had an effect on percentage volume maintenance, such as shear stress as described above 
by Lee et al. [12, 14]. Another factor that must be taken into account is the intrinsic 
compliance of the recipient site tissue. The breast tissue of a multiparous healthy woman 
may accommodate a greater volume of fat than the breast tissue of a woman with a 
history of radiation treatment to the breast [14]. While many factors contribute to fat graft 
survival, this systematic review focuses on evidence for enrichment strategies.  
Growth Factors in Fat Graft Enrichment 
Growth factors comprise a set of proteins or steroid hormones whose function is to 
stimulate the growth of specific tissues and to facilitate cellular division and 
differentiation (Figure 4). Generally, growth factors serve as intercellular signaling 
molecules that bind with particular cell surface receptors to impart their influence. Brief 
descriptions of various growth factors are articulated below, as well as their potential 
impacts on the enrichment and survivability of fat grafts.  
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Figure 9-4. Growth Factor Signaling. Growth factors comprise a set of proteins or 
steroid hormones whose function is to stimulate the growth of specific tissues and to 
facilitate cellular division and differentiation. Generally, growth factors serve as 
intercellular signaling molecules that bind with particular cell surface receptors to impart 
their influence.  
Legend: Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor 
(PDGF), Epidermal Growth Factor (EGF), Fibroblast Growth Factor (FGF) and 
respective receptors. 
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Vascular Endothelial Growth Factors (VEGF) are involved with angiogenesis and 
enhanced vascularization. While no studies have been performed to examine the effects 
of VEGF enrichment of fat in humans, VEGF enrichment has universally demonstrated 
positive effects in rodent models (Table 1). Numerous methods, including VEGF-loaded 
microspheres and nanospheres, transfected Adipose-Derived Stem Cells (ASCs), Bone 
Marrow Derived Stem Cells (BMSCS), and gene therapy, have demonstrated 
significantly improved fat graft neovascularization, enhanced survival, and quality of 
adipose tissue.  
Kakudo et al. described techniques for adipose-derived regenerative cell (ADRC)-
enriched fat grafting. ADRCs comprise a heterogeneous assortment of cells (e.g., 
vascular smooth muscle cells, adult stem cells, leukocytes, endothelial cells, endothelial 
progenitor cells) that are resident in adipose tissue subjected to collagenase digestion [15, 
16]. Recent studies suggest that fat grafts enriched with cultured ADRCs might result in 
augmented graft viability [17, 18]. Lu et al. suggested that ADRC fat grafts transfected 
with VEGF exhibited the highest density of capillaries and graft longevity [17].  
Fibroblast Growth Factors (FGF) comprise a group of heparin-binding proteins that 
are involved with the propagation, differentiation and survival of a broad range of cells 
and tissues, embryonic development, angiogenesis, wound healing, and endocrine 
signaling. β-FGF is involved in the process of vasculogenesis and angiogenesis. While no 
studies have been performed to examine the effects of FGF enrichment of fat in humans, 
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enrichment has demonstrated universally positive effects in animal models, including 
enhanced graft volume vascularization, viability, and retention compared to control 
(Table 2). Hong et al. investigated the effects of transfer media that consisted of β-FGF 
and insulin to the viability of fat grafts that were introduced to rabbit models. Enhanced 
quality and viability of transplanted adipose tissue was noted [30]. It was determined that 
β-FGF has the capacity to directly (as a mitogen for mesenchyme-derived cells) and 
indirectly (serving as an angiogenic factor) stimulate pre-adipocytes to augment the mass 
of fat grafts [31].  
Insulin-Like Growth Factors (IGF) comprise proteins that are closely akin to insulin 
and engaged in an intricate system that facilitates cell communication. These growth 
factors also promote cell proliferation and inhibit apoptosis. IGF-1 has the capacity for 
initiating preadipocyte differentiation. A study by Boney et al. suggests that IGF-binding 
proteins may have a critical role in modulating the activity of IGF-1 in adipogenesis [42]. 
Cervelli et al. described the use of activated autologous platelet-rich plasma (PRP), 
derived from blood centrifugation, as a strategy for releasing multiple growth factors, 
including IGF-1, which are thought to be significant in facilitating fat graft survival [43-
45]. No studies have been performed to examine the effects of IGF enrichment of fat in 
humans. Yuksel et al. delivered sustained doses of basic FGF, as well as insulin and IGF-
1 to rats using poly(lactic-coglycolic acid)-polyethylene glycol microspheres. It was 
discovered that each of these growth factors served to increase the fat graft mass and 
volume in contrast to control blank microspheres (Table 3) [31, 46].  
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Epidermal Growth Factor (EGF) is a low-molecular-weight polypeptide that is found 
in a number of human tissues with functionality encompassing angiogenesis, keratinocyte 
and endothelial chemotaxis, mitogenesis of epithelial and mesenchymal cells, and 
fibroblasts, and control of collagenase secretion [47]. No human studies have been 
conducted to assess the affects of EGF, but a study by Park et al. demonstrated increased 
survival rate and neovascularization in fat grafts placed within rabbits ears. In vitro, EGF 
has augmented propagation and differentiation of ASCs (Table 4). [48-51]. 
Platelet-Derived Growth Factor (PDGF) is a dimeric glycoprotein that is a potent 
mitogen for fibroblasts and angiogenisis that can form capillary tubes in adipose tissue-
derived stem cells [52]. It is created and stored in platelet α-granules and released 
subsequent to platelet activation, and is also generated by a number of other cell species, 
including endothelial cells, macrophages, and smooth muscle cells. Above a certain 
dosage threshold, PDGF exhibits an inhibitory effect on human preadipocyte 
differentiation in vitro [53]. Although an animal study by Craft et al. demonstrated 
encouraging results, a double blind clinical trial by Fontdevila et al. demonstrated no 
statistical advantage to using PDGF over controls (Tables 5 and 6). This study involved 
autologous human fat grafting to a patients face and carried a level of evidence of 2b [54, 
55]. Craft et al. bound PDGF to 20-160 µm gelatin microspheres and demonstrated its 
capability for the preservation of adipose weight and structural integrity in mouse model 
xenografts [55].  
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Erythropoietin (EPO) is a glycoprotein hormone and a cytokine that mediates the 
generation of red blood cells (erythropoiesis) [56]. It is involved in responding to 
neuronal injuries [57]. In wound healing processes it promotes cellular propagation and 
differentiation, has cytoprotective properties, and is pro-angiogenic and functions to 
inhibit apoptosis [58]. Although no in vivo human trials have been conducted, one in vitro 
human study by Sabbatini using a three-week EPO treatment regimen demonstrated 
sustained revascularization and reduced inflammation (Tables 7 and 8). [59] 
Furthermore, Hamed et al. observed that EPO-treated human fat grafts within mice had 
increased volume and weight, exhibited elevated microvascular density and angiogenic 
factor expression, and decreased inflammation [60].  
Platelet Rich Plasma (PRP) 
Platelet-Rich Plasma (PRP) consists of blood plasma enriched with approximately a five-
fold concentration of platelets in comparison to ambient plasma, and is typically prepared 
via whole blood centrifugation. It contains numerous growth factors including IGF-1, 
EGF, VEGF (A and C), PDGF (-AA, -AB, and –BB) and transforming growth factor 
(TGF-ß1 and -ß2), which are released by PRP via α-granules on their activation by blood 
resident collagen [61]. These growth factors promote proliferation of endothelial cells, 
angiogenesis, and proliferation of adipocyte progenitor cells [47, 61]. PRP has been used 
to help augment wound healing, bone regeneration, and autologous fat grafting [62].  
PRP enrichment demonstrates positive effects in both human and animal models, 
including enhanced graft volume vascularization and retention compared to control. 
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However, several studies yielded no benefits over controls (Tables 9 and 10). Li et al. 
used animal models to demonstrate that fat grafts treated with PRP prior to 
transplantation into nude mice had a significantly lower necrosis area ratio and higher 
number of micro-vessels than control [63]. Sadati et al. explored the utilization of PRP to 
augment autologous fat graft volume retention over a 30-month timeline involving 2033 
grafts. Most of the 580 patients involved in the study demonstrated greater graft volume 
retention and survival with PRP over extended durations, in contrast to control subjects 
[64]. Gentile et al. showed that patients treated with PRP-enriched autologous fat grafting 
for breast reconstruction had a significantly greater percentage maintenance of contour 
and volume compared to the control group at one year follow-up [65]. On the contrary, 
Salgarello retrospectively reviewed 42 women receiving breast fat grafting; this analysis 
of clinical outcomes per surgeons and patients, rate of liponecrosis, and necessity of 
further fat grafting offered little support for PRP enhancement [66]. 
Adipose Tissue-Derived Stem Cells (ASCs)
Adipose Tissue-Derived Stem Cells (ASCs) are distinguished by their 
immunosuppressive attributes and low immunogenicity; hence, they may be applied to 
impart graft tolerance while averting autoimmunity [82]. Both human and animal models 
have almost universally exhibited positive results using ASCs, including minimal atrophy 
and increased vascularization (see tables 12 and 13). Kølle et al. undertook a triple-blind 
placebo-controlled trial that included 13 subjects to elucidate the survival of fat grafts 
that were enriched with ASCs (20 x 10
6
 ASCs per mL of fat - 2000 times the nominal 
physiological level) as compared to non-enriched fat grafts. The results revealed that the 
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ASC-enriched fat grafts exhibited considerably higher residual volumes (>80% after four 
months) than the controls. The ASC enriched fat grafts contained higher volumes of 
adipose and new connective tissue and less necrotic tissue [83]. Sterodimas et al. 
established that patients receiving ASC-enriched fat grafts achieved results in fewer 
sessions compared to controls and had significantly higher satisfaction after 6 months, 
although by 18 months the groups were not significantly different [84]. In patients with 
craniofacial microsomia, ASC-enriched fat grafts demonstrated an 88% retention volume 
compared to 54% for controls [85].  
Gene Therapy 
Angiogenesis plays a key role in maintaining the long-term viability of autologous fat 
grafts. Neovascularization is vital for graft survival beyond 48 hours [62]. VEGF is one 
of the most important growth factors involved in this process. As discussed previously, 
PRP provides multiple growth factors, including VEGF, which may improve fat graft 
survival. However, PRP is not the only source of VEGF. A new modality being explored 
is the use of adenovirus vectors containing the VEGF gene. The goal would be to 
increase the levels of VEGF to promote neovascularization and enhance graft survival. Yi 
et al. showed that when adenovirus vectors containing the VEGF gene were mixed with 
adipose tissue and subsequently transplanted into mice, there was greater capillary 
density, and less cyst formation and fibrosis when compared to the control groups at 15 
weeks post-transplantation [28]. Using a similar approach, Lu et al. used adenovirus 
vector containing the VEGF gene to transfect adipose-derived stem cells, which were 
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then mixed with human adipose tissue and transplanted into mice. At six months post-
transplantation, there was a significant increase in graft survival, capillary density and 
significantly less fat necrosis and fibrosis relative to control [17]. These adenovirus 
vectors can be used to introduce other genes for growth factors that could augment fat 
graft viability too. However, due to the integrating nature of many viral vectors, more 
research is moving towards non-viral transfecting systems. One promising example is 
minicircle DNA vectors, which do not integrate into genomic DNA, have low levels of 
immunogenicity due to intracellular degradation of the bacterial components of the 
plasmid, and offer high intracellular expression levels of genes. Studies are needed with 
fat grafting to determine effects of this modality, but it appears to be very promising 
[126-129]. 
Adipose Tissue Engineering  
Adipose Tissue Engineering may facilitate the enrichment and subsequent survival of 
fat grafts. Wang et al. combined human adipose-derived stem cells (hASCs) with a 
decellularized human adipose tissue extracellular matrix (hDAM), including VEGF, 
collagen, and sulfated glycosaminoglycan. These subcutaneously implanted engineered 
grafts in rat models sustained their volume at eight weeks. They did not initiate an 
immune response, and proceeded to undergo remodeling as evidenced by adipose tissue 
formation, host cell infiltration, and neovascularization [100]. Lequeux et al. investigated 
the seeding of autologous ASCs onto collagen substrates to enhance fat-enriched 
hypodermal tissue in a porcine wound model. Subsequent to culturing for ten days, the 
ASC scaffolds and controls were implanted in adult porcine models. It was shown that 
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the vascularized ASC scaffolds possessed an augmented layered connective/extracellular 
tissue matrix within the subcutaneous tissue in comparison with controls [130].  
Other Studies 
The enhancement of fat grafts is not exclusive to the methods represented above. Rather, 
autologous fat grafting represents a rapidly emerging technique and investigations into 
many enhancement methods exist. These include but are not restricted to the inclusion of 
traditional eastern remedies such as salvia miltiorrhiza, employment of biological 
scaffolds, and a variety of harvesting and injection techniques (Table 13).  
Discussion 
Autologous fat grafting is a widely utilized procedure by plastic surgeons to augment 
functional and aesthetic form. However, unpredictability of volume retention and other 
complications leaves providers with the inability to determine the optimal technique. 
Multiple donor sites can be utilized in autologous fat grafting without a significant effect 
on outcomes. However, careful planning should be undertaken when determining the 
volume of fat to be grafted in relation to the volume of the recipient site, which can be 
assessed using the GC ratio. The authors suggest that there may be a positive correlation 
between a lower GC ratio and long-term percentage volume maintenance, as 
demonstrated by del Vecchio et al. [14] In addition, the intrinsic compliance of the 
recipient tissue must be taken under consideration when determining the optimal amount 
of fat to be injected for the desired outcome. If the volume of the recipient site cannot 
meet the patient’s expectations, then the surgeon should consider employing tissue 
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expansion to optimize safety, long-term percentage volume maintenance, and patient 
satisfaction.  
Inconsistent study designs and methodologies create an obstacle in determining an 
optimal fat grafting technique. The authors suggest that 3D imaging should be used as the 
gold standard to monitor volume retention in future studies, which would allow for more 
accurate comparison of results among different studies. In addition, there have been 
conflicting results among studies on the effects of aspiration pressure. Lee et al. 
concluded that harvest pressure did not affect graft viability while Cheriyan et al. showed 
that lower harvest pressure led to greater fat graft viability. [12,13] Performing large 
double-blind randomized controlled studies need to be performed should allow for a 
consensus to be reached. However, both studies demonstrated that slow fat injection, 
resulting in lower sheer stress than fast fat injection, resulted in greater fat graft viability.  
Currently, the authors propose that low-pressure aspiration and slow fat injection should 
be employed to increase fat graft viability.   
In addition to harvesting techniques and donor/recipient site considerations, studies have 
indicated that varying adjunct strategies augment fat graft survival. A process of dynamic 
tissue remodeling occurs after fat grafting, particularly in the first three months post-
operatively [6]. During this time, different degrees of adipogenesis, liponecrosis, 
scarring, oil cyst formation, and differentiation and proliferation of ASC transpires. Of 
central importance to this process is angiogenesis as it provides long-term graft viability. 
Several growth factors contribute to angiogenesis, in addition to other vital processes 
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involved in incorporation of the graft into the recipient site, including VEGF, IGF, EGF, 
PDGF, FGF, and EPO. Enrichment of fat grafts through VEGF activated autologous 
stromal vascular fraction and adipose-derived regenerative cells may assist with the 
improvement of fat graft viability. FGF has been shown to increase fat graft mass, 
volume, quality and viability, but their effects on these fat grafts were only examined in 
animals. β-FGF has the capacity to directly and indirectly stimulate pre-adipocytes to 
augment the mass of fat grafts and support metabolic requirements for enhancing their 
vascular structure. Although universally backed by affirmative results, the large number 
of animals studies provides a wanting level of evidence. The authors recommend 
performing an FDA approved double-blind randomized controlled studies in humans to 
determine the utility of VEGF and FGF for adipose graft enhancement in humans. 
According to new regulations, all fat grafting procedures should obtain FDA approval 
prior to initiation.  
IGF has the capacity to initiate preadipocyte differentiation and modulate activity in 
adipogenesis. The authors found only one study examining IGF in animals [31]. The 
results, although beneficial, raised a few questions. Yuksel et al. utilized microspheres 
with no IGF only control. Furthermore, the deficient level of evidence indicates the need 
for further studies in animals and humans with and without microspheres to determine the 
appropriate usage of IGF.  
EGF has been shown to increase the proliferation of hASCs and adipogenesis-related 
mRNAs as well as hasten the propagation and hASC differentation. However, only one 
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animal study has been conducted and the authors recommend further studies before a 
conclusion can be made [51]. 
PDGF exhibits an inhibitory effect on human preadipocyte differentiation in vitro and 
demonstrated preservation of adipose weight and structural integrity in mouse model 
xenografts. Fontdevila et al. indicated the PDGF alone provided negative results, but 
Craft et al. suggested PDGF with microsphere administration provided some benefit. [54, 
55] These studies reveal that further research should pursue the use of PDGF use with
microspheres. 
The EPO-treated fat grafts had increased volume and weight, exhibited elevated 
microvascular density and angiogenic factor expression, and decreased inflammation and 
apoptosis in a dose-linear fashion. However, there is only one in vitro study with human 
tissue involving EPO [59]. A randomized control study is recommended before EPO may 
be used in a clinical setting. 
The use of PRP, which contains multiple growth factors, can be incorporated with fat 
grafts to increase survival and long-term viability [73, 65]. However, optimal platelet 
concentration and preparation methods must be determined and standardized so that 
results of subsequent larger-scale studies can be compared. [65,66,78] The authors find 
this discrepancy worrisome and further studies involving breast tissue are necessary to 
settle the discrepancy between several PRP human studies.  
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Considerable advances have also been established in stem cell technologies, gene 
therapy, and adipose tissue engineering. ASC-enriched fat grafts exhibited considerably 
higher residual volumes of adipose and new connective tissue compared to controls. 
Rodent studies involving adenovirus vector-containing VEGF genes mixed with adipose 
tissue demonstrated greater capillary density, and less cyst formation and fibrosis when 
compared to the control groups. In a similar rodent study, VEGF transfected ASCs 
demonstrated significantly increased graft survival and capillary density, and 
significantly less fat necrosis and fibrosis relative to the control groups at six months 
following transplantation. Engineered grafts implanted in rat models undergo adipose 
tissue formation, host cell infiltration, and neovascularization without rejection. Many 
human studies with varying levels of evidence have demonstrated good functionality in 
humans. The decreased immune activity in fat grafts, decreased atrophy, decreased 
number of procedures and the good levels of evidence indicate that ASC-enriched fat 
grafts have great potential for future use in human fat grafts. Further use of non-
integrating DNA technology like minicircle vectors may also augment current strategies 
[126]. 
Future Directions 
Improved understanding of variables contributing to adipose graft survival will optimize 
lipofilling procedures, making them safer and more effective. Safety should remain a 
priority in experimental therapies such as ASCs and gene therapy. Novel methods in gene 
therapy and the use of stem cells are currently under investigation to improve fat graft 
viability and long-term survival (Figure 5, 6). Controlled clinical studies are lacking, and 
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future studies should examine factors influencing graft survival through double-blinded, 
randomized control clinical trials in order to obtain consistent outcomes and to establish 
recommendations. 
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Figure 9-5. Discussion and Future Direction 
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Figure 9-6. Future Directions for adipose graft enrichment strategies in humans. 
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virus and control 
groups 
+ 
Ding, 2014 
25180953 
Effect of 
Calcium 
Alginate (CA) 
Microsphere 
Loaded with 
Vascular 
Endothelial 
Growth Factor 
on Adipose 
Tissue 
Transplantation 
[20] 
Mice 
Subcutaneous 
abdominal fat 
from a 
healthy, 
young 
woman 
Dorsum 5 
Group 1: adipocytes + 
VEGF-enriched CA 
microspheres 
Group 2: adipocytes + 
free VEGF 
Control: adipocytes + 
empty CA microspheres 
Control: adipocytes 
Group 1-4 were 
implanted 
subcutaneously into the 
dorsum of each mouse 
(n=96) 
3, 6, 
and 12 
weeks 
Mass and 
microvascular 
density of grafts in 
the group with CA 
microspheres loaded 
with VEGF were 
statistically higher 
than that of other 
groups in a time-
dependent manner 
+ 
Li, 2014 
24740717 
Improvement in 
autologous 
human fat 
transplant 
survival with 
SVF plus VEGF-
PLA nano-
sustained 
release 
microspheres 
[21] 
Nude 
mice 
Byproduct of 
skin grafting 
surgery on 30 
yr old human 
female 
3 
random 
sites 
5 
Group 1: fat + SVF + 
VEGF-PLA (polylactic 
acid) nano-sustained 
release microspheres 
Group 2: fat + SVF 
Control: fat + DMEM 
Groups 1-3 were injected 
subcutaneously into 3 
random sites on each 
mouse (n=18) 
2 
months 
Mean wet weight of 
fat was higher in 
SVF+VEGF-PLA 
versus SVF cells 
alone and control 
graft. SVF+VEGF-PLA 
were composed of 
adipose tissue, had 
greater capillary 
density and VEGF 
expression, more 
capillaries, less fat 
necrosis and less 
fibrosis compared to 
the control 
+ 
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Zhang, 
2014 
24559057 
Effect of 
chitosan 
nanospheres 
loaded with 
VEGF on 
adipose tissue 
transplantation: 
a preliminary 
report [22] 
Nude 
mice 
Lipoaspirate 
from 
subcutaneous 
abdominal fat 
of a healthy 
young 
woman 
Dorsum 5 
Group 1: adipocytes + 
chitosan nanospheres 
with VEGF 
Group 2: adipocytes + 
free VEGF 
Control: adipocytes + 
empty chitosan 
nanospheres 
Control: adipocytes only 
Chitosan nanospheres 
loaded with VEGF were 
mixed with adipocytes 
and injected 
subcutaneously into the 
dorsa of mice at four 
points, with each mouse 
carrying four different 
grafts 
3, 6, 
and 12 
weeks 
The weight and 
vascularization of 
treated-grafts were 
significantly higher 
than controls in a 
time-dependent 
manner 
+ 
Tervala, 
2014 
24150116 
Analysis of fat 
graft metabolic 
adaptation and 
vascularization 
using positron 
emission 
tomography-
computed 
tomographic 
imaging [23] 
Mice 
Mouse 
epididymal 
region 
Forehead 5 
Group 1: fat + VEGF-A 
(n=9) 
Control: fat (n=9) 
Metabolic activity and fat 
graft volume were 
measured with PET and 
CT scans. Histologic 
analysis was also 
performed 
4 and 
12 
weeks 
VEGF-A therapy 
enhanced the 
survival and capillary 
density of the 
transferred fat after 
surgery. Both groups 
showed higher 
glucose metabolism 
in the transplanted 
fat than in the fat 
before 
transplantation 
+ 
Chang, 
2014 
23429223 
Improvement of 
the survival of 
autologous free-
fat transplants 
in rats using 
vascular 
endothelial 
growth factor 
165-transfected 
bone 
mesenchymal 
stem cells 
(BMSCs) [24] 
Sprague-
Dawley 
Rat 
Rat inguinal 
fat 
Back 5 
Each rat (n=36) received 
all 3 fat mixtures at 
randomly selected sites: 
Group 1: BMSCs with 
VEGF165 gene 
transfected 
Group 2: BMSCs without 
transfection 
Control: low glucose 
DMEM 
30, 90 
and 
180 
days 
Group 1 had a 
significantly higher 
survival rate and 
higher capillary 
density. Both groups 
1 and 2 had 
significantly less fat 
fibrosis and necrosis 
than the control 
+ 
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Chung, 
2012 
22772067 
VEGF 
microsphere 
technology to 
enhance 
vascularization 
in fat grafting 
[25] 
Nude 
mice 
Human 
lipoaspirate 
Flank 5 
Group 1: VEGF-loaded 
PLGA were injected in a 
lipoaspirate scaffold into 
mice microspheres (n=6) 
Control: empty 
microspheres (n=6) 
Control: lipoaspirate 
(n=6) 
3 and 6 
weeks 
VEGF-loaded PLGA 
injections had a 
higher mass, volume 
and vascularization 
compared to 
injections without 
VEGF 
+ 
Topcu, 
2012 
22351845 
Increasing the 
viability of fat 
grafts by 
vascular 
endothelial 
growth factor 
[26] 
Wistar 
rat 
Inguinal 
adipofascial 
flap 
Dorsal 
inter-
scapular 
region 
5 
Group 1: VEGF prior to 
fat graft (n=6) 
Group 2: VEGF with the 
graft (n=6) 
Control: empty 
microsphere with graft 
(n=6) 
Control: fat graft only 
(n=6) 
90 
days 
Graft viability of 
groups 1-3 was 
significantly higher 
than control. Groups 
1 and 2 had higher 
relative adipocyte 
index compared to 
control and group 3. 
Rats preconditioned 
with VEGF had a 
significantly higher 
microvascular 
density than other 
experimental groups 
+ 
Lu, 2009 
20009828 
Improvement of 
the survival of 
human 
autologous fat 
transplantation 
by using VEGF-
transfected 
adipose-derived 
stem cells [17] 
Nude 
mice 
Lipoaspirate 
from human 
thigh 
Four 
locations 
on each 
mouse 
5 
Each mouse (n=72) was 
injected at one of four 
locations with the 
following: 
Group 1: VEGF-
transfected ADSCs 
Group 2: ADSCs 
Group 3: 10 mmol/L 
insulin 
Control: DMEM 
6 
months 
Group 1 showed the 
highest survival 
percent (74.1 +/- 
12.6), with less fat 
necrosis and fibrosis 
and significantly 
higher capillary 
density compared to 
control 
+ 
Lei, 2008 
18230293 
Effect of rhVEGF 
gene 
transfection on 
survival of 
grafts after 
autologous free 
granular fat 
transplantation 
in rats [27] 
Sprague-
Dawley 
rat 
Inguinal fat 
pads 
Back 5 
Group 1: fat + plasmid 
cDNA with gene encoding 
rhVEGF (n=16) 
Control: fat + blank 
plasmid (n=16) 
Control: fat + normal 
saline (n=16) 
Day 7, 
15 and 
30 
Weights of the two 
control groups were 
significantly lower 
than the group 
injected with the 
rhVEGF gene. The 
expression of VEGF 
and micro-vessels 
was significantly 
higher in the group 
injected with the 
rhVEGF gene 
+ 
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Yi, 2007 
17293285 
VEGF gene 
therapy for the 
survival of 
transplanted fat 
tissue in nude 
mice [28] 
Nude 
mice 
Human 
breast 
Scalp 5 
Group 1: human breast fat 
treated with adenovirus-
mediated VEGF (Ad-
VEGF) (n=10) 
Group 2: adenovirus-
mediated green fluorescent 
protein gene (GFP) (n=10) 
Control: normal saline 
(n=10) 
15 
weeks 
Fat survival volume, 
weight, and capillary 
density were 
significantly higher 
in the group treated 
with Ad-VEGF, 
compared to groups 
2 and 3. There was 
less cyst formation 
and fibrosis in the 
group treated with 
Ad-VEGF. Mice 
treated with Ad-
VEGF also had 
significantly higher 
VEGF protein levels 
after the fat injection, 
compared to groups 
2 and 3 
+ 
Nishimura, 
2000 
10942136 
Microvascular 
angiogenesis 
and apoptosis in 
the survival of 
free fat 
grafts [29] 
Rats 
Inguinal fat 
pads 
Back 5 
Free fat grafts enhanced 
with VEGF and grafted 
tissue was examined for 
necrosis and signs of 
vascularization (n=25) 
Day 7, 
30, 90 
and 
180 
Revascularization of 
the graft around day 
7 
+ 
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Table 9-2. FGF Animal Studies 
Author, 
Year 
PMID, Title Model Donor site 
Recipient 
site 
LOE Technique 
Follow-
up 
Result Conc 
Jiang, 
2015 
25695105 
Improvement of the 
survival of human 
autologous fat 
transplantation by 
adipose-derived 
stem-cells-assisted 
lipotransfer 
combined with bFGF 
[32] 
Immuno-
compro-
mised 
nude 
mice 
Human fat 
tissue 
Back 5 
Human fat tissues were 
mixed with ASCs, ASCs plus 
100 U of bFGF, or medium as 
the control. 
12 weeks 
Mixtures with ASCs 
significantly 
increased the 
weight and volume 
of fat grafts, ASCs 
and ASCs with bFGF 
showed less fibrosis 
but more 
microvasculature 
density.  Higher 
survival and 
vascularization in 
bFGF treated 
implants. 
+ 
Nakamu
ra, 2011 
21210502 
Increased survival 
of free fat grafts and 
vascularization in 
rats with local 
delivery of fragmin/ 
protamine 
microparticles 
containing FGF-2 
[33] 
Fisher 
344 rat 
Inguinal 
region 
Dorsal side 
pockets 
5 
Group 1: fat combined with 
fragmin/protamine micro-
particles containing FGF-2 
(n=48) 
Group 2: grafts containing 
only FGF-2, only fragmin-
protamine micro-particles, 
or only PBS 
30 and 
120 days 
Control fat grafts 
were significantly 
resorbed after 30 
days, while the 
group with 
fragmin/protamine 
micro-particles 
containing FGF-2 
experienced 
minimal resorption 
and higher graft 
volume retention. 
+ 
Hong, 
2010 
19556175 
Enhancing the 
viability of fat grafts 
using new transfer 
medium containing 
insulin and beta-
fibroblast growth 
factor in autologous 
fat transplantation 
[30] 
New 
Zealand 
White 
rabbits 
Inguinal 
region 
Dorsum 5 
Group 1: modified DMEM 
(n=6) 
Group 2: modified DMEM 
with insulin (n=6) 
Group 3: modified DMEM 
with insulin and beta-FGF 
(n=6) 
Control: saline 
1, 3, 6 and 
12 months 
Groups 2 and 3 
showed 
significantly greater 
viability of fat grafts 
than the saline 
control. There were 
more mature 
adipocytes and 
reduced cyst 
formation and 
fibrosis in groups 2 
and 3 
+ 
Kuramo
chi, 
2008 
18837800 
Matrix 
metalloproteinase 2 
improves the 
transplanted 
adipocyte survival 
in mice [34] 
Mice 
Inguinal 
region 
Randomly 
chosen 
different 
areas 
5 
Transplants were combined 
with bFGF in the presence of 
MMP-2 (group 1) or with 
MMP-2 inhibitor (group 2) 
4 weeks 
Transplant with 
MMP-2 had faster 
fat accumulation, 
higher PPAR 
gamma mRNA 
levels, and faster 
glucose uptake. 
+ 
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Marra, 
2008 
18349632 
FGF-2 enhances 
vascularization for 
adipose tissue 
engineering [35] 
Nude 
mice 
Human 
abdomen 
Back 5 
Control: preadipocytes 
without FGF-2 (n=5) 
Group 2: preadipocytes with 
FGF-2 loaded microspheres 
(n=5) 
14 days 
Vascularization was 
significantly 
enhanced with FGF-
2 loaded 
microspheres 
+ 
Tamura, 
2007 
17917834 
Adipose tissue 
formation in 
response to basic 
fibroblast growth 
factor [36] 
Beagle 
dogs 
Subcutaneous 
fat 
Vocal 
cords 
5 
Recurrent laryngeal nerve 
paralysis was prepared in 12 
beagle dogs. Fat was injected 
into the ipsilateral and 
contralateral vocal cord for 
experimental and control 
groups. 
Group 1: Mixture of fat with 
bFGF, gelatin microspheres, 
and collagen sponge 
Control: Autologous fat 
8 weeks 
and 24 
weeks 
In vocal cords 
injected with bFGF 
and fat mixture, 
immature 
adipocytes were 
found at 8 weeks 
after injection. 
Vocal cords with 
untreated fat 
showed a significant 
decrease in volume 
over time 
+ 
Yazawa, 
2006 
17014671 
Influence of 
vascularized 
transplant bed on 
fat grafting [37] 
Rabbit 
Posterior 
neck 
Dorsal 
subdermal 
layer 
5 
Silicone substrate was 
coated with gelatin 
containing FGF, then 
transplanted into the dorsal 
subdermal layer in a rabbit. 
After 2-4 weeks, autologous 
fat was transplanted into the 
capsule (n=13) 
4 weeks 
In groups 
pretreated with 
growth factors, 
proliferation of 
blood vessels was 
observed, while 
overall necrosis was 
observed in 
untreated controls 
+ 
Kimura, 
2003 
12695078 
Adipose tissue 
engineering based 
on human 
preadipocytes 
combined with 
gelatin 
microspheres 
containing basic 
fibroblast growth 
factor [38] 
Mice 
Human 
adipose 
tissue from 
breast 
Back 5 
A collagen sponge acted as a 
cell scaffold and contained 
preadipocytes and gelatin 
microspheres (containing 
bFGF). 
Group 1: Sponge with 
preadipocytes and 
microspheres with bFGF 
(n=6) 
Group 2: Sponge with 
preadipocytes and free bFGF 
(n=6) 
Group 3: Sponge + bFBF 
microsphere (n=6) 
Group 4: Sponge + 
preadipocytes (n=6) 
Group 5: Preadipocytes + 
microspheres of bFGF (n=6) 
6 weeks 
Group 1 presented 
the most viable fat 
growth 
+ 
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Eppley, 
1992 
1280367 
Bioactivation of 
free-fat transfers: a 
potential new 
approach to 
improving graft 
survival [39] 
Rat 
Inguinal 
region 
Back 5 
Bioactive fat grafts were 
created by the addition of 
basic fibroblasts via dextran 
beads. There were 4 grafts 
for each animal: FGF and 
beads, free fat alone, free fat 
plus beads, and beads plus a 
control solution (n=40). 
1 and 12 
months 
The growth factor 
grafts maintained 
nearly their entire 
weight 1 year after 
the transplant. The 
free fat group lost 
more than half of 
the original graft 
weight after 1 year. 
There were more 
small-sized 
adipocytes among 
the larger 
adipocytes in the 
growth factor 
treated group. 
+ 
Eppley, 
1992 
1374121 
Autologous facial fat 
transplantation: 
improved graft 
maintenance by 
microbead 
bioactivation [40] 
Rat 
Inguinal 
region 
Face 5 
Fat grafts are either mixed 
with either bFGF alone or 
dextran beads pretreated 
with bFGF. Grafts were 
compared by weight and 
histology at one and 6 
months after the transplant 
(n=20) 
1 and 6 
months 
The grafts were 
very similar after 1 
month, but after 6 
months the bead-
containing grafts 
maintained nearly 
complete weight 
and had better 
overall graft form 
+ 
Eppley, 
1991 
1897414 
A physiochemical 
approach to 
improving free fat 
graft survival: 
preliminary 
observations [41] 
Rats 
Inguinal fat 
pad 
Lateral 
face 
5 
Bioactive free fat grafts were 
made using bFGF carried on 
positively charged, 
hydrophillic, dextran beads. 
The bioactive fat grafts were 
compared with contralateral 
free fat grafts (n=15). 
90 days 
Complete retention 
of the bioactive fat 
grafts was observed 
after 90 days, while 
the free fat grafts 
lost nearly half their 
original weight 
+ 
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Table 9-3. IGF Animal Studies 
Author, 
Year 
PMID, Title Model 
Donor 
site 
Recipient 
site 
LOE Technique Follow-up Result Conc 
Yuksel, 
2000 
10809102 
Increased free fat-
graft survival with 
the long-term, local 
delivery of insulin, 
insulin-like growth 
factor-I, and basic 
fibroblast growth 
factor by PLGA/PEG 
microspheres [31] 
Rats 
Inguinal 
fat 
Sub-
dermal 
pockets in 
the dorso-
lumbar 
region 
5 
Group 1: fat + insulin 
microspheres (n=6) 
Group 2: fat + IGF-1 
microspheres (n=6) 
Group 3: fat + basic FGF 
microspheres (n=6) 
Group 4: fat + insulin and IGF-1 
microspheres (n=6) 
Group 5: fat + insulin, IGF-1, and 
basic FGF microspheres (n=6) 
Control: fat + blank 
microsphere (n=6) 
Control: untreated fat (n=6) 
12 weeks 
All growth factor 
treatments 
significantly 
increased fat graft 
weight and volume in 
comparison with the 
untreated and blank 
microsphere-treated 
controls. Treatment 
with insulin and IGF-
1, alone or in 
combination, was 
found to increase the 
adipocyte area 
percentage in 
comparison with fat 
grafts treated with b-
FGF alone or in 
combination with 
other growth factors 
+ 
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Table 9-4. EGF Animal Studies
Author, 
Year 
PMID, Title Model 
Donor 
site 
Recipient 
site 
LOE Technique Follow
-up 
Result Concl. 
Park, 2011 
21461630 
The effect of 
epidermal growth 
factor on 
autogenous fat graft 
[51] 
New 
Zealand 
rabbits 
Inguinal 
region 
Ear 5 
Group 1: fat + EGF (n=24) 
Control: fat + normal saline 
(n=24) 
3 
month
s 
The EGF fat graft had a 
significantly higher 
survival rate compared 
to the control group. 
There was also an 
increase in 
neovascularization and 
maintenance of fat cell 
morphology observed 
in the EGF group 
+ 
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Table 9-5. PDGF Animal Studies 
Author, 
Year 
PMID, Title Model 
Donor 
site 
Recipient site LOE Technique Follow-
up 
Result Concl. 
Craft, 2009 
18178534 
Effect of local, long-
term delivery of 
platelet-derived 
growth factor 
(PDGF) on injected 
fat graft survival in 
severe combined 
immunodeficient 
(SCID) mice [55] 
Mice 
with 
SCID 
Human 
subcuta
neous 
adipose 
tissue 
from the 
abdome
n 
Pericranial region 5 
Group 1: fat + PDGF 
bound to 
microspheres (n=8) 
Group 2: fat + free 
PDGF (n=8) 
Control: fat + blank 
microspheres (n=8) 
Control: fat graft 
(n=8) 
12 weeks 
The group with 
PDGF bound to 
microspheres had an 
increased weight 
maintenance and 
preservation of 
adipose tissue 
architecture, as 
compared to the 
control groups 
+ 
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Table 9-6. PDGF Human Studies
Author, Year PMID, Title Model 
Donor 
site 
Recipient site LOE Technique Follow-
up 
Result 
Concl
. 
Fontdevila, 
2014 
25068344 
Double-blind clinical 
trial to compare 
autologous fat grafts 
versus autologous fat 
grafts with PDGF: no 
effect of PDGF [54] 
Human 
Various 
dependi
ng on 
patient 
Face 2b 
Group 1: fat + PDGF 
Control: fat 
2 and 12 
months 
Both groups 
exhibited 
significant 
increase of volume 
in the facial area 
and improvement 
in clinical facial 
atrophy grade 
after 
treatment.  There 
was no statistically 
significant 
difference in the 
volume gain 
between the 
groups. 
- 
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Table 9-7. EPO Animal Studies
Author, Year PMID, Title Model 
Donor 
site 
Recipient site LOE Technique 
Follow-up 
Result Conc 
Hamed, 2010 
21085572 
Erythropoietin improves 
the survival of fat tissue 
after its transplantation 
in nude mice [60] 
Nude 
mice 
Human 
thigh 
Scalp 5 
Experimental: low-
dose EPO + fat graft 
(n=10) 
Experimental: high-
dose EPO + fat graft 
(n=10) 
Control: VEGF + fat 
graft (n=10) 
Control: PBS + fat 
graft (n=10) 
15 weeks 
The weight 
and volume 
of EPO-
treated 
grafts were 
higher than 
PBS-treated 
and VEGF-
treated 
grafts. EPO 
treatment 
increased 
the 
expression 
of 
microvascul
ar density 
and 
angiogenic 
factors, 
while 
reducing 
inflammatio
n and fat 
cell 
apoptosis in 
a dose-
dependent 
manner 
+ 
210
1
Table 9-8. EPO Human Studies 
Author, Year PMID, Title Model 
Donor 
site 
Recipient site LOE Technique 
Follow-up 
Result Conc 
Sabbatini, 2015 
26034645 
Effects of erythropoietin 
on adipose tissue: a 
possible strategy in 
refilling [59] 
In vitro 
Anterior 
mid-
face 
N/A 5 
Fat graft was seeded 
on culture dishes for 
24 hours and then 
treated for 3 weeks 
with either 0.15 μg/ml 
of EPO, 0.30 μg/ml of 
EPO, or 0.60 μg/ml of 
EPO.  After staining 
with CD31 and CD68, 
quantification of cell 
infiltration in fat grafts 
was estimated. 
3 weeks 
EPO 
increased 
the number 
of CD31-
positive 
microvessel
s and CD31-
positive 
small 
lymphocyte
s in the fat 
grafts.  EPO 
decreased 
the number 
of CD68-
positive 
cells and 
macrophage
s in the fat 
grafts. 
+ 
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Table 9-9. PRP Animal Studies
Author, 
Year 
PMID, Title Model 
Donor 
site 
Recipie
nt site 
LOE Technique 
Follo
w-
up 
Result Conc 
Li, 2015 
25805284 
Improved fat graft 
survival by 
different volume 
fractions of 
platelet-rich 
plasma and 
adipose-derived 
stem cells. [67] 
Nude 
mice 
Human 
fat 
tissue 
and 
blood 
Subcuta
neous 
(mouse) 
5 
Lipoinjection of granular fat, PRP 
(0%, 10%, 20%, and 30%; 
volume/volume [v/v]) and ASCs 
10, 
30, 
60 
and 
90 
days 
20% (v/v) PRP and 
ASCs had higher 
residual volumes and 
improves graft survival.  
No significant difference 
between 20% and 30% 
PRP in terms of 
retaining fat grafts and 
histology. 
+ 
Por, 2009 
18550460 
Platelet-rich 
plasma has no 
effect on 
increasing free fat 
graft survival in 
the nude mouse 
[68] 
Nude 
mice 
Human 
lipoaspi
rate 
from 
subcuta
neous 
abdomi
nal 
adipose 
tissue 
Scalp 5 
Group 1: fat + PRP (n=12) 
Control: fat + normal saline 
(n=12) 
16 
week
s 
The mean weight, 
volume and histological 
parameters between the 
experimental and 
control groups were not 
statistically significant 
no sig 
diff
Nakamura, 
2010 
20548232 
Platelet-rich 
plasma (PRP) 
promotes survival 
of fat-grafts in rats 
[69] 
Rats 
Inguinal 
region 
Subcuta
neous 
dorsal 
pockets 
5 
Fat transplants prepared with PRP 
and without PRP (control) were 
transplanted into subcutaneous 
dorsal pockets on the right and 
left sides of 64 rats 
Group 1: fat + PRP + fat graft 
Control: fat 
10, 
20, 3, 
120 
days 
The control group was 
significantly resorbed 
by day 30. The PRP 
group showed little 
resorption from day 30-
120. The number of 
normal adipocytes in 
the control group 
decreased after day 20 
but the PRP group 
sustained normal 
adipocytes. PRP had 
more granulation tissue 
and capillary formation. 
PRP increased 
angiogenesis and viable 
adipocytes 
+ 
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Pires Fraga, 
2010 
20708988 
Increased survival 
of free fat grafts 
with platelet-rich 
plasma in rabbits 
[70] 
New 
Zealand 
rabbits 
Scapula
r area 
Ear 5 
Group 1: fat + PRP (n=15) 
Control: fat + normal saline 
(n=15) 
6 
mont
hs 
PRP group had a 
significantly higher fat 
survival weight, number 
of adipocytes and blood 
vessels. There was more 
necrosis and fibrosis in 
the control group 
+ 
Rodriguez-
Flores, 
2011 
21184066 
Influence of 
platelet-rich 
plasma on the 
histologic 
characteristics of 
the autologous fat 
graft to the upper 
lip of rabbits [71] 
New 
Zealand 
rabbits 
Groin 
fat pad 
Upper 
lip 
5 
One side of the rabbit's upper 
lip was injected with fat + PRP 
while the other side was 
injected with fat alone (n=8) 
8 
and 
12 
week
s 
PRP group had less 
inflammatory reactions 
and fewer oil cysts 
compared to control 
+ 
Oh, 2011 
21492303 
Activated platelet- 
rich plasma 
improves fat graft 
survival in nude 
mice: a pilot study 
[72] 
Nude 
mice 
Abdome
n 
Scalp 5 
Group 1: fat + PRP 
Control: fat + normal saline 
10 
week
s 
Increase in weight, 
volume, and vascularity; 
reduced cysts, vacuoles, 
and fibrosis; no 
difference in the cellular 
integrity and 
inflammation between 
the two groups 
+ 
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Table 9-10. PRP Human Studies
Author, 
Year 
PMID, Title Model 
Donor 
site 
Recipie
nt site 
LOE Technique 
Follo
w-
up 
Result Conc 
Sasaki, 
2015 
26335660 The 
Safety and Efficacy 
of Cell-Assisted Fat 
Grafting to 
Traditional Fat 
Grafting in the 
Anterior Mid-Face: 
An Indirect 
Assessment by 3D 
Imaging. [73] 
Human 
Anterior 
mid face 
Site 
specific 
dependi
ng on 
patient 
3 
On the voluntary principle, 
candidates selected one of four 
techniques for volumization of 
their mid-face: conventional fat 
grafting; PRP-assisted fat 
grafting; SVF-assisted fat 
grafting; and PRP/SVF- assisted 
fat grafting. For comparison 
data, comparable fat volumes, 
SVF volumes and nucleated 
cells, and PRP volumes and 
platelet concentrations were 
injected into each designated 
group. 
Up to 
one 
year 
PRP, SVF, and PRP/SVF 
cell supplementation of 
processed fat resulted in 
statistically significant 
percent mean graft 
retention over their 
baseline control at 12 
months (p < 0.01). The 
use of either PRP or SVF 
alone resulted in almost 
equal outcomes. 
Combining cell 
populations provided no 
additional advantage 
over single cellular 
therapy. 
+ 
Tajima, 
2014 
25287591 
Direct and indirect 
effects of a 
combination of 
adipose-derived 
stem cells and 
platelet-rich 
plasma on bone 
regeneration[74] 
Rat 
Inguinal 
fat pads 
Calvaria
l defect 
5 
ASCs were isolated from 
inguinal fat pads of F344 inbred 
rats, while PRP was prepared 
from these rats. The ASC/PRP 
admixture was transplanted 
into the rat calvarial defect. 
4 
and 
8 
week
s 
Transplantation of the 
ASC/PRP admixture had 
dramatic effects on bone 
regeneration overtime 
in comparison with rats 
that received other 
transplants. 
Furthermore, some ASCs 
directly differentiated 
into osteogenic cells 
+ 
Gentile, 
2013 
22964262 
Breast 
reconstruction with 
autologous fat graft 
mixed with platelet-
rich plasma [65] 
PRP 
Abdome
n 
Breast 2b 
Group 1: fat + PRP (n=50) 
Control: fat (n=50) 
1 
year 
69% maintenance of the 
contour restoring and 
volume after 1 year in 
the PRP group 
compared with 39% in 
the fat only group 
+ 
Keyhan, 
2013 
22883321 
Use of platelet-rich 
fibrin and platelet-
rich plasma in 
combination with 
fat graft: which is 
more effective 
during facial 
lipostructure? [75] 
PRP and 
platelet 
rich 
fibrin 
(PRF) 
Inner 
side of 
the knee 
Face 1b 
Patients underwent bilateral 
facial lipostructure: one side 
was treated with PRP and the 
other side was treated with 
PRF. Each patient was 
evaluated for fat resorption 
(n=25) 
1 
mont
h 
and 
1 
year 
After 1 year, the 
hemiface treated with 
PRP showed greater fat 
resorption compared to 
the side treated with 
PRF 
+ 
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Niţă, 2013 
24398999 
The synergy 
between lasers and 
adipose tissues 
surgery in 
cervicofacial 
rejuvenation: 
histopathological 
aspects [76] 
PRP, 
adipolase
r 
rejuvenat
ion 
Flanks 
or 
abdome
n 
Face 2b 
Adipolaser rejuvenation was 
compared in two zones of the 
inferior abdomen in patients 
(n=50) preparing for 
abdominoplasty. The histology 
of fat alone (area A) or 
stimulation of fat graft with 
fractional CO2 laser and 
activated PRP (area B) were 
compared 
10 
days 
and 
4 
mont
hs 
Significant histological 
difference between 
stimulated and non-
stimulated fat grafts 
with regard to number 
of young adipocytes 
present, pre-adipocytes, 
local cell growth, 
neovascularization, and 
dermal matrix 
remodeling. CO2 with 
PRP prolonged the life 
and take of the facial fat 
graft, increased collagen 
formation, and led to 
better remodeling of the 
dermal matrix 
+ 
Cervelli, 
2012 
22182435 
Treatment of 
traumatic scars 
using fat grafts 
mixed with platelet-
rich plasma, and 
resurfacing of skin 
with the 1540 nm 
nonablative laser 
[77] 
PRP 
Abdome
n 
Trauma
tic scars 
of 
differen
t body 
parts 
1b 
Group 1: fat + PRP (n=20) 
Group 2: nonablative laser 
(n=20) 
Group 3: treated with both 
procedures 1 and 2 (n=20) 
3 
and 
6 
mont
h 
inter
valfo
r up 
to 24 
mont
hs 
Group 3 was the most 
effective treatment 
(11% increase of wound 
healing vs. Group 2 and 
22% increase of wound 
healing vs. Group 1) 
+ 
Gentile, 
2012 
23197813 
A comparative 
translational study: 
the combined use of 
enhanced stromal 
vascular fraction 
and platelet-rich 
plasma improves fat 
grafting 
maintenance in 
breast 
reconstruction [78] 
PRP, e-
SVF 
(enhance
d stromal 
vascular 
fraction) 
Abdome
n 
Breast 3b 
Group 1: fat + e-SVF (n=10) 
Group 2: fat + PRP (n=13) 
Control: fat (n=10) 
1 
year 
After 1 year, the e-SVF 
fat grafts had a 63% 
maintenance of contour 
restoring and volume; 
PRP-enhanced fat grafts 
had a 69% maintenance; 
non-treated fat grafts 
had a 39% maintenance 
+ 
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Salgarello, 
2011 
21617451 
Breast fat grafting 
with platelet- 
rich plasma: a 
comparative 
clinical study and 
current state of 
the art  [66] 
PRP 
Abdome
n, flanks, 
trochant
er 
regions, 
inner 
thigh, 
and 
medial 
aspect 
of the 
knees 
Breast 3b 
Group 1: fat + PRP (10%) 
(n=17) 
Control: fat (n=25) 
3 
and 
6 
mont
hs 
Fat graft enriched with 
PRP (10%) was not 
better than Coleman fat 
graft using parameters 
of clinical outcomes 
(from surgeons and 
patients), rate of 
liponecrosis, and 
necessity for further fat 
graft 
no 
sig 
diff 
Cervelli, 
2010 
20489388 
Tissue regeneration 
in loss of substance 
on the lower limbs 
through use of 
platelet-rich plasma, 
stem cells from 
adipose tissue, and 
hyaluronic acid [79] 
PRP 
Abdome
n 
Inferior 
limbs 
ulcers 
or loss 
of 
substan
ce 
3b Fat + PRP (n=30) 
0, 1, 
2, 
and 
3 
week
s; 1, 
3, 
and 
6 
mont
hs; 
and 
1 
year 
Wound healing 
improvement after 3 
weeks in 100% of 
patients; healing in less 
than 6 weeks in 47% of 
patients; complete 
wound healing within 3 
months of 57% patients 
+ 
Cervelli, 
2009 
19156458 
Regenerative 
surgery: use of fat 
grafting combined 
with platelet-rich 
plasma for chronic 
lower-extremity 
ulcers [80] 
PRP 
Abdome
n 
Lower 
limb 
chronic 
ulcers 
2b 
Group 1: fat + PRP (n=20) 
Control: fat + hyaluronic acid and 
collagen (n=10) 
2 
and 
5 
week
s; 3, 
6, 
and 
12 
mont
hs; 
then 
annu
al 
16/20 patients had 
ulcers re-epithelialize 
during an average of 9.7 
weeks compared with 
2/10 treated with 
hyaluronic acid and 
collagen based 
treatment 
+ 
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Table 9-11. ASC Animal Studies 
Author, 
Year 
PMID, Title Model 
Donor 
site 
Recipie
nt site 
LOE Technique Follow-
up 
Result Conc 
Jung, 2015 
26207545 
Improvement of Fat 
Transplantation: Fat 
Graft With 
Adipose-Derived 
Stem Cells and 
Oxygen-Generating 
Microspheres [86] 
Rat 
Inguinal 
fat pads 
Back 5 
Group 1: Fat transplantation 
only 
Group 2: Fat transplantation 
with oxygen-generating 
microspheres 
Group 3: Fat transplantation 
with ASC’s 
Group 4: Fat transplantation 
with oxygen-generating 
microspheres and ASC’s 
2 weeks 
Compared to control 
group, weight and 
volume increased 
significantly in group 
3 and 4; group 3 and 
4 had the largest 
survival distance of 
fat cells from 
transplanted tissue. 
Group 3 had the most 
FGF-2 at 14 days and 
Group 4 had the most 
FGF-2, IGF-1, EGF at 
14 days. 
+ 
Kashimura
, 2015 
26375247 
The Effect of 
Mature Adipocyte-
Derived 
Dedifferentiated Fat 
(DFAT) Cells on a 
Dorsal Skin Flap 
Model [87] 
Sprague-
Dawley 
rat 
Intraperi
toneal 
adipose 
tissue 
from 
male SD 
rat 
Back 5 
Group 1: Flap base injection 
where DFAT cells injected 2 cm 
from the flap base 
Group 2: Flap center injection 
where DFAT cells injected in 
flap center 
14 days 
Connective tissue 
thickened in the flap 
base injection group 
of rats. The survival 
rates for flap base 
injection group were 
the highest. 
+ 
Loder, 
2015 
25185931 
Wound Healing 
after thermal injury 
is improved by fat 
and adipose-derived 
stem cell isografts 
[88] 
C57BL/6 
mice 
Inguinal 
fat pads 
Burn 
sites 
5 
Group 1: processed adipose 
Group 2: ASCs 
Group 3: mixed adipose 
(adipose and ASCs) 
Group 4: saline 
5 and 
14 days 
No significant 
changes in 
proliferation or 
vascularization were 
seen at 5 days 
between groups. All 
groups showed 
improved healing 
over controls. 
no sig 
diff
Zhu, 2015 
24172865 
Adipocyte 
regeneration after 
free fat 
transplantation: 
Promotion by 
stromal vascular 
fraction cells [89] 
BALB/c‐
nu/nu 
mice 
Human 
abdomin
al 
lipoaspir
ate 
Back 5 Group 1: fat with SVF cells 
Control: fat with DMEM 
1, 4, 7, 
14, 30, 
60, 90 
days 
Adipose tissue mixed 
with SVF cells 
showed a higher 
retention rate, new 
vessels on graft at 
day 3, neonatal 
adipocytes 
surrounding new 
vessels, and higher 
levels of VEGF and 
bFGF compared to 
the control group 
(adipose tissue with 
+ 
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culture medium and 
no SVF cells). 
Derby, 
2014 
24334307 
Adipose-derived 
stem cell to 
epithelial stem cell 
transdifferentiation: 
a mechanism to 
potentially improve 
understanding of fat 
grafting's impact on 
skin rejuvenation 
[90] 
Mice 
Abdomi
no-
inguinal 
fat pads 
from 
GFP+ 
mice 
Parasca
pular 
region 
5 
Group 1: whole fat graft (n=6) 
Group 2: ASC + peptide 
hydrogel carrier (n=6) 
Control: Contralateral side 
8 weeks 
Both whole fat and 
ASC groups have 
increased dermal 
vessels. GFP+ cells 
express p63. 
Significantly higher 
levels of p63 were 
expressed in ADSC + 
hydrogel group 
versus gel alone and 
control 
+ 
Koellensp
erger, 
2014 
24703751  
Intracutaneously 
injected human 
adipose tissue-
derived stem cells in 
a mouse model stay 
at the site of 
injection [91] 
Immuno
deficient 
BALBc/n
ude mice 
Human 
abdomin
al 
lipoaspir
ate 
Back 
5 
Group 1: MSC injected (n=21) 
Control: Culture medium 
injected 
4 
weeks, 
6 
months
12 
months 
MSCs move deeper in 
subcutaneous tissue 
and exhibit partial 
differentiation to 
adipocytes, 
successfully stay at 
the injection site and 
survive up to one 
year. Some 
differentiate into 
adipocytes with no 
inflammation, 
ulceration, or tumor 
induction 
+ 
Kono, 
2014 
24300011 
Phenotypic and 
functional 
properties of feline 
dedifferentiated fat 
cells and adipose-
derived stem cells 
[92] 
Animal 
Feline 
omental 
fat tissue 
N/A 5 
Mature adipocyte-derived 
dedifferentiated fat (DFAT) 
cells were compared to ASCs for 
growth kinetics, colony-forming 
unit fibroblast (CFU-F) 
frequency, immunophenotypic 
properties, and multilineage 
differentiation potential 
N/A 
DFAT cells and ASCs 
had similar 
immunophenotypes. 
CFU-F's were 
significantly higher 
in DFAT and both 
cells exhibited 
multipotent activity 
in vitro 
No 
sig diff
Tian, 2014 
25608789 
Effects of rat 
allogeneic adipose-
derived stem cells 
Sprague-
Dawley 
rats 
Inguinal 
region 
Back 5 
A = allogeneic adipose granule 
(AG) group; 
B=autologous adipose granule 
group; 
7 days 
Groups C and D had 
higher wet weights 
and more 
surrounding cells 
+ 
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on the early 
neovascularization 
of autologous fat 
transplantation [93] 
C= autologous 
ADSCs+autologous AG group; 
D= allogeneic 
ADSCs+autologous AG group 
with positive CD31 
than groups A and B. 
Trivisonno
, 2014 
24687265 
Harvest of 
superficial layers of 
fat with a 
microcannula and 
isolation of adipose 
tissue-derived 
stromal and vascular 
cells [94] 
Mice 
Abdome
n and 
hip of 
human 
females 
(n=6) 
N/A 
5 
Group 1: rounded-tip cannula 
with a length of 170 mm, a 
diameter of 3 mm, and a single 
elliptic suction port on the side 
near its distal end (port 
diameter: 3 × 9 mm) 
Group 2: rounded-tip 
infiltration cannula with a 
length of 170 mm, a diameter of 
2 mm, and 5 round ports placed 
spirally along the sides of the 
distal cannula shaft (each port 
diameter: 1 mm) 
ASCs expressing firefly 
luciferase were injected into 
immunosuppressed mice 
Several 
weeks 
Number of cells 
collected by 
microcannula were 
significantly higher 
and cells implanted 
into the mice 
survived multiple 
weeks in areas 
experiencing 
neovascularization 
+ 
Dong, 
2013 
24260375 
The survival 
condition and 
immunoregulatory 
function of adipose 
stromal vascular 
fraction (SVF) in 
the early stage of 
nonvascularized 
adipose 
transplantation [95] 
Nude 
mice 
Human 
abdomin
al 
lipoaspir
ate 
Flank 5 
Mice (n=28) were injected on 
contralateral sides with: 
Group 1: human lipoaspirate 
mixed with marked SVF cells 
Control: human lipoaspirate 
mixed with PBS 
1, 4, 7 
and 14 
day 
SVF cells contained 
blood-derived cells, 
adipose-derived 
stromal cells 
(ADSCs), and 
endothelial cells. 
ADSCs moved to the 
periphery of the 
implant 
+ 
He, 2013 
23210496 
Effect of ASCs on 
the graft survival 
rates of fat particles 
in rabbits [96] 
Rabbit 
Inguinal 
regions 
Dorsal 
midline 
5 
Experimental: SVF containing 
ASC transplanted with fat graft 
into one side of rabbit's dorsal 
midline; Control: untreated fat 
graft transplanted into the 
other side of the dorsal midline 
3 
months 
Survival rate of ASC 
treated grafts after 3 
months was 23.56 
+/- 2.49%, while the 
survival rate of the 
untreated control 
grafts was 11.06 +/- 
2.10%. 
+ 
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Lee, 2013 
23471894 
Orbital volume 
augmentation after 
injection of human 
orbital adipose-
derived stem cells 
in rabbits [97] 
Rabbits 
Human 
orbital 
adpiose 
tissue 
Rabbit 
orbit 
5 
Group 1: injection with 
hyaluronic acid gel (HAG); 
Group 2: injection wtih HAG + 
human orbital stromal vascular 
fraction (hoSVF); Group 3: 
injection with HAG + hoADSCs 
4 
weeks, 
8 
weeks, 
and 12 
weeks 
Group with 
HAG+hoADSCs had 
the largest 
exophthalmometric 
value difference from 
injection to 4 weeks 
at 2.43 mm and 2.56 
at 12 weeks. Specific 
inflammation at 
week 4 but went 
away 8 weeks after 
injection (all groups). 
+ 
Liu, 2013 
22681647 
The adjuvant use of 
stromal vascular 
fraction and 
platelet-rich fibrin 
for autologous 
adipose tissue 
transplantation [98] 
Rabbit 
Scapular 
region 
(rabbit) 
Rabbit 
Ear 
5 
Group 1: adipose granules 
(AG)+saline; Group 2:(AG)+SVF; 
Group 3: (AG+PRF); Group 4: 
(AG+SVF+PRF). 
Weekly 
up to 24 
weeks 
Group 4 had a higher 
microvessel density 
at 4 weeks post-
implant and the 
resorption rates 
were the lowest of all 
the groups 
+ 
Philips, 
2013 
23783061 
Prevalence of 
endogenous CD34+ 
adipose stem cells 
predicts human fat 
graft retention in a 
xenograft model 
[99] 
Nude 
mice 
Human 
lipoaspir
ate 
Flank 5 
Lipoaspirate from human 
subjects (n=8) were injected 
into mice. The fat was evaluated 
for SVF percentage and relevant 
markers. 
8 weeks 
High correlation 
between SVF 
percentage of CD34+ 
progenitors and high 
graft retention 
+ 
Wang, 
2013 
23816649 
Combining 
decellularized 
human adipose 
tissue extracellular 
matrix and adipose-
derived stem cells 
for adipose tissue 
engineering [100] 
Fischer 
rats 
Human 
abdomin
al 
lipoaspir
ate 
Back 5 
Group 1: engineered fat grafts 
(ASCs with hDAM 
microparticles and fresh fat) 
Control: fresh fat grafts 
harvested via the Coleman 
technique 
1, 2, 4, 
and 8 
weeks 
Engineered fat grafts 
maintained their 
volume for 8 weeks 
and the ASCs 
contributed to 
adipose tissue 
formation 
+ 
Zamperon
e, 2013 
23777308 
Isolation and 
characterization of a 
spontaneously 
immortalized 
multipotent 
mesenchymal cell 
line derived from 
mouse subcutaneous 
adipose tissue [101] 
Mice 
epididy
mal/par
ametrial 
fat pads 
of mice 
Intrasple
nic 
injection 
5 
NOD/SCID-gnull male mice 
were treated with monocrotalin 
and the next day, 2x10^6 GFP-
m17 ASCs were 
infused 
Daily , 
varying
1 week 
up to 6 
weeks 
Despite exposure to 
pro-tumor agents, 
this cell line was 
non-tumorigenic and 
immortalized as it 
was found stable 
after 180 passages. 
+ 
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Zhu, 2013 
23392800 
Effects of 
xenogeneic adipose-
derived stem cell 
transplantation on 
acute-on-chronic 
liver failure [102] 
Rabbit 
Porcine 
fat tissue 
Rabbits 5 
Rabbits with acute-on chronic 
liver failure (ACLF) received 
either ASC transplantation or 
the same volume of saline 
2, 7, 14, 
21, and 
28 days 
ASC transplantation 
were found in the 
periportal region of 
the liver, improved 
survival rate, 
biochemical 
parameters, and 
there was less 
histomorphological 
scoring 
+ 
Zografou, 
2013 
23636118 
Autologous 
transplantation of 
adipose-derived 
stem cells enhances 
skin graft survival 
and wound healing 
in diabetic rats 
[103] 
Rats 
Pannicul
us 
carnosus 
tissue 
from the 
midline 
of the 
back 
Muscle-
fascial 
layer of 
midline 
of the 
back 
5 
A full thickness skin graft model 
was used with ASCs (n=10) or 
without ASCs (n=10) in diabetic 
mice. The stem cells were 
derived from the same rat's 
inguinal fat pad. The grafts 
were assessed after 1 week 
1 week 
Increased survival, 
angiogenesis and 
epithelialization in 
the ASC group. In 
addition, the ASC 
group had less 
necrosis and 
increased capillary 
density, collagen 
intensity, VEGF and 
TGF-beta expression 
+ 
Butler, 
2012 
22655687 
Cotransplantation of 
adipose-derived 
mesenchymal 
stromal cells and 
endothelial cells in a 
modular construct 
drives 
vascularization in 
SCID/bg mice [104] 
Mice 
Abdomi
nal fat 
samples 
(human) 
Dorsum 5 
Group1: modules coated with 
EC, without 
embedded adMSC; Group 2: 
modules embedded with adMSC 
and coated with EC; Group 
3:modules with embedded 
adMSC, without EC 
3, 7, 14, 
21, 30, 
60, and 
90 days 
Vessel number 
increased up to day 
14, then decreased 
afterwards (pointing 
to maturation of 
vessels). Vessel 
perfusion was 
confirmed (day 21). 
Implant volumes 
decreased over time 
but HMEC+adMSC 
implants were larger 
than control (adMSC 
without HMEC 
coating). 
+ 
Venugopal
, 2012 
22374846 
Adipogenesis on 
biphasic calcium 
phosphate using rat 
adipose-derived 
mesenchymal stem 
cells: in vitro and in 
vivo [105] 
Sprague 
Dawley 
rat 
Subcuta
neous 
fat pad 
Dorsal 
muscle 
5 
Cell-ceramic-engineered 
construct with ASCs and BCP 
implanted into rat dorsal 
muscle 
3 weeks 
Histology of 
implanted tissue 
construct showed 
chicken wire net-like 
adipose cells within 
the construct 
+ 
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Li, 2011 
21774351 
The effect of 
adipose-derived 
stem cells on 
viability of random 
pattern skin flap in 
rabbits  [106] 
Rabbits 
Human 
fat 
Back 5 
Random pattern skin flaps were 
designed on the backs of rabbits 
and then injected with either 
ADSCs or medium (without 
ADSCs) as a control on the 
contralateral side. 
1 week 
side with ADSCs had 
a significant increase 
of flap survival and 
significantly higher 
capillary density 
+ 
Ko, 2011 
21448310 
Effects of expanded 
human adipose 
tissue-derived 
mesenchymal stem 
cells on the viability 
of cryopreserved fat 
grafts in the nude 
mouse [107] 
Nude 
mice 
Human 
adipose 
Subcuta
nous 
injection 
over the 
skull 
5 
Single donor ADSC were mixed 
with fat that had been 
cryopreserved at -70c for 8 
weeks. This mixture was 
injected subcutaneously into 
nude mice. 
4 and 
15 
weeks 
At 4 weeks post-
transplantation, the 
adipose-derived 
stem cell group 
showed significantly 
improved fat cell 
integrity as well as 
greater volume and 
weight. At 15 weeks 
the two groups 
showed no 
significant difference 
in size, weight or 
histological 
parameters. 
+ 
Fu, 2010 
21046778 
Experimental study 
of the effect of 
adipose stromal 
vascular fraction 
cells on the survival 
rate of fat 
transplantation. 
[108] 
Rabbit 
Autologo
us fat 
tissue 
Back 5 
Fat graft mixed with SVFs 
(Group A), ASCs (Group B), or 
untreated (Group C) 
6 
months 
Groups treated with 
SVFs (Groups A) and 
ASCs (Group B) 
consisted of adipose 
tissue with less fat 
necrosis and fibrosis 
and higher capillary 
density as compared 
to untreated fat 
grafts (Group C). 
+ 
Moyer, 
2010 
20842001 
Alginate 
microencapsulation 
technology for the 
percutaneous 
delivery of adipose-
derived stem cells 
[109] 
Nude 
mice 
Human 
Dorsal 
subcuta
neous 
pocket 
5 
Experimental: Nude mice were 
implanted with ADSC-treated 
alginate microspheres; Control: 
untreated microspheres 
1 and 3 
months 
Microspheres 
showed durability of 
up to 3 months, and 
ADSCs remained 
viable and 
demonstrated signs 
of mitosis. 
+ 
Jiang, 
2009 
19873723 
Proliferation of the 
mesenchymal stem 
cells in a delayed fat 
flap: an 
experimental study 
in  rabbits [110] 
Rabbit 
Delayed 
fat flap 
in 
inguinal 
region of 
rabbit 
N/A 
5 
Expression rates of ASCs taken 
from a delayed fat flap 
21 days 
In the delayed fat 
flap, CD29 and CD44 
were higher but 
CD14 and CD45 were 
lower. 
+ 
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Li, 2009 
19558169 
Experimental study 
of the effect of 
adipose tissue 
derived stem cells 
on the survival rate 
of free fat 
transplantation 
[111] 
Nude 
mice 
Human 
liposucti
on 
Back 5 
ASCs were harvested from 
liposuction and differentiated 
into adipogenic, chondrogenic 
and osteogenic lines. These 
stem cells were mixed with fat 
and injected to group A. Group 
B was insulin + fat and group C 
was medium +fat. Each 
preparation was injected 
subcutaneously on the backs of 
the 18 mice. 
6 
months 
Wet weight of the 
transplant was 
highest in group A 
(165.97mg), 
followed by 
B(93.42mg) followed 
by C(67.64mg). The 
rate of fibrosis and 
steatonecrosis was 
significantly lower in 
the ASC group than 
either of the other 
two. It was also 
shown that some of 
the remaining 
adipose-derived 
stem cells expressed 
CD31 and FITC 
suggesting the 
differentiated into 
Vascular endothelial 
cells 
+ 
Li, 2009 
19275095 
Comparison 
between kinds of 
myofascial flap 
encapsulating 
adipose-derived 
stromal cells carrier 
complex in terms of 
adipogenic efficacy 
in vivo [112] 
Rabbits Neck 
(Autoge
nous 
ASCs 
transpla
nt) 
5 
Group A: muscle flap and 
collagen protein scaffold to 
encapsulate ADSCs; Group B: 
dextral gluteus maximus fascial 
flap with no specific vessel 
pedicle 
8 weeks 
Neovascularization 
was seen in group A, 
but very little in 
group B. Group A had 
a higher weight of 
cambium. There 
were regenerated 
adipocytes and 
partial capillary 
endothelium in both 
groups. 
+ 
Lu, 2009 
20009828 
Improvement of the 
survival of human 
autologous fat 
transplantation by 
using VEGF-
transfected adipose-
derived stem cells 
[17] 
Nude 
mice 
Liposuct
ion 
aspirate 
from 
human 
thigh 
Four 
random 
locations 
on the 
mouse 
(1 spot 
per 
group, 
four 
injection
s per 
mouse) 
5 
Group 1; VEGF transfected 
ASCs; Group 2: stem cells; 
Group 3: 10 micromol/liter 
insulin; Group 4: Dulbecco's 
modified Eagle medium. 
6 
months 
Group 1 showed the 
highest survival 
percent (74.1 +/- 
12.6) and 
significantly higher 
capillary density 
+ 
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Yoo, 2009 
19270821 
Tissue engineering 
of injectable soft 
tissue filler: using 
adipose stem cells 
and micronized 
acellular dermal 
matrix [113] 
Nude 
mice 
Human 
abdome
n 
Dorsal 
cranial 
region 
5 
Implants included ASCs and 
micronized acellular dermal 
matrix (Alloderm). 
2 
months 
ASCs differentiated 
into adipocytes. 
+ 
Lu, 2008 
18176205 
Improved viability 
of random pattern 
skin flaps through 
the use of adipose-
derived stem cells 
[114] 
ICR mice 
Inguinal 
fat pads 
of ICR 
mice 
Pedicle 
base or 
1.5 cm 
distal to 
the 
pedicle 
5 
Skin flap was elevated, then 
injected with either ASCs from 
inguinal pads of ICR mice or a 
combination of mature 
adipocytes and bFGF (control 
group). 
1 week 
Addition of ADSCs 
resulted in a 
significant increase 
in flap viability and 
capillary density 
compared to 
untreated control 
groups. 
+ 
Mizuno, 
2008 
17975300 
In vivo adipose 
tissue regeneration 
by adipose-derived 
stromal cells 
isolated from GFP 
transgenic mice 
[115]  
Nude 
mice 
Inguinal 
fat pads 
of GFP 
mice 
Dorsum 5 
ASCs isolated from inguinal fat 
pads of GFP mice were 
incubated in an induction 
medium to induce adipogenesis. 
These induced ASCs were 
combined with fibrin glue and 
injected subcutaneously into 
the dorsum of athymic mice. 
4 and 8 
weeks 
Regenerated tissue 
was soft with slight 
angiogenesis. 
Fluorescence 
microscopy revealed 
strong emitted green 
fluorescence, 
suggesting the ASCs 
contributed to 
adipogenesis. 
+ 
Matsumot
o, 2006 
17518674 
Cell-assisted 
lipotransfer: 
supportive use of 
human adipose-
derived cells for soft 
tissue augmentation 
with lipoinjection 
[116] 
Mice 
with 
SCID -
severe 
combine
d 
immuno
deficienc
y 
Abdomi
nal or 
thigh 
liposucti
on 
(human) 
Back 5 
Experimental: Human aspirated 
fat transplanted with vascular 
stromal fractions containing 
isolated ASCs; Control: Human 
aspirated fat transplanted 
without vascular stromal 
fractions 
4 weeks 
Injected fat 
containing ASCs 
survived better by 
approximately 35% 
and contained more 
microvasculature 
than untreated fat. 
+ 
Clavijo-
Alvarez, 
2006 
17016179 
A novel 
perfluoroelastomer 
seeded with 
adipose-derived 
stem cells for soft-
tissue repair [117] 
Nude 
mice 
Human 
abdome
n 
Back 5 
One of two fluoropolymers that 
differ in pore size (U48 and 
P54) were mixed with human 
adipose-derived stem cells, and 
then implanted subcutaneously 
in a nude mouse for 30 days. 
30 days 
Fluoropolymer U48 
increased the 
adherence and 
provided a superior 
surface for 
proliferation of 
adipose-derived 
stem cells. 
+ 
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Hong, 
2006 
17108684 
Adipose tissue 
engineering by 
human adipose-
derived stromal 
cells [118] 
Mice 
with 
SCID 
Human 
ASCs 
Back 5 
ASCs seeded on gelatin sponges 
were exposed to adipogenic 
differentiation medium and 
then implanted into the backs 
of mice with SCID. 
4 weeks 
Adipogenic 
constructs turned 
into fat tissue within 
4 weeks after 
transplantation. No 
fat formation was 
observed when 
ADSCS were exposed 
to a control medium 
without 
differentiation 
factors. 
+ 
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Table 9-12. ASC Human Studies
Author, 
Year 
PMID, Title Model Donor site 
Recipient 
site 
LOE Technique Follow-
up 
Result Conc 
Charles-
de-Sá, 
2015 
25811565 
Antiaging treatment 
of the facial skin by 
fat graft and 
adipose-derived 
stem cells. [119] 
Human 
Liposuction 
from 
abdomen 
Face 4 
Preauricular areas on the 
patient were injected with fat 
and its stromal vascular 
fraction or with fat and 
expanded mesenchymal stem 
cells. 
3 
months 
Modified reticular 
dermis architecture and 
evidence of a richer 
microvascular bed 
+ 
Hanson, 
2013 
23908304 
Comparative 
analysis of adipose-
derived 
mesenchymal stem 
cells isolated from 
abdominal and 
breast tissue [120] 
Human 
cells 
Abdomen 
and Breast 
N/A 5 
Comparison of surface marker 
expression, differentiation 
capabilities, fibroblast growth 
factor (FGF) and receptor 
expression, and 
immunophenotype of 
macrophages between ASCs 
taken from breast and 
abdominal tissue. 
N/A 
Between the two sets of 
ASC they showed 
similar cell surface 
phenotype and both 
showed multilineage 
differentiation. The 
ASCs taken from breast 
tissue had a higher FGF 
expression level versus 
the ASCs taken from 
abdominal tissue. 
Kølle, 
2013 
24075051 
Enrichment of 
autologous fat grafts 
with ex-vivo 
expanded adipose 
tissue-derived stem 
cells for graft 
survival: a 
randomised 
placebo-controlled 
trial [83] 
Human Abdomen 
Posterior 
part of 
right and 
left upper 
arms 
2b 
Fat grafts with or without ASCs 
injected into upper arms 
121 
days 
ASC-enriched fat grafts 
had significantly higher 
residual volume than 
control grafts 
+ 
Marino, 
2013 
23773718 
Therapy with 
autologous 
adipose-derived 
regenerative cells 
for the care of 
chronic ulcer of 
lower limbs in 
patients with 
peripheral arterial 
disease [121] 
Human Abdomen 
Lower 
limb ulcer 
4 
ASCs were injected into edges 
of lower limb ulcer 
4, 10, 
20, 60 
and 90 
days 
With ASC injection there 
was a decrease in 
diameter, depth and 
pain. Also, 6/10 patients 
experienced total 
healing of the ulcer 
+ 
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Tanikawa, 
2013 
23806916 
Fat grafts 
supplemented with 
adipose-derived 
stromal cells in the 
rehabilitation of 
patients with 
craniofacial 
microsomia [85] 
Human Abdomen Face 
2b 
Patients with craniofacial 
microsomia received a graft 
with adipose-derived stromal 
cells or without (control group). 
They were assessed 
preoperatively and 6 months 
post-operatively. 
6 months 
88% of the original 
fat volume suvived 
for the patients 
with ASC and only 
54% fat volume 
survived for the 
control group. 
+ 
Doornaert, 
2012 
22777036 
Intrinsic dynamics 
of the fat graft: in 
vitro interactions 
between the main 
cell actors [122] 
Human Abdomen N/A 5 
CD34+ ASCs were co-cultured 
with mature adipocytes. 
N/A 
CD34+ ASCs 
proliferate and 
differentiate into 
adipose tissue upon 
exposure to mature 
adipose cells. 
+ 
Koh, 2012 
22907186 
Clinical application 
of human adipose 
tissue-derived 
mesenchymal stem 
cells in progressive 
hemifacial atrophy 
(Parry-Romberg 
disease) with 
microfat grafting 
techniques using 3-
dimensional 
computed 
tomography and 3-
dimensional camera 
[123] 
Human Abdomen 
Face 
(Parry-
Romberg 
disease) 
2b 
Group 1: Received microfat 
grafts with ASC enrichment 
Control: Received microfat 
grafts without ASCs 
15 
months 
Fat graft survival 
was better in the 
patients with the 
adipose-derived 
stem cell 
enrichment. Overall 
resorption was 
20.59% in ASC 
group and 46.81 in 
control group. 
+ 
Sterodima
s, 2011 
21813882 
Autologous fat 
transplantation 
versus adipose-
derived stem cell-
enriched lipografts: 
a study [84] 
Human 
Autologou
s fat or 
ASCs 
Face 
(congenital 
or 
acquired 
facial 
tissue 
defects) 
2b 
Ten patients were treated with 
autologous fat transplantation, 
and the other ten received 
adipose-derived stem cell-
enriched lipografts. 
6, 12, and 
18 
months 
The patients with 
the adipose-derived 
stem cell treatment 
only needed one 
treatment, while 
only 3/10 control 
patients achieved 
the desired result in 
one session. There 
was significantly 
higher patient 
satisfaction in the 
experimental group 
after 6 months, but 
by the 18 month 
evaluation the 
groups were not 
significantly 
different. 
+ 
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Tiryaki, 
2011 
21487913 
Staged stem cell-
enriched tissue 
(SET) injections for 
soft tissue 
augmentation in 
hostile recipient 
areas: a preliminary 
report [124] 
Human 
Various 
sites 
"Hostile 
recipient 
areas" 
4 
Autologous ASCs were injected 
into recently grafted sites. 
Monitore
d over 3 
years 
Postoperative 
atrophy was 
minimal and did not 
change after 8 
weeks. This was 
compared to 
historical atrophy 
rates of 20-80%. 
+ 
Yoshimura
, 2008 
17763894 
Cell-assisted 
lipotransfer for 
cosmetic breast 
augmentation: 
supportive use of 
adipose-derived 
stem/stromal cells 
[125] 
Human 
Thighs, 
abdomen, 
and lower 
legs 
Breast 4 
Stromal vascular fraction 
containing ASCs combined with 
aspirated fat and injected into 
breasts for cosmetic breast 
augmentation (n=40) 
2 months 
Postoperative 
atrophy of injected 
fat was minimal and 
did not change 
drastically after 2 
months. Cyst 
formation was 
detected in 4 
patients. Almost all 
patients were 
satisfied with the 
augmentation. 
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Table 9-13. Other studies
Author
, Year 
PMID, Title Model 
Donor 
site 
Recipient 
site 
LOE Technique 
Follow-
up 
Result Conc 
Bae, 
2015 
25899889 
Effects of human 
adipose-derived 
stem cells and 
stromal vascular 
fraction on 
cryopreserved fat 
transfer. [131] 
Human 
to nude 
mice 
Lower 
abdomen 
of human 
Back of 
nude mice 
5 
The cryopreserved fat grafts 
were treated with ADSC, 
SVF, or normal saline in 30 
six-week-old male nude 
mice to test whether ADSC 
and SVF could improve the 
survival of the transplanted 
fat tissue. 
8 weeks 
There was no 
difference between 
the control and SVF 
groups with respect 
to weight, volume, 
and histological 
findings. However, 
the ADSC group 
showed a significant 
increase in weight 
and volume 
compared with the 
control and SVF 
groups. Histological 
examination 
showed that the 
ADSC 
supplementation 
improved the 
quality of the 
transplanted fat 
grafts. 
+ 
Garza, 
2015 
25502860 
Studies in fat 
grafting: Part IV. 
Adipose-derived 
stromal cell gene 
expression in cell-
assisted lipotransfer 
[132] 
Human 
to 
mouse 
Flank, 
thigh, and 
abdomen 
(Human) 
Scalp 
(Mice) 
5 
Adipose-derived stromal 
cells isolated from human 
lipoaspirate were labeled 
with green fluorescent 
protein and luciferase. Fat 
grafts enhanced with 
adipose-derived stromal 
cells were injected into the 
scalp and bioluminescent 
imaging was performed to 
follow retention of adipose-
derived stromal cells within 
the fat graft. 
1,5, and 
10 days 
Although adipose-
derived stromal cell 
survival in the 
hypoxic graft 
environment 
decreases 
significantly over 
time, these cells 
provide multiple 
angiogenic growth 
factors. Therefore, 
improved fat graft 
volume retention 
with adipose-
derived stromal cell 
enrichment may be 
attributable to 
improved graft 
vascularization. 
+ 
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Gillis, 
2015 
26218392 
Effect of N-
Acetylcysteine on 
Adipose-Derived 
Stem Cell and 
Autologous Fat 
Graft Survival in a 
Mouse Model [133] 
Mouse Inguinal Scalp 5 
Inguinal fat pads were 
harvested using tumescent 
solution with or without N-
acetylcysteine. N-
Acetylcysteine-treated or 
control grafts were injected 
under recipient mouse 
scalps. 
3 months 
In vivo, N-
acetylcysteine 
treatment resulted 
in improved graft 
retention compared 
with control N-
Acetylcysteine-
treated grafts 
demonstrated less 
fibrosis and 
inflammation, and a 
33 percent increase 
in adipocyte density 
compared with 
controls (p < 0.001) 
that was not 
associated with 
increased 
vascularity. 
+ 
Li, 
2015 
23509085 
Construction of 
engineering 
adipose-like tissue 
in vivo utilizing 
human insulin gene-
modified umbilical 
cord mesenchymal 
stromal cells with 
silk fibroin 3D 
scaffolds [134]   
Rat 
Human 
insulin 
gene-
modified 
umbilical 
cord 
mesench
ymal 
stromal 
cells 
(hUMSCs) 
Under 
dorsal skin 
5 
hUMSCs infected with Ade-
insuline-EGFP were seeded 
in silk fibroin 3D scaffolds, 
cultured for 4 days in 
adipogenic medium, and 
transplanted. A control 
group received the silk 
fibroin 3D scaffolds with 
untransfected hUMSCs. Both 
groups were analyzed at 8 
and 12 weeks. 
8 and 12 
weeks 
More tissue 
regeneration, more 
fat-like cells with 
larger volume, and 
more degradation of 
the scaffolds in the 
group with hUMSCs 
infected with Ade-
insulin-EGFP in the 
scaffolds. 
+ 
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Luo, 
2015 
25675023 
Coimplanted endothe
lial 
cells improve  adipos
e 
tissue grafts'  survival
 by  increasing 
vascularization [135] 
Human 
to Mice 
Human 
Mice 
(Subcutan
eous) 
5 
The isolated ECs were 
labeled, then added to 0.5-
mL fat grafts at different 
numbers (0.5 × 10(6), 1 × 
10(6), 2 × 10(6), and 4 × 
10(6) cells) before 
subcutaneous implantation 
in nude mice. Grafts were 
harvested at 1 week, 1 
month, and 2 months after –
transplantation. 
1 week, 1 
month 
and 2 
months 
Stromal vascular 
fraction-derived 
vascular cells exhibi
ted typical EC 
characteristics. The 
observed 
differences in 
explanted graft 
weight, vessel 
density, vascular 
gene expression, 
and cell tracking 
result indicated that 
coimplantation with 
ECs 
accelerated vascular
ization that 
increased 
graft survival in a 
concentration-
dependent manner. 
+ 
Osinga, 
2015 
26017597 
Effects of 
intersyringe 
processing on 
adipose tissue and 
its cellular 
components: 
implications in 
autologous fat 
grafting [136] 
Human 
in vitro 
Abdomin
al 
NA 5 
Lipoaspiration was 
performed, followed by 
shuffling the fat either zero, 
five, or 30 times between 
two 10-cc syringes. 
Thereafter, fat was applied 
through a 1.5-mm cannula 
for autologous fat grafting. 
N/A 
The process of 
shuffling changed 
the macroscopic but 
not the microscopic 
structure. No 
difference in cell 
number, viability, 
number of lipid 
droplets, vascular 
architecture, or 
ratio of cell 
composition was 
found. Analysis of 
the stromal vascular 
fraction did not 
show significant 
changes. 
+ 
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Phipps, 
2015 
25539302 
Alternatively 
activated M2 
macrophages 
improve autologous 
Fat Graft survival in 
a mouse model 
through induction 
of angiogenesis 
[137] 
Mouse Inguinal Scalp 5 
Grafts from C57BL/6 mouse 
inguinal fat pads were 
supplemented with M2 
macrophages generated by 
intraperitoneal Brewer's 
thioglycollate injection and 
in vitro culture. Grafts with 
saline or M2 macrophages 
were injected under 
recipient mouse scalps and 
assessed by serial micro-
computed tomographic 
analysis. 
1 month 
and 3 
months 
One month after 
graft injection, no 
significant 
difference was 
noted between M2 
macrophage-
supplemented (105 
± 7.0 mm) and 
control graft 
volumes (72 ± 22 
mm). By 3 months 
after injection, M2 
macrophage-
supplemented 
grafts remained 
stable, whereas 
controls 
experienced further 
volume loss (103 ± 
8 mm versus 39.4 ± 
15 mm; p = 0.015). 
+ 
Soares, 
2015 
25626795 
Targeted protection 
of donor graft 
vasculature using a 
phosphodiesterase 
inhibitor increases 
survival and 
predictability of 
autologous fat grafts 
[138] 
Mice Inguinal Dorsa 5 
Inguinal fat of donor 
Tie2/LacZ mice was 
infiltrated with sildenafil or 
saline, harvested, and 
transplanted onto the dorsa 
of recipient FVB mice. 
Additional donor mice were 
perfused with intraarterial 
trypsin. 
12 and 24 
weeks 
Compared with 
controls, targeted 
sildenafil treatment 
improved early 
graft perfusion, 
doubled graft 
retention at 12 
weeks (83 percent 
versus 39 percent; p 
< 0.05), ultimately 
retaining 64 percent 
of the original graft 
volume by 24 weeks 
(compared to 4 
percent; p < 0.05) 
with superior 
histologic features. 
+ 
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Yu, 
2015 
26446419 
Traditional Chinese 
Medicine: Salvia 
miltiorrhiza 
Enhances Survival 
Rate of Autologous 
Adipose Tissue 
Transplantation in 
Rabbit Model [139] 
Rabbit 
Scapular 
region 
Dorsum of 
the ear 
5 
Minced adipose tissue 
harvested from the scapular 
region was transplanted 
into the dorsum of the ears 
of New Zealand rabbits. The 
experimental groups were 
intra-peritoneally injected 
with S. miltiorrhiza for a 
total 4 weeks. Levels of 
VEGF, CD31, perilipin and 
cell survival were 
monitored. 
2,4,and 
12 weeks 
At 12 weeks, the 
survival rates in the 
experimental group 
were statistically 
greater than that in 
the control group, 
respectively 
(p < 0.05). Plasma 
levels of VEGF in the 
experimental group 
at different time 
points were 
significantly higher 
than that in the 
control group 
(p < 0.05). 
Histologically, grafts 
in the experimental 
group showed 
better survival of 
adipocytes and neo-
vascularization. By 
perilipin immuno-
histochemical 
staining, the 
experimental group 
demonstrated 
better adipocyte 
survival. 
+ 
Beitzel, 
2014 
24581253 
Properties of 
biologic scaffolds 
and their response 
to mesenchymal 
stem cells [140] 
Human 
rotator 
cuff 
Bone 
marrow, 
proximal 
humerus 
Various 
various 
biologic 
scaffolds 
5 
MSCs were cultured on 
human rotator cuff tendon, 
human highly cross-linked 
collagen membrane, porcine 
non-cross-linked collagen 
membrane, a human 
platelet-rich fibrin matrix, 
and a fibrin matrix based on 
platelet-rich plasma and 
then counted for adhesion, 
proliferation and live/dead 
stain. 
N/A 
More cells adhered 
to both the non-
cross-linked porcine 
collagen scaffold 
and PRF-M. Cell 
proliferation was 
higher in the non-
cross-linked porcine 
collagen scaffold 
compared with PRF-
M and fibrin matrix. 
based on platelet-
rich plasma 
+ 
Chung, 
2014 
24622574 
Studies in fat 
grafting: Part I. 
Effects of injection 
technique on in 
vitro fat viability 
and in vivo volume 
Mice 
Not 
specified 
(Human) 
Scalp 5 
Lipoaspiration samples 
were obtained from five 
donors, and cellular 
viability, proliferation, and 
lipolysis were evaluated 
following injection using 
either a modified coleman 
4,6,8, and 
12 weeks 
In vivo fat volume 
retention was 
significantly greater 
than with the 
modified Coleman 
technique 
+ 
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retention [141] technique or an 
automated,low shear device 
Li, 
2014 
24740717 
Improvement in aut
ologous human fat t
ransplant survival w
ith SVF plus VEGF-
PLA nano-
sustained release-
microspheres [21]    
Human 
cells 
into 
mice 
Human Mouse 5 
SVF cells were harvested 
and constructed VEGF-
PLA nano-
sustained releasemicrosphe
res in 
vitro. Human fat tissues was 
mixed 
with SVF cells plus VEGF-
PLA, SVF cells alone or 
Dulbecco's modified Eagle's 
medium as the control. 
These three mixtures were 
injected into random sites 
in 18 nude mice. 
2 months 
The mean wet 
weight of fat in 
the SVF plus VEGF-
PLA, SVF alone, and 
control transplants 
were 0.18 ± 0.013 g, 
0.16 ± 0.015 g, and 
0.071 ± 0.12 g, 
respectively; the 
differences between 
groups were 
statistically 
significant. More 
vessels were 
present in 
the SVF plus VEGF-
PLA transplants 
than in the other 
two types. 
Transplants mixed 
with SVF cells also 
had an acceptable 
density of 
capillaries. 
+ 
Saliba, 
2014 
24307457 
Growth factors 
expression in 
hyaluronic acid fat 
graft myringoplasty 
[142] 
Guinea 
pigs 
Nuchal 
area of 
guinea 
pig 
Tympanic 
membrane 
5 
Hyaluronic acid fat graft 
myringoplasty (HAFGM) 
technique and levels of EGF, 
IGF, TNFalpha, VEGF, and 
KGF were investigated. 
0,3,8, 21 
days 
HAFGM had higher 
levels of all growth 
factors tested 
except KGF and the 
tympanic 
membrane closure 
was 
neovascularizaed 
and scarless, versus 
spontaneous 
closure in the 
control group. 
+ 
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Sezgin, 
2014 
24529693 
Improving fat graft 
survival through 
preconditioning of 
the recipient site 
with microneedling 
[143] 
Albino 
rats 
Inguinal 
fat pad 
Dorsal 
area 
5 
The dorsal area was 
preconditioned with 
standard technique micro-
needling 1-week prior to fat 
graft transfer in the study 
group while the control 
group did not undergo 
micro-needling 
15 weeks 
Fat grafts in the 
study group had 
better integrity and 
a higher level of 
vascularity 
compared to the 
control group. 
Volume analysis 
demonstrated 
higher graft survival 
in the study group 
in comparison to 
the control group 
+ 
Willem
sen, 
2014 
24984784 
The effects of 
platelet-rich plasma 
on recovery time and 
aesthetic outcome in 
facial rejuvenation: 
preliminary 
retrospective 
observations [144] 
Human 
Upper 
legs 
Face 3a 
For the first part of this 
study, i.e., evaluation of 
recovery time after surgery, 
the following selection 
criteria were used: 
nonsmoking females, aged 
35-65 years, with a
complete documented 
follow-up.  For the second 
part of the study, evaluation 
of potential differences in 
aesthetic outcome, the 
records of these 82 patients 
were screened for the 
presence of pre- and 
postoperative standardized 
photographs in three views. 
N/A 
Adding PRP to facial 
lipofilling reduces 
recovery time and 
improves the 
overall aesthetic 
outcome of a MACS-
lift. 
+ 
Xu, 
2014 
25562157 
Human breast 
adipose-derived 
stem cells 
transfected with the 
stromal cell-derived 
factor-1 receptor 
CXCR4 exhibit 
enhanced viability 
in human 
autologous free fat 
grafts [145] 
Human 
to 
mouse 
Breast 
adipose-
derived 
stem cells 
(Human) 
Random 
(Mice) 
5 
Human breast adipose-
derived stem cells (HBASCs) 
were expanded ex vivo for 3 
passages, labeled with 
green fluorescent protein 
(GFP) and transfected with 
CXCR4 or left untransfected. 
Autologous fat tissues were 
mixed with the GFP-labeled, 
CXCR4-transfected HBASCs 
(group A), GFP-labeled 
HBASCs (group B), the 
known vascularization-
promoting agent VEGF 
(group C), or medium 
(group D) and then injected 
subcutaneously into 32 
nude mice at 4 spots in a 
random fashion. 
6 months 
Our data 
demonstrated that 
HBASCs can 
enhance the 
survival and quality 
of transplanted free 
fat tissues. 
Moreover, CXCR4 
transfection of these 
HBASCs could 
augment this effect. 
+ 
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Zhou, 
2014 
25405913 
In vivo bioimaging 
analysis of stromal 
vascular fraction-
assisted fat grafting: 
the interaction and 
mutualism of cells 
and grafted fat 
[146] 
Mouse Inguinal Back 5 
Fat tissue and SVF 
separated from luciferase 
(Luc)-transgenic rats were 
applied for bioimaging 
analysis. The Luc-fat (0.2 
mL) was subcutaneously 
injected into the back of 
nude mice with or without 
SVFs from 0.2 mL wild type 
rat fat 
Up to 63 
days 
The bioimaging 
results showed that 
fat tissues 
transplanted with 
SVFs had higher 
survival ratio than 
those transplanted 
without SVFs  
Stromal vascular 
fraction-assisted fat 
grafts had more 
integral structure 
and less necrosis 
cysts. The results 
showed that, with 
the existence of 
grafted fat, 
transplanted SVF 
survived for a 
significantly longer 
time and could 
contribute to fat 
graft survival and 
regeneration by 
differentiating into 
structural cells. 
+ 
Arono
witz, 
2013 
24281640 Adipose 
stromal vascular 
fraction isolation: a 
head-to-head 
comparison of four 
commercial cell 
separation systems 
[147] 
Human Abdomen N/A 5 
Comparison of 
commercially available 
systems for isolating 
stromal vascular fraction 
cells 
N/A 
Each system (1) 
PNC's Multi Station, 
(2) CHA Biotech 
Cha-Station, (3) 
Cytori Celution 
800/CRS System, 
and (4) Medi-Khan's 
Lipokit with 
MaxStem yielded 
stromal vascular 
fraction cells but 
there are 
differences in the 
viability, number, 
and safety profiles 
of the collections. 
N/A 
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Bulgin, 
2013 
24024064 
Autologous bone-
marrow-derived-
mononuclear-cells-
enriched fat 
transplantation in 
breast 
augmentation: 
evaluation of 
clinical outcomes 
and aesthetic 
results in a 30-year-
old female [148] 
Human 
BMMNCs 
from 
bone 
marrow 
in 
posterior 
iliac 
crest; fat 
from 
abdomen, 
thighs, 
flanks 
Breasts 3b 
BMMNCs and purified fat 
mixture injected directly 
into patient's breasts 
2 weeks, 
4 weeks, 
3 months, 
6 months, 
and 12 
months 
Postoperative 
atrophy of injected 
fat was minimal and 
did not change 
significantly after 
12 months; patient 
experienced 
improvement in 
circumferential 
breast 
measurement 
+ 
Hamed, 
2013 
23897352 
The chemokine 
stromal cell-derived 
factor-1α promotes 
endothelial 
progenitor cell-
mediated 
neovascularization 
of human 
transplanted fat 
tissue in diabetic 
immunocompromis
ed mice [60] 
Mice 
Human 
fat tissue 
Scalps of 
mice 
5 
Human fat tissue with 
phosphate-buffered saline 
or stromal cell-derived 
factor-1α was injected into 
the scalp of each mouse. 
18 days 
and 15 
weeks 
After 18 days:group 
with stromal cell-
derived factor-1α 
treatment of the 
grafts in the diabetic 
mice expressed 
higher levels of 
VEGF, increased 
VEGF receptor 2, 
CXCR4, endothelial 
nitric oxide 
synthase, and 
protein kinase B 
expression levels, 
and lower caspase 3 
and cytochrome c 
levels. After 15 
weeks:that same 
group had increased 
vascularization and 
prevented 
resorption of the fat 
graft. 
+ 
Luo, 
2013 
23509085 
Construction of 
engineering 
adipose-like tissue 
in vivo utilizing 
human insulin gene-
modified umbilical 
cord mesenchymal 
stromal cells with 
silk fibroin 3D 
scaffolds[149] 
Nude 
mice 
Human 
thigh 
liposuctio
n 
Back of 
nude mice 
5 
Mice received human ADSC 
fat grafts with or without 
esteridiol enrichment, or 
culture medium alone. 
Survival rate of the fat grafts 
was calculated. 
12 weeks 
Estradiol enriched 
fat grafts had a 
higher tissue 
survival rate than 
the ADSC alone 
group (76.9% vs 
55.5%). there was 
also increased 
capillary formation 
+ 
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Yanaga
, 2013 
24281577 
Two-stage 
transplantation of 
cell-engineered 
autologous 
auricular 
chondrocytes to 
regenerate 
chondrofat 
composite tissue: 
clinical application 
in regenerative 
surgery [150] 
Human 
Auricular 
concha 
Nasal/chin 
area 
2b 
Two-stage transplantation: 
1st = abdomen for growth 
(6 months), 2=nasal/chin 
area for reconstruction 
1 to 5 
years 
Chondrofat tissue 
was stable after 1-5 
years, maintained 
good shape, no 
infections, 5.6% 
absorption 
+ 
Zhao, 
2013 
24165597 
Enhancement of fat 
graft survival by 
bone marrow-derived 
mesenchymal stem 
cell therapy[151] 
Nude 
mice 
Inguinal 
area 
Paraverteb
ral 
5 
Three groups of nude mice 
recieved transplants of cells 
containing .3ml of adipose 
granula and .2ml of cell 
components. Group A 
received mesenchymal stem 
cells, group B received 
expanded mesenchymal 
stem cells, group C received 
Dulbecco's medium. Four 
months later the grafts were 
harvested measured. 
4 months 
Fat graft survival 
rates were .2052 in 
group A 
(mesenchymal), 
.1761 in group B 
(expanded 
mesenchymal) and 
.1350 in group C 
(Dulbecco's) 
+ 
Alghou
l, 2012 
22745452 
The effect of 
hyaluronan 
hydrogel on fat graft 
survival [152] 
Rat Groin Dorsum 5 
Two groups. Group 1: fat 
alone; Group 2: fat and 
hyaluronan hydrogel in a 
1:1 mix. In vivo scans at 4, 
12, and 20 weeks to 
quantify fat-HA graft 
volume and volume of fat 
alone 
4,12 and 
20 weeks 
Fat-HA yielded 
reduced fat necrosis 
(statistical diff. at 12 
and 20 weeks), 
higher blood vessel 
density (sig. at 12 
weeks only) and 
less volume loss (at 
20 weeks). 
+ 
Butala, 
2012 
22495210 
Endogenous stem 
cell therapy 
enhances fat graft 
survival [153] 
Mice 
Abdomen 
and thigh 
(Human) 
Tail 5 
Male 8-week-old FVB mice 
were grafted with either 
high density or low-density 
human lipoaspirate. Half of 
the mice receiving low-
density fat were treated 
with a stem cell mobilizer 
for 14 days 
2 and 10 
weeks 
Endogenous 
progenitor cell 
mobilization 
enhances low-
density fat 
neovascularization, 
increases 
vasculogenic 
cytokine expression, 
and improves graft 
survival to a level 
equal to that of 
high-density fat 
grafts 
+ 
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Frerich
, 2012 
22023101 
Comparison of 
different fabrication 
techniques for 
human adipose 
tissue engineering 
in severe combined 
immunodeficient 
mice [154] 
SCID 
mice 
Grown on 
microcarr
iers 
Under the 
skin 
5 
Mice received implantations 
of human adipose tissue 
derived stromal cells with 
or without endothelial cells. 
Another group of mice 
received the particles in a 
fibrin matrix with and 
without endothelial cells. 
The mice were harvested 12 
days, 4 weeks and 4 months 
and grafts analyzed. 
12 days, 
4 weeks 
and 4 
months 
There was a limited 
improvement in the 
group with the 
endothelial cells 
after 4 weeks. There 
were significantly 
fewer necrotic 
regions after 4 
weeks and 4 
months. 
+ 
Lee, 
2012 
23094251 
Facial Soft Tissue 
Augmentation using 
Autologous Fat 
Mixed with Stromal 
Vascular Fraction 
[155] 
Human 
Lower 
abdomen, 
hip and 
thigh 
Face 3a 
SVF cells were freshly 
isolated from half of the 
aspirated fat and were used 
in combination with the 
other half of the aspirated 
fat during the procedure. 
Between March 2007 and 
February 2008, a total of 9 
SVF-assisted fat grafts were 
performed in 9 patients. 
1 time a 
week up 
to 12 
weeks, 1 
time a 
month up 
to 11 
months 
Scores of the left 
facial area grafted 
with adipose tissue 
mixed with SVF 
cells were 
significantly higher 
compared with 
those of the right 
facial area grafted 
with adipose tissue 
without SVF cells. 
+ 
Ma, 
2012 
21607534 
Utilizing muscle-
derived stem cells 
to enhance long-
term retention and 
aesthetic outcome 
of autologous fat 
grafting: pilot study 
in mice [156] 
Mice 
Autologo
us 
Intramusc
ular 
5 
MDSCs and fat were 
transplanted 
intramuscularly in mice. 
The mice were assessed 
after 3 months. 
3 months 
Group containing 
MDSCs showed 
higher fat signal, 
intact fat cells, less 
fibrosis, less fat 
graft loss, and 
higher capillary 
density. 
+ 
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Sarkan
en, 
2012 
22738319 
Bioactive acellular 
implant induces 
angiogenesis and 
adipogenesis and 
sustained soft tissue 
restoration in vivo 
[157] 
Rat 
Subcutan
eous fat  
(Human 
and mice) 
Dorsal 
subcutis of 
rodents 
5 
Groups: rat (rATE, allograft) 
or human (hATE, xenograft) 
derived ATE included in 
implant to be injected into 
rat through a hyaluronan 
hydrogel (HA) 
12 weeks 
to 9 
months 
ATE-HA implant 
showed bioactivity, 
compatibility, 
sustainability, 
microvessel 
induction, adipose 
tissue deposition 
(starting at week 
12), included 
capillaries, nerve 
bundles and healthy 
connective tissue, 
and had large fat 
pads at the end of 
the study. 
+ 
Yang, 
2012 
21629060 
Role of anti-TNF-α 
therapy in fat graft 
preservation [158] 
Rat 
Autologo
us 
Back 5 
Two groups: Group 1: 
antirat TNF-alpha 
monoclonal antibody was 
added to fat graft; Group 2: 
fat graft on its own. 8 rats 
were killed and assessed on 
days 7, 14, 30 and 60 
7,14,30,6
0 days 
Group 1 had a 
higher preservation 
ratio of tissue 
compared to Group 
2 at 60 days (no 
significant 
difference in days 
before this). Group 
1 had lower 
numbers of 
apoptotic cells at 
each time point and 
expression of TNF 
alpha was lower in 
Group 1 versus 
Group 2 for days 7 
and 14. 
+ 
Keck, 
2012 
21964747 
Coenzyme Q10 does 
not enhance 
preadipocyte 
viability in an in 
vitro lipotransfer 
model [159] 
In vitro 
Subcutan
eous 
adipose 
N/A 5 
Preadipocytes were treated 
with coenzyme Q10 or a 
control and incubated with 
lidocaine. FACS and western 
blot were used to assess 
viability and apoptosis. 
NA 
Coenzyme Q10 did 
not improve 
viability or have any 
impact on the 
observed apoptosis 
parameters 
- 
Koh, 
2011 
21393582 
Stromal vascular 
fraction from 
adipose tissue 
forms profound 
vascular network 
through the 
dynamic reassembly 
of blood endothelial 
Mice 
Epididym
al 
adipose 
tissue 
Flank 
region 
5 
Cells were mixed with 
Matrigel or PBS, BSA, VEGF 
or cartilage oligomeric 
matrix protein-angiopoietin 
and implanted into the flank 
region 
1 week 
Freshly isolated SVF 
can effectively 
induce new vessel 
formation through 
the dynamic 
reassembly of blood 
endothelial cells 
+ 
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cells [160] 
Mojalla
l, 2011 
21590499 
Stem cells, mature 
adipocytes, and 
extracellular 
scaffold: what does 
each contribute to 
fat graft survival? 
[161]
Nude 
mice 
Human 
fat 
Nude mice 5 
Preparations of purified 
adipose tissue, isolated 
mature adipocytes, cultured 
adipose derived stem cellls 
without scaffold, collagen 
scaffold only, cultured 
adipose-derived stem cells 
in a collagen scaffold with 
and without bioactive 
factors and freshly isolated 
adipose derived stem cells 
in a collagen scaffold were 
used. Each preparation was 
grafted onto the nude mice 
2 months 
Free-cell grafts 
were resorbed in 
50% of the mature 
adipose group and 
60% of the ADSC 
group. Purified 
adipose tissue had 
an 81.8% survival 
rate. The remaining 
weight was greater 
in the Scaffold 
groups, but the 
difference was not 
statistically 
significant. 
no sig 
diff 
Kamak
ura, 
2011 
21533662 
Autologous cell-
enriched fat grafting 
for breast 
augmentation [162] 
Human 
Thighs, 
hips, 
buttocks, 
or 
abdomin
al 
Breast 3b 
After adipose harvesting 
using syringe liposuction, 
the tissue is processed in 
the Celution 800 System. 
tThe mean cell viability 
measured using an 
automated cell counting 
system before graft delivery 
was 85.3%. 
3 and 9 
months 
All patients 
demonstrated 
improvement in 
circumferential 
breast 
measurement 
(BRM) from their 
baseline state, and 
breast 
measurements were 
stable by 3 months 
after surgery. T 
+ 
Conde-
Green, 
2010 
20442104 
Effects of 
centrifugation on 
cell composition 
and viability of 
aspirated adipose 
tissue processed for 
transplantation 
[163] 
Human Abdomen N/A 5 
Samples of adipose tissue 
were centrifuged and 
samples of adipose tissue 
that were not centrifuged 
were compared. 
N/A 
The pellet in the 
centrifuged sample 
had the highest 
concentration of 
MSCs and 
endothelial cells 
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Keck, 
2010 
21042106 
Local anesthetics 
have a major impact 
on viability of 
preadipocytes and 
their differentiation 
into adipocytes 
[164] 
Human 
Subcutan
eous 
N/A 5 
Human preadipocytes were 
isolated from subcutaneous 
adipose tissue of 15 patients 
and treated with 
bupivacaine, mepivacaine, 
ropivacaine, 
articaine/epinephrine, and 
lidocaine for 30 minutes. 
N/A 
There is a marked 
influence of local 
anesthetics not only 
on the quantity but 
also on the quality 
of viable 
preadipocytes as 
determined by their 
ability to 
differentiate into 
mature adipocytes. 
+ 
Zhu, 
2010 
20098110 
Supplementation of 
fat grafts with 
adipose-derived 
regenerative cells 
improves long-term 
graft retention [18] 
Mice 
Inguinal 
fat pads 
Skull 5 
Adipose-derived 
regenerative cells and fat 
was transplanted into mice 
and compared to mice that 
were injected with non-
treated fat graft. Fat grafts 
were analyzed at both 6 and 
9 months after the 
transplantation. 
6 months, 
9 months 
At both 6 and 9 
months, ADRCs 
increased graft 
retention by 2-fold, 
enhanced the 
quality of the fat 
grafts, and had a 
higher capillary 
density. 
+ 
Umeno, 
2009 
19460200 
Efficacy of 
autologous fat 
injection 
laryngoplasty with 
an adenoviral 
vector expressing 
hepatocyte growth 
factor in a canine 
model [165]
Dogs Dog 
True vocal 
cords 
5 
Autologous fat plus an 
adenoviral vector 
expressing hepatocyte 
growth factor was injected 
into the right vocal cord. 
Harvested fat plus an 
adenoviral vector with no 
gene was injected into the 
left vocal cord. One year 
later a total laryngectomy 
was performed one year 
after the intracordal fat 
injection. 
1 year 
The fat area was 
significantly larger 
and the number of 
vasculoendothelial 
cells surrounding 
adipocytes was 
significantly greater 
in the intracordal 
injection with 
hepatocyte growth 
factor. 
+ 
Zhong, 
2009 
18162449 
Improved fat graft 
viability by delayed 
fat flap with 
ischaemic 
pretreatment [166] 
New 
Zealand 
rabbits 
Inguinal 
region 
Dorsal 
midline 
5 
U-shaped fat flap was raised 
in the inguinal region to 
induce ischaemia. Three 
weeks later, fat flap was 
transferred to a pocket next 
to the dorsal midline of the 
rabbit. 
Up to 12 
months 
VEGF protein in the 
ischaemia treated 
fat flaps was 
significantly higher 
than the controls at 
12 hours after the 
treatment. There 
was no difference in 
number of vessels, 
fat graft size, and 
weight at 1 and 3 
months after 
transplantation. The 
fat grafts in control 
group disappeared 
after 6 months, 
+ 
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while the treated 
group maintained 
the fat graft up to 12 
months. 
Mojalla
l, 2008 
19065020 
Does adipose tissue 
cultured with 
collagen matrix and 
preadipocytes give 
comparable results 
to the standard 
technique in plastic 
surgery? [167] 
Nude 
mice 
Various – 
with 
scaffoldin
g 
interscapul
ar 
5 
Preadipocytes were seeded 
on collagen scaffolds and 
then implanted. The other 
group, adipose tissue taken 
by the Coleman technique 
was also implanted but in a 
different site for 
comparison. Grafts were 
assessed after 8 weeks. 
8 weeks 
The group with the 
preadipocytes 
showed adipose 
appearance and 
peripheral 
neovascularization. 
+ 
Piaseck
i, 2008 
19083503 
Purified viable fat 
suspended in 
matrigel improves 
volume longevity 
[168]
Mice 
Mice 
(unspecifi
ed) 
Mice 
(Unspecifi
ed) 
5 
Purified fat cells were 
suspended in GFR Matrigel 
and then implanted. The 
other experimental groups 
were unpurified fat (group 
2), and then a control of 
GFR-Matrigel (group 3). The 
grafts were then assessed at 
1 week, 1 month and 3 
months 
1 week, 1 
month, 
and 3 
months 
Fat in GFR Matrigel 
grafts had a higher 
fat volume at 3 
months, whereas, 
the unpurified fats 
developed fibrosis. 
N/A 
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Piaseck
i, 2008 
19083542 
Beyond the cells: 
scaffold matrix 
character affects the 
in vivo performance 
of purified 
adipocyte fat grafts 
[169] 
Mice 
Mice 
(unspecifi
ed) 
Mice 
(unspecifie
d) 
5 
PuraMatrix (peptide 
hydrogel) with adipocytes 
were compared against just 
PuraMatrix and then against 
syringe-harvested fat alone 
1 week, 1 
month 
and 3 
months 
PuraMatrix with 
purified fat had 
higher volume and 
longer fat graft 
survival 
N/A 
Torio-
Padron
, 2007 
17380359 
Engineering of 
adipose tissue by 
injection of human 
preadipocytes in 
fibrin [170] 
Nude 
mice 
Subcutan
eous 
(human) 
Back 
(mouse) 
5 
Different concentrations of 
undifferentiated human 
preadipocytes in fibrin were 
injected into athymic mice, 
while the control group was 
injected with just fibrin. 
1,3,6 and 
9 months 
Within 4 weeks 
after initial volume 
reduction of the 
implants, the 
volume and shape 
of the implants with 
preadipocytes 
remained stable. 
The control group 
implants with just 
fibrin were 
completely 
resorbed within 3 
weeks. The best 
results were 
observed after 
implantation of 30 
million 
preadipocytes. 
+ 
Shosha
ni, 
2005 
15731687 
The effect of 
interleukin-8 on the 
viability of injected 
adipose tissue in 
nude mice [171] 
Mice 
Suction-
assisted 
lipectomy 
Scalp 5 
Group 1: interleukin-8 
(0.25ng) injected 24 hours 
before fat graft with 25 ng 
of interleukin-8 per 1 cc of 
injected fat. Group 2: fat 
without interleukin-8 
15 
Group 1 had 
significantly less 
cyst formation. No 
significant 
difference between 
the groups 
concerning weight 
or volume of graft, 
adipose cell size. 
+ 
Yamag
uchi, 
2005 
16246901 
Revascularization 
determines volume 
retention and gene 
expression by fat 
grafts in mice [172] 
Mice 
Epididym
al fat 
Subcutane
ous 
5 
Fat grafts were transplanted 
into mice either with TNP-
470 (an inhibitor of 
angiogenesis) or without. 
Mice with TNP-470 
had fat grafts with 
lower weight and 
smaller adipocytes 
than mice without 
inhibitor. VEGF and 
leptin were also 
+ 
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lower in TNP mice. 
Moore, 
1995 
7484471 
Viability of fat 
obtained by syringe 
suction lipectomy: 
effects of local 
anesthesia with 
liodcaine (173)
Human- 
in vitro 
Abdomen N/A 5 
Fat obtained 
intraoperatively and by 
lipectomy was digested 
with collagenase to isolate 
adipocytes. These cells were 
exposed to lidocaine 
10 days 
Lidocaine potently 
inhibited glucose 
transport and 
lipolysis in 
adipocytes and their 
growth in culture. 
however, persisted 
only as long as 
lidocaine was
present
+ 
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Chapter 10: Conclusions 
Autologous fat grafting is a common surgical procedure that involves the transfer of fat 
from one area of the body to another in order to improve contour deformities. There is 
tremendous clinical interest in the utilization of fat grafting for soft tissue reconstruction, 
with thousands of cases performed each year in the treatment of volume loss due to 
trauma, scars, wounds, fistulas, disease, congenital defects, or the natural process of 
aging. In the setting of breast reconstruction, fat grafting provides significant contour 
improvement and improves patient satisfaction. Although fat could become the ideal soft 
tissue filler, it is plagued by its tremendous variability in long-term graft retention, with 
volume survival rates of 20-80%, resulting in suboptimal outcomes and repetitive 
procedures. The goals of this dissertation were to generate and critically appraise 
evidence for the safety and efficacy of fat grafting in the setting of breast reconstruction 
and to provide evidence-based recommendations to guide future therapies.  
While there is tremendous interest in the use of fat grafting for aesthetic and 
reconstructive breast surgery, concerns have been raised regarding efficacy and safety of 
adipose-derived stem cells and fat grafting in the setting of breast reconstruction. In light 
of the recent FDA regulatory changes regarding the processing of fat, a systematic review 
was undertaken to determine the safety, efficacy, satisfaction, and oncological outcomes 
of fat grafting to the breast. Based on our review of the literature and the data collected 
from our institution, fat grafting appears to be oncologically safe in breast reconstruction. 
Several adipose graft enrichment strategies encompassing growth factors, platelet-rich 
2
4
7
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plasma, adipose-derived and bone marrow stem cells, gene therapy and tissue 
engineering have been attempted to augment and improve the viability of fat grafts. 
While these strategies are promising, most of the evidence is level five and only in animal 
models, however, well-designed clinical trials are indicated to establish safety and 
efficacy of interventions.  
Due to the significant variability in fat grafting outcomes and tremendous interest of 
ASCs graft retention, the final study attempts to describe the impact of a specific donor 
physiological condition, obesity, on ASC functionality. Understanding how obesity 
affects ASC function may help to elucidate why lean patients anecdotally have better fat 
graft retention compared to obese patients. Our research suggests that obese patients may 
have lower levels of satisfaction with fat grafting procedures and lower retention rates, 
possibly due to reduced ASC proliferation and differentiation potential. Collectively, the 
studies that comprise this dissertation generate and critically appraise evidence for the 
safety, efficacy and outcomes of fat grafting in the setting of breast reconstruction.  
2
4
8
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